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General introduction
101 General introduction
An epileptic seizure is a clinical manifestation characterized by an intermittent, stereotyped,
paroxysmal disturbance of consciousness, behavior, emotion, motor function, or sensation
which arises because of abnormal and excessive discharges from a set or neurons in the brain
(1,2). According to the presence or absence of a acute precipitating insult, epileptic seizures
can be categorized as provoked (acute symptomatic) or unprovoked seizures respectively.
Patients who experience recurrent (two or more) unprovoked seizures obtain the diagnosis
epilepsy. The time between these recurrent seizures has to be at least more than 24 hours,
since multiple seizures occurring in a 24-h period are considered a single event (2, 3).
Epilepsy is a chronic neurological condition and one of the earliest recorded illnesses. The
oldest known report of epilepsy is provided by a Babylonian tablet written in the neo-
Assyrian script dated between 718 and 612 B.C. (4). At this tablet is recorded that an
individual with epilepsy is considered as a "possessed" person due to the "vow of the father"
and by demons and ghosts who. childless themselves, looked on human children and young
brides with envy and spite.
Over the years it became clear that epilepsy is not associated with any mystic, magic or
religious cause but is rather a heterogeneous disorder. It results from many different cerebral
disorders and physiological processes, and has a variable anatomical basis. Advances in
technology and the conduct of descriptive epidemiological studies have increased the
knowledge regarding the mechanisms of epileptogenesis, the natural history of epilepsy, its
incidence and prevalence, and the risk factors associated with its development. In particular,
the incidence studies of epilepsy indicate that the incidence of epilepsy varies considerably
with age and that epilepsy is slightly more higher in males. However, these studies are
difficult to interpret and compare because of methodological differences (5, 6).
In incidence studies, a prerequisite for a comprehensive case-ascertainment is an accurate
diagnosis and classification of the cases. The diagnosis and classification of epilepsy depends
highly on a meticulously obtained seizure description and on the use of ancillary tests (EEG,
ncuroimaging studies) (5. 7). The diagnosis of epileptic seizures may be hampered because
these events arc usually short-lived and sporadic, and occur too infrequently to be directly
studied by physicians (8) In addition, different physical and psychological factors may cause
paroxysmul phenomena which may be mistaken for epilepsy. As a result, these non-epileptic
events may receive inappropriate, ineffective treatment often for long periods of time. The
consequences of misdiagnosis are considerable: exposure to the toxicity of antiepileptic drugs,
unnecessary health care costs, imposition of the lifestyle restrictions associated with epilepsy,
and possible delay of appropriate psychological or other specific medical treatment (9-11).
Thus, it is important to distinguish epileptic from non-epileptic seizures at an early stage of
the seizure disorder.
Among the non-epileptic events, syncope and non-epileptic seizures (NES) are most often
confused with epilepsy (1). The etiology of NES is probably multifactorial and involves
several environmental and psychological factors (11). Early identification of the risk factors
that underlie the development and maintenance of the NES would assist physicians in
distinguishing epileptic from non-epileptic seizures at an early stage, and in establishing
adequate treatment strategies.
In studies of the prognosis after a first unprovoked seizure, not only an accurate diagnosis and
classification of seizures, but also other factors, which may influence the assessment of the
outcome, have to be considered (e.g. referral patterns within the population studied, the
timing of assessment for inclusion in the study, and the prevalence of a variety of potential
risk factors within the population studied) (12-14). The reported estimates of the risk of
recurrence vary between 40% and 52% in studies that have employed first-seizure methods
(14). In general. 70-80% of the patients who developed seizures for the first time will
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eventually achieve remission, whereas the remaining 20-30% will continue to have seizures
and will be classified as having chronic epilepsy (13).
Patients with chronic epilepsy differ in their pattern of service use and medical consumption
from patients whose seizures are effectively controlled with regular treatment Moreover,
these patients are at greatest risk of unemployment and underemployment (15). Thus, patients
with epilepsy, especially patients with poorly controlled seizures, incur significant direct and
indirect costs to society. The International League Against Epilepsy (ILAE) recognized that
epilepsy creates significant economic and social burdens and formed a Commission on the
Economic Aspects of Epilepsy (ICEE) in 1994 (16. 17).This Commission emphasized the
need to investigate the economic aspects of epilepsy in order to ensure that epilepsy care will
be tailored to the needs of patients with epilepsy.
Aims and outline of this thesis
Based on these considerations, we considered in the first part of this thesis the
epidemiological aspects of epilepsy (chapters 2 to S) whereas in the second part we focused
on the costs of epilepsy (chapters 6 to 8).
In summary, this thesis aims to answer the following questions:
1. What is the distribution of the incidence of unprovoked seizures and of epilepsy in
different countries in relation to age. sex, etiology and seizure type?
We therefore reviewed systematically the incidence studies of unprovoked seizures and
epilepsy in order to assess the methodological quality of these studies and to synthesize
their results in a systematic way (chapter 2).
2. Which risk factors and mechanisms have been recently associated with the non-cpilcptic
seizures?
For this purpose, we reviewed systematically the recent literature on the etiology ol non-
epileptic seizures with the aim to provide more insight into the recent evidence of the risk
factors and mechanisms associated with NES (chapter 3).
3. How is the incidence of epilepsy and unprovoked seizures distributed in Maastricht and its
surroundings in relation to age, sex. etiology and seizure type? (chapter 4)
4. Which factors are strong predictors for epileptic and non-epileptic seizures?
To answer these questions, we conducted a prospective population-based incidence study
study in Maastricht and its surroundings to estimate the incidence of unprovoked seizures
and epilepsy in a well-defined population and to identify predictive factors of the several
seizure types with which epileptic seizures can be distinguished from non-epileptic
seizure disorders more accurately (chapter 4).
5. Which items from the history, hetero-anamnesis and findings from physical examination
and from diagnostic tests can assist in the early identification of patients with epileptic and
non-epileptic seizures?
We therefore investigated in a prospective population-based study in Maastricht and its
surroundings whether there is a cluster of diagnostic items which can differentiate patients
with epileptic seizures from patients with non-epileptic seizures (chapter 5).
6. Which methodological issues have to be considered in order to make epilepsy cost studies
more relevant for health policy decisions? (chapter 6)
7. What are the national and per capita estimates of the costs of epilepsy in different
countries? (chapter 7)
To answer this questions, we performed a systematic review of epilepsy cost studies with
the aim to assess their methodological quality and to systematically compare their direct
cost estimates (chapters 6 and 7).
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8. How are the costs of epilepsy distributed in three different populations of patients with
epilepsy? (chapter 8)
9. How are the direct costs in three different populations of patients with epilepsy associated
with the patients' perception of their quality of life and with their seizure severity?
We conducted a study of the costs of epilepsy care in three different populations of
patients with epilepsy in the Netherlands (general practices, university hospital, and
epilepsy center) and used cost questionnaires, cost diaries and a quality of life inventory in
an attempt to answer these questions (chapter 8).
Finally, a general discussion of the findings in this thesis is presented in chapter 9, followed
by a summary of the main conclusions.
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Systematic review and meta-analysis of incidence studies of
epilepsy and unprovoked seizures
Authors: Kotsopoulos IAW, van Merode T, Kessels FGH, de Krom MCTFM, Knottnerus JA
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Summary
To evaluate the methodology of incidence studies of epilepsy and unprovoked
seizures and assess the value of their findings by summarizing their results.
A/e//W.v A Medlinc literature search from January 1966 to December 1999 was conducted.
In each selected study, key methodologic items such as case definition, and study design were
evaluated. Furthermore, a qualitative meta-analysis of the incidence data was performed,
ffaru/tt / 40 incidence studies met the inclusion criteria. There was considerable heterogeneity
in study methodology and the methodological quality score was generally low. The median
incidence rate of epilepsy and unprovoked seizures was 47.4 and 56 per 100,000 respectively.
The age-specific incidence of epilepsy was high in those aged 60 years or older, but was
highest in childhood. Males had a slightly higher incidence of epilepsy (median 50.7/100,000)
than females (median 46.2/100.000) and partial seizures seemed to occur more often than
generalized seizures Developing countries had a higher incidence rate of epilepsy (median
68.7/100,000) than industrialized countries (median 43.4/100,000). Similar results were found
for unprovoked seizures. The incidence of epilepsy over time appears to decrease in children,
whereas it increases in the elderly.
(Vjm.7u.vff>m" The age-specific incidence of epilepsy showed a bimodal distribution with the
highest peak in childhood No definitive conclusions could be reached for the incidence of
unprovoked seizures and other specific incidence rates of epilepsy. More incidence studies
with an adequate study methodology are needed to explore geographical variations and time
trends of the incidence of epilepsy and unprovoked seizures.
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INTRODUCTION
Incidence studies provide important information regarding the natural history of epilepsy and
its risk factors. During the last three decades, several incidence studies of epilepsy have been
performed.These studies indicate that the incidence of epilepsy varies considerably with age
and that epilepsy is slightly more common in males. Moreover, recent studies suggest a
secular trend in the age-specific incidence, with a decline in children and an increase in
elderly people (1, 2).
However, the available data are difficult to interpret and compare because of methodological
differences (3,4) and so far, the existing literature has not been reviewed systematically in
order to assess the methodological quality and summarize the results of incidence studies.
We performed a systematic review and a quantitative meta-analysis of incidence studies of
epilepsy and unprovoked seizures (US) in order to study the effect of methodological quality
on the incidence reported, on the magnitude of possible geographic differences in incidence,
on the epidemiology of different types of seizures, and the possible changes of incidence over
time.
METHODS
Study selection
We identified previously published incidence studies by conducting a Medline literature
search from January 1966 to December 1999, using the MeSH subject headings
"epidemiology", "epilep*" and "incidence". Additional relevant articles were found by
tracking references. We considered studies eligible for inclusion if they recorded the
incidence of epilepsy or of US and were published in English, French, German or Dutch. We
excluded studies which included only acute symptomatic seizures, certain seizure patterns or
epileptic syndromes such as absence epilepsy, reflex epilepsy, and Lennox-Gastaut syndrome.
We also excluded studies which were restricted to selected populations (e.g. patients with
gliomas or a stroke) or hospital-based studies, and studies published as a review, a letter or in
abstract form only. If one study had several reports, we used the most recent and complete
data for analysis.
Methodological quality
Based on earlier published proposals for reporting meta-analyses of observational studies (5),
we developed a checklist (Appendix 1) to evaluate the methodological quality of all included
studies. Each incidence study was scored on the following items: adequacy of case definition,
type of study design, description of demography and selection criteria of the study population,
type of described incidence rates, and type of epilepsy or epileptic seizure of which the
incidence was defined. In accordance with the guidelines for epidemiologic studies on
epilepsy of the ILAE (International League Against Epilepsy) (6, 7), we considered the items
adequacy of case definition and type of study design as important quality items. The total
quality score of each study is given in round numbers from 0 to 30. Two authors (TvM and
IK) independently evaluated all the incidence studies and reached a consensus with the aid of
a third author (FK) in cases of disagreement. The degree of agreement was defined by using
the Spearman correlation coefficient.
Meta-analysis of results
From each included study we extracted the country, year of publication, incidence rate of
epilepsy or US. upper or lower age limits of the study, gender- and seizure-specific incidence
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rates, and total quality score. Furthermore, we recorded whether first attendance rates and
age-adjusted or crude incidence rates were reported.
The median and ranges of the incidence rate of epilepsy and US were determined for three
different age categories (children, adults, elderly) as well as by gender and seizure type. We
estimated incidence rates from figures if a study did not present them in numbers and from
original data if a study provided detailed demographic data (denominator) and the number of
cases included (numerator). Wherever possible, we used crude incidence rates, as the methods
used to adjust the results varied from study to study. Similarly, wherever possible, we used
first attendance rates instead of incidence rates because first attendance rates are not subject to
a selection bias, thereby giving a better representation of the size of the incident case
population (3). Partial and generalized seizures were pooled, and simple partial, complex
partial and secondary generalized partial seizures were combined.
We examined differences in the distribution of the several incidence rates by using the Mann-
Whitney or the Kxuskal-Wallis tests. As a sensitivity analysis, the pooling process was
repeated after the successive removal of incidence studies with a low quality score. All
statistical tests were two-sided, with a P-value <0.01 for statistical significance.
RESULTS
Selected studies
The Mcdline search yielded 161 English publications, eight French, one German and one
Dutch (Table I). Application of the exclusion criteria resulted in 30 incidence studies and
reference tracking yielded another 10 studies. Only four studies (8-11) out of 40 were
conducted earlier than 1980. Seven (12-18) of the 40 incidence studies were carried out in
developing countries, and two (19, 20) in eastern European countries. Three studies (21-23)
reported incidence rates of other diseases as well.
TABLE 1. A
Included
161 English
8 French
1 German
1 Dutch
!WM//5 <y A/ed/ine 5eart'«
Excluded
14 certain seizure patterns
35 selected population
11 review
57 no incidence study
4 letters
1 selected population
3 review
3 no incidence study
1 no incidence study
0
No of selected
studies
28
1
0
1
Methodological quality
The quality score ranged from 6 to 30 (median 16). Table 2 shows the methodological quality
scores of the 40 included studies.The interrater agreement on the scale was good (r=0.98.
P=0.0001). Most disagreement was caused by slight differences in interpretation and was
easily resolved. Consensus was reached in all cases. Quality score and publication year of the
study did not correlate (r=0.20. P=0.21). Subgroup analysis provided similar results for
industrialized and developing countries, and showed that recently published studies were not
associated with a high quality score.
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TABLE 2. .Vfefnoob/ojfica/ awa/ify jcorw o/fn* incidence sri/oV«
Studies Score
Sidenvall (32). Forsgren (25), Jalk» (33), Beilmaim 26-30
(19), Jallon(12)
Forsgren (24), Verity (34). Ellenberg (35), Hauser (2), 21-25
Braathen (36), Olafsson (37), Häuser (10). Annegers
(38). Lavados (13)
Doerfer (39). Granieri (40). Tsuboi (41). Kerinen (42), 1430
Pavlovic (20). de Graaf (9), Blom (II), Placencia (14).
Tekle-Haimanot (15). Mani (16)
Juul-Jensen (43). Doose (44). Cockerell (1), Joensen IMS
(45), Cockerell (21), Camfield (46), Rwiza (17),
Gissler (22). Kurtz (47). Rantala (48). LOhdorf (49),
vd Berg (8), Ishida (50). Cavazutti (51). Okkes (23) 6-10
TABLE 3. Äeportea" inciaence rates o/ep/Ve/wy (/700,000/year)
Study
Beilmann (19)
Verity (34)
Häuser (2)
Braathen (36)
Olafsson (37)
Häuser (10)
Annegers (38)
Lavados (13)
Doerfer (39)
Granieri (40)
Tsuboi (41)
Keranen (42)
Pavlovic (20)
de Graaf (9)
Blom (II)
Placencia (14)
Tekle-Haimanot (15)
Mani (16)
Juul-Jensen (43)°
Doose (44)
Cockerell (I)
Joensen (45)
Cockerell (21)
Camfield (46)
Rwiza (17)
Kurtz (47)
Rantala (48)
LQhdorf (49)
Li(18)
Ishida (50)
Cavazutti (51)
Okkes (23)
Median 47.4 82.2 34.7 39.7 50.7 46.2
'divided the cumulative incidence reported in the study by the length of the observation period in years
otal
440
46.5
48.7
35.5
113.0
33.1
24.0
32.8
190.0
64.0
49.3
124.3
48.3
42.8
23.0
73.3
25.0
100.0
Children
(0-14 yr)
45.0
430.0
53.0
53.0
67.5
124.4
52.1
430.0
650.0
82.3
219.0
86.0
61.0
72.4
60.9
71.5
41.0
93.2
840.0
130.0
145.0
82.0
Age
Adults
(l5-59yr)
31 8
28.0
103.4
23.0
158.0
36.0
420
33.4
29.0
43.3
Elderly
(260 yr)
826
107.3
7.5
27.0
150.3
20.5
23.2
75.2
15.0
39.7
87.0
Male
total
49.0
55.9
51.8
125.3
39.1
31.0
173.0
72.0
507
39.0
33.3
68.9
32.0
Female
total
41.0
36.6
46.2
100 9
27.3
17.0
207.0
57.0
477
28.0
58.0
77.5
19.0
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Renults from the incidence studies
Table 3 and 4 summarize the results from the incidence studies. One study (22) did not
provide the total incidence of the study population.
Figure 1 shows the distribution of the several incidence rates of epilepsy on a logaritmic scale.
Because of the small number of incidence studies of US, we could not reasonally determine
the distribution of the specific incidence rates of US.
TABLE 4. Aeywrf«/ ;nci<fence ra/e\i o /
Study Total Age Male Female
total lota)
Children Adults Elderly
(0-14 yr) (15-59 yr) (260 yr)
37.0 139.0 SS.O 56.0
38.5 28.7
Sidmvall (32)
Pongren (23)
Jallon (33)
Jallon (12)
Forsgren (24)
Verity (34)
lllcnbcrg(35)
Mauser (2)
Annegcr*(38)
Tiuboi (41)
Juul-Jenscn (43)°
LOhdorf (49)
vd Ben ( I )
56.0
45.6
64.1
33.6
61.0
50.9
198.3
94.7
S70.0
124.0
900.0
93.0
104 0
Median 560 1240 37 0 1215 46 8 42.4
"divided the cumulative incidence reported in the study by the length of the observation period in years
The age-specific incidence of both epilepsy and US shows a U-shaped pattern with higher
rates for children and the elderly than for adults. Overall, the distribution of the age-specific
incidence rates of epilepsy differed significantly (P=0.008). In particular, children differed
significantly from the other age categories (P=0.002).
Furthermore, the incidence of epilepsy and US is slightly higher for males than for females.
However, this difference was not significant.
In comparison with the industrialized countries (median 43.4), developing countries (median
68.7) have a higher median incidence rate of epilepsy but this difference was non-significant.
Moreover, in these studies higher rates are found in children and adults than in the elderly.
Generally, the median seizure-specific incidence rates are higher for partial than for
generalized seizures but this difference was not significant (Table 5). The median incidence
rate of partial seizures is higher in children (30) than in adults (7). Correspondingly, the
median incidence rate of generalized seizures is 45.2 in children and decreases to 21 in adults.
Two studies (10, 24) were repeated in the same area using the same methodology allowing an
assesment of the incidence of epilepsy and US over time.
In the studies of Hauser et al. (2, 10) there was no significant difference in total incidence of
epilepsy over time. However, they (2) observed significant changes in the age-specific
incidence over time. The incidence in children aged less than 10 years decreased by 40% over
the 10-year interval between the early study and the most recent one, whereas the incidence in
the elderly population almost doubled during the same period.
Forsgren et al. (25) determined the incidence of US in adults prospectively and they found
significantly higher incidence figures than a previous study (24). According to the authors
(25). the most likely explanation for the increased incidence is a better case ascertainment in
the latest study.
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FIG. 1. Median and ranges of the incidence of epilepsy
TABLE 5.5e/zMre-5pec«y?c /ncüfefice rare* {y/00,000/y<?ar;
Study Partial Generalized
total
Forsgren (25)
Forsgren (24)
Häuser (2)
Olafsson (37)
Häuser (10)
Lavados (13)
Granieri (40)
Joensen (45)
Rwiza (17)
31.0
24.2
40.0
14.4
30.4
60.8
10.6
21.9
39.7
9.0
5.6
17.0
32.1
22.0
432
19.6
I6.S
72.1
Median 30 4 19 6
As a sensitivity analysis, incidence studies with a quality score lower than 15,20 and 25 were
removed successively, resulting in a decrease of the median incidence of epilepsy and US
(from 47.6 through 46.5 to 45, and from 58.5 through 53.4 to 50.8 respectively). Comparably,
there was a decrease in the median incidence of generalized seizures (from 19.6 through 19.5
to 7.3 respectively) and in the median incidence of epilepsy for females (from 46.2 to 43.6),
whereas the median incidence of partial seizures and the median incidence of epilepsy for
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males slightly increased (from 30.4 through 34.2 to 31.1, and from 50.7 through 51.3 to 53.8
respectively). The median gender-specific incidence for US remained constant.
DISCUSSION
Our mcta-analysis shows that the incidence studies of epilepsy and US differ considerably in
their study methodology, resulting in a wide variation of the incidence rates. However, the
methodological quality was generally low and despite the guidelines for epidemiological
studies offered by the II.AF. (7) in 1993, recently published studies did not significantly
correlate with a high quality score.
Epidemiology
The incidence of epilepsy and US showed a bimodal distribution, with the highest peak in
childhood. In particular, this distribution was significant for the incidence studies of epilepsy.
The information from studies using selected age groups is consistent with the incidence data
found in total population studies when age-specific incidence rates are evaluated. Possible
causes of epilepsy in childhood arc congenital, developmental, and genetic conditions (4, 26).
The most common cause of epilepsy in the elderly population is cerebrovascular disease (4,
26. 27).
Overall, the gcndcr-spccific incidence was slightly higher for males than for females which
may be the result of the higher incidence in males of definite risk factors for epilepsy (i.e.
head injury, stroke, central nervous system infection). However, a similar pattern is seen
when only cases with idiopathic or cryptogenic epilepsy are considered (4, 26).
Partial seizures seem to be the predominant seizure type in incidence studies. Studies which
reported higher rates of generalized seizures may have, therefore, underreported partial
seizures.
Geographic differences
The few studies that have been performed in developing countries have found higher
incidence rates than in developed countries, and demonstrated a decrease of the incidence of
epilepsy with age. It is likely that this different pattern of age-specific incidence of epilepsy
reflects a different actiological profile of epilepsy. In general, life expectancy in developing
countries is shorter, resulting in fewer elderly people with strokes of cerebral tumours, which
are common causes of epilepsy in developed countries. Furthermore, a number of specific
tropical risk factors such as infections (i.e. schistomiasis, cysticercosis) and trauma (perinatal
or lifelong) arc associated with epilepsy, but the exact extent of this contribution is unknown
(28).
Changes over time
There is some evidence that the incidence of epilepsy over time decreases in children whereas
it increases in the elderly (4. 26, 29). Several factors may be involved in this pattern, such as
improved antenatal and prenatal care for children, and an increase in life expectancy in the
elderly, associated with an increased risk for causes of epilepsy common in old age.
Methodology of incidence studies
Our mctu-analysis of incidence data is accompanied by some limitations related to several
methodological issues of the selected incidence studies.
Most of the incidence studies had a retrospective design and did not provide enough data for a
further subgroup analysis of the incidence data (in separate age categories and by gender and
seizure type). Furthermore, incidence studies often used different age-adjustment methods and
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defined age limits differently. However, there are studies which did define similar age limits
(0-15 years for children, 16-59 years for adults and > 60 for the elderly) or whose results
could be synthesized and analysed as such.
Another limitation is the issue of classification of epileptic seizures. Recent studies have
classified epilepsy and epileptic seizures differently than older studies. Older studies often
used the international classification of epilepsies and epileptic syndromes by the ILAE in
1989 (30). This classification appeared to be difficult to apply in retrospective studies or field
surveys (4). Moreover, the extent to which an epileptic seizure is diagnosed and classified
depends on a meticulously obtained seizure description and neurologic investigation (3. 4).
A further difficulty concerns the definition of epileptic seizures. Many incidence studies did
not provide thorough definitions of epilepsy and epileptic seizures, of the selection criteria
and demography of the population studied, and did not fully explain their methods,
introducing potential uncertainties into the results. In addition, incidence studies may differ in
the inclusion of single seizures, neonatal seizures, febrile seizures and seizures in acute illness
resulting in high incidence rates (3). In this meta-analysis, we have excluded the
aforementioned seizures from the analysis. Moreover, in spite of the fact that non-febrile
seizures can be distinguished in provoked and unprovoked seizures, a few studies, especially
incidence studies in children, categorised all non-febrile seizures as US.
Taking into account all these limitations, we carried out a sensitivity analysis. This resulted in
lower median incidence rates of epilepsy and US, reflecting a better case ascertainment
method, classification, and definition of epileptic seizures. Mauser (26) reported that in
incidence studies in France and Rochester, Minnesota, at least half of the newly occuring
afebrile seizures did not fulfill the criteria for epilepsy.
Recommendations
The results of our meta-analysis were significant only for the age-specific incidence rates of
epilepsy. For the other specific incidence rates of epilepsy and the incidence rates of US our
findings did not reach significance, probably due to the small number of incidence studies.
Similarly, our conclusions regarding the time trends of both the incidence of epilepsy and US,
and the pattern of age-specific incidence of epilepsy in developing countries, cannot be
definitive due to the low power of the studies. There is an urgent need for further incidence
studies with appropiate methodology to document reliably the incidence of epilepsy and US
worldwide, noting possible geographic differences and changes in the incidence over time.
Therefore, the use of the guidelines of the ILAE (6, 7) should be emphasized, and incidence
studies should clearly state the demography of the studied population, the selection criteria
and case ascertainment method. Preferably, in such studies, multiple overlapping search
strategies for the identification of incident cases should be used (e.g. including review of
neuroradiology reports and EEG files) to avoid selection bias by referral (31).
24 I Systematic review of incidence studies
REFERENCES
1. Cockerell OC, Eckle I, Goodridge DM, Sander JW, Shorvon SD. Epilepsy in a population of 6000 re-
examined: secular trends in first attendance rates, prevalence, and prognosis. 7 Afairo/ AVurojurg
/»jycA/o/rv 1995:58:570-6
2. Hauser WA. Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester,
Minnesota: 1935-1984. £pi/epj/o. 1993.34:453-68
3. Sander JW, Shorvon SD. Incidence and prevalence studies in epilepsy and their methodological
problems: a review. J/Veuro/ AVurofwrg yjycMa/ry l987;50:829-39.
4. Sander JW. Shorvon SD. Epidemiology of the epilepsies. ./AVuro/ AVuraii/rg />jyc>»arr>
1996:61(5)433-43
5. Stroup DF, Berlin JA, Morton SC, el al. Meta-analysis of observational studies in epidemiology. X4M4.
2000,283:2008-12
6. ILAE Commission Report The epidemiology of the epilepsies: future directions. £/7i/r/>j/a.
1997,38:614-8
7. Commission on Epidemiology and Prognosis, International League Against Epilepsy. Guidelines for
epidemiologic studies on epilepsy £/>//e/*tia 1993.34 592-6
8 Berg BJvd, Yerushalmy J Studies on convulsive disorders in young children. /VoVa/r /?e$. 1969;3:298-
304
9. Griaf ASd. Epidemiologie«! aspects of epilepsy in Northern Norway. £p//epi(a. 1974,15:291-9
10 Hauser WA, Kurland LT The epidemiology of epilepsy in Rochester. Minnesota, 1935 through 1967.
£/»/r/v#<i. 1975:16:1-66
11. Blofn S. lleijbel J, Bergfon PG Incidence of epilepsy in children: a follow up study three years after
Ihe firs! seizure £/>//*/M<a 1978:19:343-50
12. Jallon P, Smadja D, C'abre P. Mab GL. Bazin M. Group E EPIMART: Prospective incidence study of
epileptic seizures in newly referred patients in a French Carribean island (Martinique). £/»/f/>5fa.
1999,40 1103-9
13 1 j v i d o i J. Germain L, Morales L, Campero M. Lavados P. A descriptive study of epilepsy in the
district of El-Salvador. Chile. 1984-1988 /<rta A>i/ro/ .Scanj 1992:85:249-56
14. Placencia M. Shorvon SI). Parades V. et al Epileptic seizures in an Andean region of Ecuador Aram.
1992.115 771-82
15. Tekle-Haimanol R, Forsgren L, Ekstedt J. Incidence of epilepsy in rural central Ethiopia, £/»7epsia.
1997;38:541-46.
16. Mani KS, Rangan G, Srinivas HV, Kalyanasundaram S, Narendran S, Reddy AK. The Yelandur study:
a community-based approach to epilepsy in rural South India-epidemiological aspects. .Seizure.
l998;7:28l-8
17. Rwiza HT, Kilonzo GP, Haule J. et al. Prevalence and incidence of epilepsy in Ulanga, a rural
Tanzanian district: a community-based study. £p//ep$id. 1992;33:1051-6.
18. Li S, Schoenberg BS. WangC, Cheng X, Zhou S, Bolis CL. Epidemiology of epilepsy in urban areas of
the people's republic of China. £/>i7<?/wia. 1985;26:39l-4.
19. Beilmann A, Napa A. Hämank M, Soot A. Talvik I, Talvik T. Incidence of childhood epilepsy in
Estonia, flrain one/ D«vWo/>m««. l999;2l:l66-74.
20. Pavlovic M, Jarcbinski M. Pekmezovk T, Levic Z. Seizure disorders in preschool children in a Serbian
district. AVuroe/j/demm/ogy. 1998:17:105-10.
21. Cockerell OC. Goodndge DMG. Brodie D. Sander JWAS. Shorvon SD. Neurological disease in a
defined population: the results of a pilot study in two general practices. AVi<roepi<femio/ogy.
1996:15:73-82.
22. Gissler M, JSrvelin M-R. Louhiala P, Hemminki E. Boys have more health problems in childhood than
girls: follow up of the 1987 Finnish birh cohort. /<c»a /Vdiarr. 1999:88:31-4.
23. Okkes IM, Lamberts H. Verschillende frequentiecijfers van aandoeningen bij gezondheidsenquete en
huisartsregistraties. AW 77/<fcc->ir GeneesiW. 1997:141:634-9.
24. Forsgren L. Prospective incidence study and clinical characterization of seizures in newly referred
adults. Epi/«yMia. 1990:31:292-301.
25. Forsgren L. Bucht G. Eriksson S. Bergmark L. Incidence and clinical characterization of unprovoked
seizures in adults: a prospective population-based study. £/>j/e/Mia. 1996:37:224-9.
26. Mauser WA. Incidence and prevalence. In: jr JE, Pedley TA. eds. £p//epjy /< compreAjrnLrfv? 7ex/6ooi.
Philadelphia l.ippincott-Raven Publishers: 1997:47-57.
27. Stephen U . Brodie MJ Epilepsy in elderly people £<mo« 2000:355:1441-6
28. Bittencourt PRMd. Adamolekum B. Bharucha N. et al. Epilepsy in the tropics: I. Epidemiology,
socioeconomic risk factors, and etiology. fy/Vcpsia. 1996,37:1121-7.
Chapter 2 I 25
29. Everitt AD. Sander JW. Incidence of epilepsy is now higher in etderiv people than in children.
1998:316:780
30. Commission on Classification and Terminology of the International League Against Epilepsy Proposal
for revised classification of epilepsies and epileptic syndromes. £pi/c/uia. 1989:30:389-99
31. Knottnerus JA. The effects of disease verification and referral on the relationship between symptoms
and diseases. Afco" Dec« Maiin^. l987;7:139-48.
32. Sidenvall R. Forsgren L, Blomquist HK. Heijbel J. A community-based prospective study of epileptic
seizures in children. Xc/a Pa<?u7a/r 1993:82:60-65.
33. Jallon P. Goumaz M. Haenggeli C. Morabia A. Incidence of first epileptic seizure in the canton of
Geneva. Switzerland. £pi/</u;a. 1997:38:547-52
34. Verity CM. Ross EM, Golding J. Epilepsy in the first 10 years of life: findings of the child health and
education study. BAt/ 1992:305:857-61.
35. Ellenberg JH. Hinz DG, Nelson KB. Age at onset of seizures in young children, ^mt A/euro/.
1984:15:127-34.
36. Braathen G, Theorell K. A general hospital population of childhood epilepsy. <4c/a Pa«/ia/r.
1995:84:1143-6.
37. Olafsson E, Hauser WA. Ludvigsson P. Gudmundsson G. Incidence of epilepsy in rural Iceland: •
population-based study. £/>i/e/Mio. 1996:37:951-5
38. Annegers JF, Dubinsky S. Coan SP. Newmark ME. Roht L. The incidence of epilepsy and unprovoked
seizures in multiethnic, urban health maintenance organizations. £/>i'/e/ui<i. |944;40:502-6.
39. Doerfer J. Wasser S. An epidemiologic study of febrile seizures and epilepsy in children. fyi/epsv /?«.
1987:1:149-51.
40 Granieri E, Rosati G. Tola R. et al. A descriptive study of epilepsy in the district of Copparo, Italy,
1964-1978. £pi/e/)5)a. 1983:24:502-14.
41. Tsuboi T. Prevalence and incidence of epilepsy in Tokyo. £pi/<?/w/a. 1988:29:103-10.
42. Keranen T, Riekkinen Pj, Sillanpaa M. Incidence and prevalence of epilepsy in adults in Eastern
Finland. £/»/e/u;a. 1989:30:413-21.
43. Juul-Jensen P, Foldspang A. Natural history of epileptic seizures. £pi7<ywia l983;24:297-312.
44. Doose H, Sitepu B. Childhood epilepsy in a German city. Mruro/xroVa/ncj. 1983;l4:22O-4.
45. Joensen P. Prevalence, incidence, and classification of epilepsy in the Faroes. /<c/a A/wo/ Scam/.
1986.74:150-5.
46. Camfield CS, Camfield PR, Gordon K, Wirell E, Dooley JM. Incidence of epilepsy in childhood and
adolescence: a population based study in Nova Scotia from 1977 to 1985. £/j//«?/w/a. I996;37:19-23.
47. Kurtz Z, Tookey P, Ross E. Epilepsy in young people: 23 year follow up of the British national child
development study. ßW/ 1998:316:339-42.
48. Rantala H, Ingalsuo H. Occurence and outcome of epilepsy in children younger than 2 years. 7 /VdVa/r.
1999:135:761-4.
49. LUhdorf K, Jensen LK, Plesner AM. Epilepsy in the elderly: incidence, social function, and disability.
£/»/e/»ia. 1986:27:135-41.
50. Ishida S. Prevalence of epilepsy in Okayama prefecture: a neurocpidemiologic study. Fo//o Pnr/iial/-
Neuro/Jpn. 1985:39:325-32.
51. Cavazzuti GB. Epidemiology of different types of epilepsy in school age children of Modena, Italy.
£/»Vq»/a. 1980;21:57-62.
26 I Systematic review of incidence studies
APPENDIX 1. Checklist of incidence studies*
1. Definition of epilepsy, epileptic seizures
2. Type of study
3. Study population
a. Demography
b. Description of selection criteria
4. L-pilcpsy, epileptic seizuresf
5. Incidence}
Score
0
1
5
0
2
Dno
D yes -» D not clear
D clear
9 D prospective
4 D review of medical records
and reexamination of positive cases
3 D review of medical records
2 D survey and reexamination of
positive cases
1 D survey
Dno
Dyes
0 Dno
1 D yes -• D not clear
3 D clear
3 D epilepsy
2 D certain seizures
3 D unprovoked seizures
0 D epileptic seizures
(provoked and unprovoked)
D age adjusted incidence rates
D age specific incidence rates
D syndrome specific incidence rates
D sex-specific incidence rates
D cumulative incidence rates
0 D incidence rates
1 D time trends of incidence rates
•Maximal score: 30
tType of epilepsy or epileptic seizure of which the incidence was defined
{Maximal score on this item:
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Summary
e/ To provide insight into the recent evidence on risk factors and mechanisms that are
associated with non-epileptic seizures (NES).
A/e//io<&. Studies on the etiology of NES were selected by a Medline literature search from
January 1995 to December 1999. The methodological quality of the selected studies was
evaluated. In addition, in each selected study several items which can provide evidence about
the possible risk factors for NFS were assessed, such as: medical history, neuropsychological
testing, psychiatric assessment, reporting of possible causes and the use of control groups.
Ai.vu//.r. 33 studies met the inclusion criteria. There was a considerable heterogeneity in study
methodology, and the methodological quality score was generally low. 59% of the studies
included 25 cases or less. 56% did not have any control groups and the most frequent control
group consisted of patients with epilepsy (41%). The most frequently used
neuropsychological tests were the Dissociative Experience Scale (DES) (12.5%) the
Minnesota Multiphasic Personality Inventory (MMPI) (9%) and depression scales (9%).
f 7»m7u.v;'»n.v While several psychological factors may underlie the development and
maintenance of NES, no definite conclusions could be reached regarding their etiology. More
studies with an adequate methodology are required to identify the underlying mechanisms of
NES. These studies should preferably be prospective studies in populations unselected by
referral.
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INTRODUCTION
The etiology of non-epileptic seizures has been the subject of study in medical and psychiatric
literature for some time. Theories regarding the causes of these seizures are probably as
diverse as the phenomenology of this type of seizures.
Information about the mechanisms that underlie the onset of non-epileptic seizures (NES)
may assist in the early identification of patients with NES, and is therefore of primary
importance for the adequate and specific treatment of these patients, and for preventing
inappropriate, ineffective, and unnecessarily costly management.
NES have been studied by neurologists as well as by psychiatrists and are considered to be
psychiatric disorder which can be influenced by several environmental, and psychological
factors (1). They are defined as "a sudden disruptive change in a person's behavior, which is
usually time limited, and which resembles, or is mistaken for, epilepsy, but which in EEG
analysis is unaccompanied by the excessive electrical discharge of brain cells which indicates
true epilepsy, and is not caused by an organic disease" (2). Psychiatrists have often classified
NES as a symptom of a specific psychiatric disorder by using the Diagnostic and Statistical
Manual of Mental Disorders (DSM). whose most recent edition (DSM IV) was published in
1994 (3).
The purpose of our study was to review systematically the recent literature on the etiology of
NES in order to provide insight into recent evidence of the risk factors and mechanisms that
are associated with NES.
METHODS
Study selection
As our aim was to identify recently published studies on the etiology of NES, we searched the
Medline database from January 1995 (i.e. one year after the edition of DSM IV (3)) to
December 1999, using as search terms 17 synonyms for non-epileptic seizures:
hysteroepilepsy, hysterical seizures, hysterical epilepsy, pseudoepilepsy, pseudoseizures,
pseudoepileptic seizures, psychogenic seizures, psychoscizures, psychoepilepsy, psychogenic
nonepileptic seizures, psychogenic pseudoseizures, nonconversion noncpileptic seizures,
nonepileptic conversion seizures, nonepileptic attack disorder, functional seizures, simulated
epilepsy and emotional seizures.
For additional relevant articles, we also searched the references of review articles and of the
selected articles. Furthermore, we reviewed the abstracts produced by the literature search to
identify studies which focused on the risk factors for the development of NHS. Moreover, we
collected indexed studies for which an abstract was not available in the Medline database, and
evaluated whether they supplied information about the etiology of NES. We excluded studies
published in languages other than English, studies published as a narrative overview, as a
letter or in an abstract form only. If one study had several reports, we used the most recent
and complete cohort for analysis.
Evaluation of the selected studies
We developed a checklist (Appendix 1) in order to evaluate the methodological quality of the
selected studies and assess the information provided by these studies regarding the etiology of
NES.
In each study, the methodological quality was scored on the following items: adequacy of
definition, study design (a retrospective or a cross-sectional design), description of selection
criteria, identification of non-epileptic seizures (with an EEG or video-EEG monitoring), and
classification of the phenomenology of non-epileptic seizures (according to the epileptic
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seizures they resemble or to patterns of presentation (4). More specifically, we evaluated
whether NES had also been psychiatrically diagnosed and classified as a symptom of a
conversion disorder, since most of the NES can be classified as a Conversion Disorder with
Seizures or Convulsions (S).
We considered that for interpreting the results of a study, a clear definition of the NES and a
thorough description of the selection criteria of the patient population are needed.
In addition, we included in the checklist items which can provide evidence about the possible
risk factors for NES. These items are: medical history, neuropsychological testing, psychiatric
assessment, report of possible causes and use of control groups (patients with epilepsy or
patients with psychiatric disorders). Furthermore, we noted the number of cases included in
the empirical study and we assumed that the higher the number of cases included in a study,
the higher the statistical power of the results of the study. The total quality score of each study
is given in round numbers from 0 to 30.
Two authors (IK and 'I'M) independently evaluated all the included studies with this checklist
and reached a consensus, with the aid of a third author (FK) in cases of disagreement. The
degree of agreement was defined by using the Spearman correlation coefficient, a non-
parametric test.
TABLE 1. Results of Mcdline search regarding common terms of NES
Search term
Hyslcroepilepsy
Hysterical seizures
Hysteric«! epilepsy
Ptradoapilepsy
PMudoMlzurat
Pscudoepiteptlc seizures
Psychogenic seizures
Psychoseizures
Psychoepilepsy
Psychogenic non-epileptic seizures
Psychogenic pseudoseizures
Nonconversion non-epileptic seizures
Non-epileptic conversion seizures
Non-epileptic attack disorder
Functional seizures
Simulated epilepsy
Emotional seizures
Total
No of studies
0
1
0
0
S3
4
35
0
0
18
1
2
4
6
1
0
0
137
No of selected
studies
0
0
0
0
18
1
6
0
0
2
1
1
1
3
0
0
0
33
RESULTS
Selected studies
Our search identified 137 articles; 33 were selected according to the defined criteria (Table 1).
Excluded were 4 letters, 10 studies published in languages other than English, 15 overviews
and 75 studies because they did not supply any information about the etiology of NES. It
appeared that the most common terms for NES were pseudoseizures, psychogenic seizures
and psychogenic non-epileptic seizures. The terms hysteroepilepsy, hysterical seizures,
hysterical epilepsy, pseudoepilepsy, psychoseizures, psychoepilepsy, simulated epilepsy, and
emotional seizures seemed to be abandoned, probably because of their pejorative meaning (6).
These terms were commonly used in the 1960s and 1970s.
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Table 2 shows the basic study characteristics. Only 9 (7-15) of the 32 studies were published
before 1997.
TABLE 2. Baseline characteristics and quality score of studies of NES
Study Year No of cases Score
Aldenkamp (27)
Alper(I6)
Bowman (12)
Ferracuti (28)
Frances (29)
Bowman (30)
Deny (II)
Jawad(U)
Barry (31)
Rechlin (32)
Arnold (10)
Alper(15)
Harden (33)
Blumer (13)
Wyllie(34)
Berkhoff(35)
Krahn (9)
kalogjera (36)
Ney(37)
Sigurdardottir (38)
Etlinger (39)
Reilly (40)
Griffith (41)
Wood (42)
Bell (43)
Wolanczyk (44)
Carman! (8)
Breier (45)
Evans (46)
Kalogjera (47)
Moore (17)
Baker (7)
Methodological quality
The quality score ranged from 9 to 29 (median 17). The interrator agreement on the scale was
good (rho= 0.96, P= 0.0001). Most disagreement was caused by slight differences in
interpretation and was resolved easily (Fig. 1). Consensus was reached in all cases. Quality
score and publication year did not correlate (rho= -0.075, P= 0.68), showing that recently
published studies did not associate with a high quality score.
The majority of the studies (62.5% ) scored lower than 20, indicating insufficient
methodological quality. In particular, many studies (47%) did not have clear selection criteria
and 69% of the studies had no clear definition of NES. Only two studies diagnosed and
classified NES according to the DSM criteria as well (15, 16). With respect to the study
design, more than the half of the studies (56%) had a cross-sectional design. Unsurprisingly,
in 75% of the studies, patients with NES were identified with a video-EEG, a reliable
instrument for the diagnosis of NES (1). Furthermore, only a few studies (19%) classified the
phenomenology NES and in most cases they classified them according to the epileptic
seizures they resemble.
Only 41% of the studies included more than 25 cases and the maximum number of cases
included in a study was 185 (17). It appeared that the more cases a study included, the higher
1997
1997
1996
1999
1998
1999
1996
199S
1998
1997
1996
I99S
1997
199S
1999
1998
1995
1999
1998
1998
1999
1999
1998
1998
1998
1998
199S
1998
1999
1997
1997
1995
24
132
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16
30
58
24
46
37
18
14
91
2
21
38
10
6
S3
s14
56
40
14
9
13
1
2
25
1
SS
185
1
29
28
28
27
25
24
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22
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IS
18
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17
16
16
16
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15
15
IS
IS
14
14
12
11
11
10
9
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the methodological quality score: a linear regression model showed that there was a
significant relationship between the methodological quality score, calculated without the
score of the item "number of cases", and the number of cases included in a study (P=0.002).
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FIG. 1. Interrater disagreement
Ktiology
More than half of the studies reported the medical history of patients with NES, the possible
causes for these seizures, and evaluated the psychological aspects of patients with non-
epileptic seizures with neuropsychological tests and a psychiatric assessment. However, many
studies (56%) did not have any control groups. The most frequent control group consisted of
patients with epilepsy (41% of the studies). Only one study used psychiatric patients as
control group (14).
The most frequently used neuropsychological tests were the Dissociative Experience Scale
(DES) (12.5%), the Minnesota Multiphasic Personality Inventory (MMP1) (9%). and
depression scales (9%). However, many studies (34%) used other, less widely applied,
neuropsychological tests to evaluate patients with NES, such as the Neurobehavioral
Inventory (NBI). Perceived Stress Scale (PSS), Social Avoidance and Distress Scale (SADS),
Halstead-Reitan Neuropsychological Test Battery, and the Family Emotional Involvement
and Criticism Scale (FEICS).
Studies of NES suggested that several psychological factors may underlie the development
and maintenance of these seizures, such as mood disorders (e.g. anxiety, depression),
personality disorders (e.g. somatisation disorder), trauma, physical or sexual abuse,
relationship problems, family dysfunctioning, and stress.
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DISCUSSION
This systematic review indicates that no definite conclusions can be drawn regarding the
etiology of NES. The studies reviewed suggest that patients with NES tend to have been
exposed to various types of trauma (e.g. head trauma, sexual and physical abuse) and that
their families have generally disturbed patterns of communication (1. 18). In addition, several
co-morbid psychiatric diagnoses may contribute to the development and maintenance of NFS
(5).
The majority of the studies reviewed had a small sample size of cases, and usually identified
patients with NES in tertiary centers, which limits the value of their conclusions (19). Cases
derived from tertiary centers may cause a selection bias regarding the identification of risk
factors associated with NES, as these cases are often patients with long-standing NHS who
have been misdiagnosed with epilepsy (1, 20).
Although many of the reviewed studies attempted to identify precipitating events and
underlying mechanisms of NES by taking an adequate neuropsychiatric history, few studies
used control groups to obtain additional information regarding the risk factors for NFS. The
most frequent control group were patients with epilepsy, since epilepsy may coexist with
NES. Up to 20% of patients identified as having NES have been reported to have epileptic
seizures as well (21). In these studies, the association between possible risk factors and NES
is not expressed in terms of OR (odds ratio) or RR (relative risk), probably due to the small
sample sizes and the short follow-up period. Nonetheless, many patients with NFS do not
have epilepsy (21) and a number of psychiatric disorders may include NES in their symptoms
(1, 22). Thus, the choice of the control group (patients with epilepsy, patients with psychiatric
disorders or the general population) will depend on the purpose of the study. A study aiming
at the etiology of NES generally needs a control group different from that of a study whose
aim is to distinguish NES from other paroxysmal disorders (e.g. non-epileptic from epileptic
seizures).
With respect to the methodological quality of the reviewed studies, this systematic review
shows that studies of NES are characterized by a wide methodological heterogeneity and
generally have a low methodological quality. Therefore, the quality of evidence regarding the
possible risk factors for NES is low.
The definition of NES and the selection criteria of patients with NES were often unclear due
to a lack of consensus regarding the terminology of NES and of standardized methods to
assess patients with NES.
Patients with NES are a heterogeneous group with different symptomatology and underlying
psychopathology. For instance, men may have a different phenomenology of NES from
women (4), and long-standing NES are more likely to be found in patients with severe
personality disorders, whereas recent-onset NES are more likely to have occurred in patients
who have experienced extreme Stressors (23). Consequently, it is important to identify
subgroups of patients with NES. However, the studies reviewed have scarcely described and
classified patients with NES.
Depending on the symptom pattern, NES can be classified either according to their pattern of
presentation or to the epileptic seizures they resemble. Moreover, NES can also be diagnosed
and classified into three major DSM categories: somatoform disorders (i.e. somatisation
disorders, and conversion disorders associated with major or minor psychopathology),
factitious disorders and malingering (1). Francis et al. (24), however, argued that the DSM IV
classification lacks specificity to NES, given the heterogeneous presentation of these attacks.
Similarly, Trimble (20) pointed out that a subgroup of patients with NES may have no
apparent underlying neurological or psychiatric morbidity. Therefore, the DSM classification
cannot be applied to these patients and their attacks will remain unclassifiable.
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Furthermore, differences in theoretical approaches taken by researchers have resulted in
different neuropsychologica) tests and in surveys of different sets of psychopathological
conditions in patients with NES. For instance, in at least one subgroup of patients. NES can
be considered a dissociative phenomenon (18, 22, 25). In these patients, dissociation acts as a
central defensive mechanism to keep painful or unendurable affects out of conscious
awareness. This cognitivc-behavioristic theory (26) has been explored in 12.5% of the studies
reviewed by applying the DES to patients with seizures. Similarly, from a psychodynamic
perspective, certain personality types are associated with various diseases (24). Therefore, 9%
of the studies reviewed used the MMPI to measure specific attributes of personality in
patients with NES.
Such diversity in ncuropsychological tests gives rise to discrepancies, as it is difficult to
interpret and compare the results of the studies.
In sum, there are a number of factors which limit the value of the findings of the studies
reviewed: unclear definition and selection criteria, lack of standardized methods to assess and
describe patients with NHS (medical history, neuropsychological tests, psychiatric assessment
and classification), groups of patients selected (mostly from tertiary neurological centers),
small sample size, short follow-up and lack of control groups.
Thus, there is an urgent need for further studies of NES to identify the underlying
mechanisms of NHS. Such studies of NES should use a transparent methodology and analysis
of (he data, clearly describe the definitions used, the selection criteria of the population, the
way subtypes of patients with NKS were identified and patients with NES were assessed, the
choice of the control group and the limitations of the data. Prospective studies with a long
follow-up, and a large sample size, preferably from populations not selected by referral,
should be encouraged, as the studies published until now provide little evidence about the risk
factors for NES
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APPENDIX 1. Checklist of the methodological quality of studies of non-epileptic seizures
1. Definition
2. Number of cases in empirical
3.Diagnosis of NES
4. Selection criteria
5.History
6. Neuropsychological testing
7. Psychiatric assessment
8. Cause of NES:
9. Classification of NES:
10. Type of study t
11. Control group
Score
0
J
7
study /
J
7
2
0
2
0
J
0
2
0
J
0
2
0
2
7
7
0
2
1 Gno
2 Gyes-»
1 Gl
2D2-5
3 G 5-20
4 Ü >20
G clear
D not clear
1 G EEG
2 G Video-EEG monitoring
lDno
2 G yes ->
I Gno
2Gyes
1 Gno
2Gycs->
1 G no
2 G yes
1 G no
2 G yes
' G consistent with definition
D not/partly consistent with
definition
. UMMPI
ODES
D Depression Scales
D Anxiety Scales
G Coping Scales
D Other Scales
1 Gno
2 G yes, according to -> G imitated epileptic sz
0 presentation
1 G Retrospective
2 G Cross-sectional
1 G no
2 G yes -i• G patients with epilepsy
Q patients with psychiatric disorders
•Maximal score: 30
tThe literature search identified no prospective study that could be further evaluate
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Summary
To estimate the incidence of unprovoked seizures (US) and epilepsy in the area of
Maastricht in relation to age, sex, etiology and seizure type, and to identify predictive factors
of the epileptic and non-epileptic seizures.
A/e7/icuft>. All patients aged > 14 years residing within certain zip-code areas at time of their
first seizure or who had undiagnosed seizures before the study period were included. Patients
were identified from different sources and were independently evaluated and classified by a
team of neurologists. A predictive profile for the occurrence of epileptic and non-epileptic
seizures was obtained by step wise logistic regression analysis.
«MM//I: The overall annual incidence was 55/100,000 and 30/100.000 for US and epilepsy
respectively. The age-specific annual incidence of US and epilepsy increased with age and
reached 120/100,000 and 62/100,000 for the 2 65 years of age group respectively. In males
the incidence of epilepsy and US was higher than in females and partial seizures prevailed
over generalized seizures (40 vs. 9/100,000). The etiology was mainly cerebrovascular
disease and brain tumors Predictors for epileptic versus non-epileptic seizures of organic
origin were an epilcpliform KF.Ci pattern vs. a history of hypertension or cardiovascular
disease. Strong predictors for patients with seizures of non-organic origin were female sex
and head injury.
Canr/u.w'um ITic incidence of US and epilepsy (overall, and age-, sex-, seizure-specific) was
similar to those reported by other developed countries. The predictive factors found in this
study may assist in the early diagnosis of seizures.
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INTRODUCTION
Prospective population-based studies on the occurrence of epilepsy provide information
regarding the incidence, natural history, associated mortality and risk factors for epilepsy.
Furthermore, with these studies a more complete case ascertainment can be achieved, while
excluding non-epileptic disorders, in order to investigate the distribution of epilepsy by
etiology and prognosis and to determine initial treatment and management strategies.
In several countries the incidence of epilepsy has been studied but only a few of these studies
had a prospective population-based approach In the Netherlands, so far. no incidence study of
epilepsy has been performed.
This chapter is based on an epidemiological project of seizure disorders in Dutch adolescents
and adults in the area of Maastricht. The purpose of the presented prospective population-
based study was to estimate the incidence of unprovoked seizures and epilepsy in a well-
defined population in relation to age. sex, etiology and seizure type, and to compare the
results with that of incidence studies in other countries. It also focused on the characteristics
of the cohort with epileptic and non-epileptic seizures with the aim to identify predictive
factors of the several seizure types. Thus, these factors can enable the diagnostic process of
epileptic seizures.
METHODS
Study population
The study was conducted from October 1. 1998 to September 30. 2000 in Maastricht and its
surroundings, which is a well circumscribed area located at the southern part of the
Netherlands. Its total population on December 31. 1999 was 190.860 and it is representative
of the overall population of the Netherlands in terms of age, sex and ethnic structure. 83.4%
of the population were aged S14 years old and comprised of 48.5% males and 51.5% females
(Central Bureau of Statistics, the Netherlands). The health facilities in this area, which lies
within the zip-code areas 6200 to 6299, consist of 90 general practitioners, three nursing
homes and one hospital, the Maastricht University Hospital.
Case ascertainment
Multiple overlapping strategies were used to identify cases. First, before the start of the study
and every two months during the study, we supplied information to all general practitioners
and to the physicians and nurses of the nursing homes. All general practitioners in the study
area were asked to refer patients with newly diagnosed seizures directly to the investigators.
Second, we asked all residents of neurology, neurologists and child neurologists to refer
patients with seizure-like disorders identified at the emergency room, department of
neurology or other hospital departments, and at the outpatient department of neurology. In
addition, we surveyed the medical files of all the individuals who had received the diagnoses
syncope, convulsion, epilepsy or attacks of unknown type during the inclusion period of the
study to find patients who had not been reported through other sources. Furthermore, we
regularly scrutinized all EEGs and neuroradiology reports performed during the study in order
to overcome the problem of identifying patients who had not been admitted or had been
miscoded on hospital discharge data. The medical files of all persons identified in this process
were evaluated and, whenever possible, these patients were reexamined. All identified cases
were examined in a standardized manner by one of the authors (IK) (medical history, physical
and neurological examination). Blood screening tests and an ECG were performed in all
cases. EEG (standard and/or sleep deprived), radiological examinations of the brain (CTs or
MRIs), and video EEG were performed if indicated for a more precise diagnosis.
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Inclusion and »elusion criteria
All individuals aged £ 14 years who were residents in the investigated area at the time of their
first seizure were included. Included were also patients who had undiagnosed seizures before
the study period and had not received any antiepileptic drugs yet. Children with seizures aged
between 0 and 13 years were not included in our study since we had not the possibility to
(re»examine these cases (these children are referred to pediatricians and child neurologists).
Excluded were all patients who had an acute symptomatic seizure.
Nursing homes
During one year, the nurses in the nursing homes provided monthly reports of all residents
with seizures and their possible cause. They also reported the age and sex of these patients
and if they had been treated with antiepileptic drugs before the study period. Some of these
elderly patients had not been referred to the department of Neurology and, therefore, were not
examined by one of the authors and did not have any EEG or neuroradiological investigation.
For reasons of confidentiality we could not define the number of these patients and we were
not able to review the medical files of the reported cases in the nursing homes in order to
obtain more information about their seizures and their possible etiology. Thus, for the
determination of incidence, cases from nursing homes were analyzed separately from the
other cases. If for these patients a known remote symptomatic cause had been reported, it was
considered as the cause of the seizures; if not. the seizures were determined as unclassified.
Definitions
The seizure that led the patient to seek for medical advice (general practitioner, emergency
room, or outpatient department of neurology) was defined as index seizure.
Epilepsy and epileptic syndromes were defined and classified by seizure type (partial and
generalized seizures) and etiology (remote symptomatic, cryptogenic, idiopalhic) according to
the Commission on Classification and Terminology and the Commission on Epidemiology
and Prognosis of the International League Against Epilepsy (ILAE) (1-3).
The incidence of unprovoked seizures was defined as the number of patients with a first
unprovoked seizure per 100,000 inhabitants at risk per year. The incidence of epilepsy was
defined as the number of new cases with epilepsy in a population at risk per 100,000 person-
years. The denominator for the incidence was the number of residents aged > 14 years at the
census year 1999.
Diagnosis and classification of cases
Two authors (the neurologists MdK and JL) independently evaluated all cases and classified
the patient's index seizure as an epileptic seizure, a non-epileptic seizure of organic origin
(e.g. syncope, benign drop attacks), or a non-epileptic seizure of non-organic origin (e.g.
panic attacks, hyperventilation attacks, non-epileptic psychogenic seizures). The classification
of cases was based on the clinical manifestations, EEG findings, neuroimaging findings,
laboratory and ECG data acquired within six months after the index seizure. As such, for all
cases there is a first diagnosis, obtained immediately after the index seizure, and a definite
diagnosis obtained six months after the index seizure. For statistical analysis, only the definite
diagnosis was token into account. In cases of disagreement a consensus was reached with the
aid of a third neurologist (the author JT).
The two neurologists (MdK. JL) also classified all cases with unprovoked seizures or epilepsy
by seizure type and etiology according to the classification proposed by the ILAE (1.2).
based on the clinical description of the seizures and on data from ancillary tests. For instance,
a patient with generalized seizures and focal findings on EEG or neuroimaging was classified
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as having localization-related epilepsy and secondarily generalized seizures. Patients in the
category of undetermined epilepsy or unclassified seizures had no sufficient seizure
description with normal or lacking EEG and neuroimaging findings. A single seizure
irrespective of the EEG and neuroradiological findings was classified as an isolated seizure.
This seizure could be partial, generalized or unclassified.
Statistical analysis
The percentage distribution of all incident cases was computed by seizure type and etiology.
Age-specific and sex-specific incidence rates were also determined.
Furthermore, predictive factors for the diagnosis of epileptic and non-epileptic seizures were
examined by means of logistic regression analysis. The following variables were entered into
the predictive model: age. sex, living situation (e.g. living alone or with others), occupation
(e.g. full-time, part- time, unemployed), education level (e.g. low or high), concomitant
diseases (e.g. head injury, depression, cardiovascular diseases), family history of epilepsy,
febrile seizures, medication (e.g. against hypertension or diabetes), provoking factors (alcohol
abuse, sleep deprivation, tiredness, and stress), and findings from diagnostic procedures
(EEG, CT and MR1). The variable age, which is the only continuous variable, was
transformed into a categorical variable according to the age limits defined by the Central
Bureau of Statistics for the general population (i.e. 14-24, 25-44, 45-64. and £65 years). A
predictive model was obtained by stepwise logistic regression retaining only the most strongly
related variables. Ninety-five percent confidence intervals (CI) for the statistically significant
predictive factors were calculated. Two outcome contrasts were defined. First, the
unprovoked seizures and non-epileptic seizures of organic origin were compared to the non-
epileptic seizures of non-organic origin. Second, the unprovoked seizures were contrasted
with the non-epileptic seizures of organic origin. In total, the first predictive model included
25 predictors for 313 cases, and the second predictive model included 22 predictors for 252
cases. As a form of sensitivity analysis and to ensure the entry of variables with coefficients
different from zero, we successively used as a criterion for the inclusion of a variable the
values 0.05,0.15, and 0.20, as recommended by Hosmer and Lemeshow (4).
RESULTS
Study population
A total of 350 cases was entered in the study. This sample consisted of 163 (46.6%) men and
187 (53.4%) women aged between 14 and 92 years (mean, 49 years for men and 51 years for
women). In all, 71.1% of the patients were examined in a standardized manner by one of the
authors (IK) whereas 28.9% of the patients were not seen by this author. This last group of
patients was consisted mostly of patients who had a bad clinical condition at the time of their
admittance and were usually discharged to the nursing homes directly. In a few cases, this last
group of patients included patients with a known neurological disease such as brain tumor or
cerebrovascular disease. These patients were often referred to the neurologists who had seen
them regularly at the outpatient department of neurology.
Unprovoked seizures were diagnosed in the majority of the cases (49.7%), followed by the
non-epileptic seizures of organic origin (22.3%), the non-epileptic seizure of non-organic
origin (18%), and the acute symptomatic seizures (7.7%). In 8 cases (2.3%) no definite
diagnosis could be determined due to lack of data. Ninety-four (54%) of the 174 cases with
unprovoked seizures fulfilled the diagnostic criteria for epilepsy as they appeared to have had
two or more recurrent unprovoked seizures.
A neuroimaging study and an EEG was conducted in most of the cases. Specifically, in 125
(72.7%) patients with unprovoked seizures and in 74 (78.7%) patients with epilepsy a CT
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TABLE 1. /00.000/year>
Age group (yr)
14-24
25-44
45-64
265
Totti
Sex
Male
Female
n
26
29
55
64
174
90
84
US
Incidence
59.7
25.3
514
119 7
54.6
58 3
51.2
Epilepsy
n
14
16
31
33
94
47
47
Incidence
32.2
13.9
29.0
61.7
29.5
30.4
28.6
scan was performed whereas in 66 (38.4%) patients with unprovoked seizures and in 38
(40.4%) patients with epilepsy a MRI was performed. Furthermore, 140 (80.4%) patients with
unprovoked seizures and 74 (78.7%) patients with epilepsy had an EEG (standard and/or
sleep deprived).
With respect to the unprovoked seizures, in 45.7% of the cases the first seizure was also the
index seizure. Only 17.9% of the cases had more than five recurrent unprovoked seizures
before the index seizure. In more than half of the patients (62.4%) the first seizure had
appeared in u period of less than a month whilst a few patients (14.4%) had experienced their
first sei/ure more than 12 months ago before admittance to the study. The duration of the
index seizure was less than one minute in 6.2% of the patients, between one and five minutes
in 55%. between five and 15 minutes in 34.9%, and more than 15 minutes in 3.1%. It
appeared that more than half of the patients who had seizures lasting less than one minute
had experienced five of more recurrent unprovoked seizures before the index seizure (53.1%).
The nursing homes reported 16 cases with epileptic seizures, five of whom had recurrent
epileptic seizures. The mean age of these patients was 78.2 years and the most frequently
reported cause of their seizures was cerebrovascular disease.
TABLE 2. /4ge-.speci/i
Seizure type
All partial
Simple partial
Complex partial
Secondarily generalized
All generalized
Primarily generalized
Absences
Atonic
Total
fence (per
14-24
n
II
-
2
9
II
10
1
.
22
Incidence
25.3
-
4.6
20.7
25 3
22.3
2.3
.
50.6
/00,000/year; q/se/zwrcr
Age groups (yr)
25-44
n
15
2
4
9
8
8
.
23
Incidence
13.1
1.7
3.5
7.8
6.9
6.9
20.1
45-64
n
47
6
4
37
7
6
.
1
54
Incidence
43.9
5.6
3.7
34.6
6.5
5.6
.
0.9
50.5
265
n
54
8
11
35
2
2
56
Incidence
101.0
14.9
20.6
65.5
3.7
3.7
.
-
104.8
Total
Incidence
39.9
5.0
6.6
28.3
8.8
8.2
0.3
0.3
48.7
Annual incidence of epilepsy and unprovoked seizures
The overall annual incidence was 55 cases with unprovoked seizures and 30 cases with
epilepsy per 100.000 person-years (Table 1). The age-specific incidence for unprovoked
seizures and epilepsy increased with age and reached 120/100.000 or 62/100,000 for the >65
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age group respectively. If in this age group the cases from the nursing homes would be added
then the age-specific incidence for unprovoked seizures and epilepsy would increase further
to 180/100.000 or 80/100,000 respectively. In males the incidence of both epilepsy and
unprovoked seizures was higher than in females. The age-specific distribution of the
incidence of epilepsy and unprovoked seizures for both males and females was similar with
the age-specific distribution of these incidences in the total population.
TABLE 3. .dge-specj/zc incidence (per 700.000/)*ar) o/ep;7</My />>• Y
Syndrome
Localization-related
epilepsies
ldiopathic
Symptomatic
Cryptogcnic
Generalized epilepsies
and syndromes
ldiopathic
Symptomatic
Cryptogenic
Unclassified
Total
14-24
n
-
4
4
4
-
1
4
17
Incidence
-
9.2
9.2
9.2
-
4.6
9.2
39.1
Ages
25-»4
n
1
3
4
2
-
2
9
21
Incidence
0.9
2.6
3.5
1.7
-
1.7
7.8
18.3
iroups (yr)
45-64
n Incidence
1
12
9
2
1
-
7
32
0 9
11.2
8.4
1.9
0.9
-
6.5
299
2*5
n
1
27
5
2
1
-
7
43
Incidence
19
50.5
9 3
3.7
1.9
-
13.9
80.5
Total
Incidence
09
144
6.9
3.1
06
0.9
85
35.5
TABLE 4. Frequency o/e7»o/ogicfactors iew/.v wifA wnprowiteJ *<?/zure5
CT or A/Ä/
Etiologic factors on CT US Epilepsy
Frequency Frequency
lschemic stroke
Intraccrcbral hemorrhage
CNS tumor
CNS metastases
Others
Etiologic factors on MRI
lschemic stroke
Intracerebral hemorrhage
CNS malformation
Mesial temporal sclerosis
CNS tumor
CNS metastases
Others
28
1
II
11
10
11
1
1
3
10
5
20
16.3
0.6
6.4
6.4
5.8
6.4
0.6
0.6
1.7
5.8
2.9
11.6
18
-
6
8
4
7
-
-
3
6
3
10
19.1
-
6.4
8.5
4.2
7.4
-
-
3.2
6.4
3.2
10 6
CNS, central nervous system.
The total incidence of partial seizures was 40/100,000 and that of generalized seizures was
9/100.000. The highest incidence of generalized seizures was in the 14-24 years of age group
and thereafter it decreased continuously with increasing age. In contrast, the incidence of
partial seizures was highest in the >65 age group and lowest in the 14-24 years of age group.
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The incidence of localization-related epilepsies prevailed over that of the generalized
epilepsies and syndromes. The incidence of localization-related epilepsies peaked in the
oldest age group. In this group of patients the incidence was highest for symptomatic epilepsy
syndromes followed by cryptogenic and idiopathic localization-related epilepsies. The
generalized epilepsies and syndromes were most frequent in the youngest age group. Among
the generalized epilepsies and syndromes the idiopathic syndromes had the highest incidence
in this age group. Only 27 (16.7%) cases could not be classified according to the syndrome
classification of epilepsy.
For the group of patients with unprovoked seizures it was possible to identify a predisposing
cause in 35.5% or 29.6% of all the cases on the CT or MRI respectively. In comparison, for
the group of patients with epilepsy a possible cause was identified in 38.3% or 30.8% of all
(he cases on the CT or MRI respectively (Table 4). Ischemic stroke, followed by central
nervous system (CNS) tumors and mctastases, were the most frequent found causes of
unprovoked seizures and epilepsy. Mesial temporal sclerosis was present only in 1.7% and
3.2% of all patients with unprovoked seizures or epilepsy respectively.
TABLE 5. fi
Predictors for
/jr«/ic/(ve
/fcru/tt o/
OR(95%CI)
NF.S of non-organic
origin
Age groups (yr)
45-64
£65
Sex
Female
EEG
Epileptiform
discharges
CT
abnormal
History of head
injury'
0.42 (0.19-0.94)
0.13 (0.45-0.41)"
2.2 (1.15-4.06)
0.18 (0.50-0 62)
0.13 (0.31-0.59)
2.4 (I.I 1-5.18)
Predictors for NES
of organic origin
History of
hypertension
History of CV
disease
EEG
Epileptiform
discharges
2.8 (1.10-7.09)
5.4 (1 89-15.61)
0.06 (0.02-0.26)
iv ra/»Yw fO/ty w/7/i 95% con/IdW/ice »n/erva/j ("95% C
./iic/ors /for f/ie e/j»/e/?//c am/«ort-ep/7e/J/ic seizures.
f/»e mu/fip/f /o^f«/i'c re/jrMjiow ana/y.j/.s
US and NES of organic origin
n-252
Prevalence
n
83
85
131
46
68
43
US
n-174
Prevalence
n
18
13
43
(V.)
32.9
33.7
51.9
23
27.3
17
(V.)
14
10
31
7) o//Ae
NES of non-organic origin
n-63
PreYllcn.£C.
n
19
5
42
3
2
16
(%)
30
S
67
7
3
26
NES of organic origin
n=78
Prevalence
n
11
II
3
(%)
21
21
S
US, unprovoked seizures: NES, non-epilcp»ic seizures; CV, cardiovascular.
°pv0 0l
* Added after changing the significance level into p**0.15 or 0.20
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Predictors for epileptic and non-epileptic seizures
Table 5 shows only the predictive factors for epileptic and non-epileptic seizures that
appeared to be statistically significant from the logistic regression analysis. Older age. an
epileptiform EEG pattern, and an abnormal CT were more likely to appear in patients with
unprovoked seizures and non-epileptic seizures of organic origin than in the group of patients
with non-epileptic seizures of non-organic origin. Alternatively, the latter group was
significantly associated with a history of head injury and included more females than the
group of patients with seizures of somatic origin.
Furthermore, a history of hypertension and cardiovascular disease were significantly
associated with non-epileptic seizures of organic origin whereas an epileptiform HEG pattern
was more likely to be found in the group of patients with unprovoked seizures only.
DISCUSSION
In this prospective population-based study the total incidence of unprovoked seizures and
epilepsy was calculated and certain predictive factors of the epileptic and non-epileptic
seizures were identified.
In this study a strong effort was made to identify all possible cases and to avoid selection bias.
Therefore, the surveillance procedure used several sources to identify cases and all cases were
discussed collectively and decisions were consensus-based. In addition, in the Netherlands a
patient with a seizure, even if he or she has experienced this seizure in a region outside the
region of his of her residency, is likely to visit his or her general practitioner. Thus we assume
that the case ascertainment was reasonably complete.
Furthermore, this study can contribute to a comprehensive characterization of seizures and
epilepsy, since it is population-based. Population-based studies have the advantage to provide
a representative sample to carry out unbiased evaluations of several variables of interest (5,
6).
Concerning the unprovoked seizures, it appeared that in 45.7% of the cases the first seizure
was also the index seizure and in more than half of the patients (62.4%) the first seizure had
appeared in a period of less than a month before admittance to the study. Furthermore, in the
majority of the cases, the duration of the index seizure varied between one and five minutes or
five and 15 minutes. As expected, only in a few cases (6.2%) the index seizure lasted less than
one minute. More than half of these patients (53.1%) had experienced five of more recurrent
unprovoked seizures before the index seizure. It is likely that these patients probably
experience mild seizures which may not be recognized immediately and so do not prompt a
doctor's visit.
The total annual incidence of unprovoked seizure in the present study (55/100,000) is similar
to results from US American studies (61/100,000) (7), (50.9/100,000) (8), from Sweden
(56/100,000) (9), and from Switzerland (45.6/100,000) (10).
Similarly, the overall incidence of epilepsy in this study (30/100,000) is of the same order as
those documented in other population-based studies in industrialized countries: in the USA
35.5/100,000 (8), 44/100,000 (7), and 48.7/100,000 (11), in the Faroes 42.8/100,000 (12), in
Iceland 46.5/100,000 (13), in Italy 33.1/100,000 (14), and in Finland 24/100,000 (15).
Differences in the overall incidence of unprovoked seizures and epilepsy in the several studies
are, in part, due to different case ascertainment methods and due to the varying age
distribution of the population across the countries.
The age-specific incidence in the present study increases with age in concordance with other
studies in developed countries. This increase of age-specific incidence is found for both the
unprovoked seizures and epilepsy and, in particular, most studies have reported a significant
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increase of incidence in the elderly (9, 13, 16-19). In addition, a large prospective population-
based study in the UK has observed that most of the incident cases were recruited among the
elderly (20, 21).
In the present study, the incidence of unprovoked seizures and epilepsy is higher for males
than for females and the age-specific distribution for both males and females is similar with
the age-specific distribution of these incidences in the total population. The same pattern has
also been found in other incidence studies (7, 11, 13-15, 20, 22).
The classification of epileptic seizures and syndromes, as it has also been stressed by other
authors (23, 24), depends highly on the use of ancillary tests (EEG, neuroimaging studies).
Berg et al. (25) demonstrated that it is possible to identify and classify a large part of the
epilepsy syndromes in children accurately early in the course of the disorder depending on the
quality and extent of the information available at the time of the initial diagnosis. They (25)
found that two years after the initial diagnosis in only 9.8% of the cases a rectification was
needed. Approximately 80% of the cases with unprovoked seizures or epilepsy in this study
was evaluated with an EEG, CT or MRI. This high rate of diagnostic tests permitted a
classification of epileptic seizures and syndromes in most of the cases. However, 10.9% of the
epileptic seizures and 28.7% of the epilepsy syndromes remained unclassified due to the
limited data. The relatively high proportion of unclassified epilepsy syndromes found in our
study compared to other studies (23.3% in the study by Manford et al. (26), 18% in the study
by Zarclli ct al. (27), 2.6% in the study by Loiseau et al. (28), and 1.4% for the group of
patients with more than one seizure at diagnosis in the study by Jallon et al. (23)) reflects
partly differences in the interpretation of the ILAE classification system. For instance, Jallon
ct al. (23) and Loiseau ct al. (28) classified also cases after a single epileptic event whereas in
our study a syndromic diagnosis was limited to the cases with epilepsy.
In the present study, the incidence of all partial seizures is markedly higher than the incidence
of all generalized seizures, which corroborates with the findings from other incidence studies
(7, 9, 11, 12, 22). The majority of the partial seizures was secondarily generalized whilst the
majority of the generalized seizures was primarily generalized. These differences in the
incidence of certain seizure types reflect distribution differences across the age groups.
Certain seizure types such as absences are seldom observed after midlife and some seizure
types are characteristic of specific epilepsy syndromes which are more likely to occur at
younger age (i.e. myoclonic seizures in patients with juvenile myoclonic epilepsy, absences in
patients with juvenile absence epilepsy). Moreover, the distribution of certain seizure types
and epilepsy syndromes depends on the prevalence of different etiologic factors in each age
group. For example, in the present study, complex partial seizures, secondarily generalized
seizures and localization-related symptomatic epilepsy occurred more often in the elderly.
This is in accordance with other studies (23, 27) which report an increase of localization-
related symptomatic epilepsy in the elderly. Elderly patients often have concomitant
neurodegenerative, cerebrovascular, or neoplastic disease which can give rise to partial
seizures (29, 30). Stephen et al. (30) stated that the most common cause of seizures in the
elderly is cerebrovascular disease (49%), followed by tumors (up to 45%), and head injury
(up to 21%).
In most of the population-based incidence studies the proportion of cases with an identified
cause ranges from 23% to 39% (31). Equally, in this study, in approximately 35% of the
patients with epilepsy or epileptic seizures an underlying cause could be identified. The most
common causes were cerebrovascular disease and brain tumors. These results are in keeping
with the literature (32).
In the present study, we also focused on predictive factors which may discriminate patients
with epileptic seizures from patients with non-epileptic seizures. As expected, the strongest
predictor for patients with epileptic seizures is an epileptiform EEG pattern. Similarly, for the
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group of patients with non-epileptic seizures of organic origin, there is a high probability of a
history of hypertension or cardiovascular disease which may be assumed as the underlying
causes of their seizures. Furthermore, older age, which is frequently correlated with
concomitant diseases, an abnormal EEG pattern and CT were more likely to appear in the
group of patients with seizures of somatic origin. These items can be regarded as factors
associated with several underlying causes that can give rise to seizures and result in abnormal
findings on CT and EEG. Alternatively, the predictive model for the group of patients with
non-epileptic seizures of non-organic origin included the factors female sex and a history of
head injury. Females appear to account for a large proportion of the non-epileptic seizures of
psychogenic origin, and head trauma has recently been recognized as one of the provoking
factors for this type of seizures (33, 34). However, the reason for these findings is not entirely
clear. Sociologic and cultural factors may account for the high incidence of seizures of non-
organic origin in women. In addition, head trauma may occur as a consequence of physical
abuse, which may be quite common in patients with this type of seizures (34). Head trauma
can also be considered as an independent factor that causes stress in susceptible individuals.
Non-epileptic seizures arc often misdiagnosed as epileptic seizures. Obviously, in case of a
single seizure, the potential of misdiagnosis is increased. The predictive factors found in this
study may assist clinicians in the diagnosis of seizures. Hence, based on certain issues such as
findings from diagnostic tests (CT or EEG), they may distinguish patients with epileptic
seizures from patients with non-epileptic seizures. However, it should be noted that in case a
patient experiences both types of seizures (i.e. epileptic and non-epileptic seizures) probably
more predictive factors are needed for an accurate diagnosis.
We conclude that the incidence of unprovoked seizures and epilepsy found in this study
(overall, and age-, sex-, seizure-specific) was similar to those reported by other developed
countries and that certain factors appeared to be strong predictors for the epileptic and non-
epileptic seizures. These findings need to be verified by other prospective population-based
studies with larger samples of patients. Moreover, these studies can provide additional
predictive factors enabling an early diagnosis of the epileptic and non-epileptic seizures.
50 I Incidence of epilepsy and US
REFERENCES
1. Commiiiion on Classification and Terminology of the International League Against Epilepsy. Proposal
for revised classification of epilepsies and epileptic syndromes £p//epj/<3 1989,30:389-99.
2. Commission on Epidemiology and Prognosis, International League Against Epilepsy Guidelines for
epidcmiologic studies on epilepsy £pi/ep.jia 1993:34:592-6
3. ILAE Commission Report.The epidemiology of the epilepsies: future directions. £pi/epj;a.
1997,3« 614-8
4. Hosmer DW, Lcmcshow S. /</>p/i«//^>j;u;/c Äe>;/-«jion New York: Academic Press: 1989.
5. Knottncrm JA, Leffers P The influence of referral patterns on the characteristics of diagnostic tests. 7
(7m £/»</rm;»/. 1992;45:1143-54
6. Knottnerus JA The effects of disease verification and referral on the relationship between symptoms
•ltd diseases AS*/ DCCM MaJt/zig 1987.7 139-48
7. Hauler WA. Anneger» JF, Kurland LT Incidence of epilepsy and unprovoked seizures in Rochester.
Minnesota: 1935-1984 fy/fc/u/o 1993.34 453-68
S. Annegcrs JF. Dubinsky S, Coan SP, Newmark ME, Roht L The incidence of epilepsy and unprovoked
seizures in multiethnic, urban health maintenance organizations. £/7//*pjia 1999:40:502-6.
9. Fongren L, Bucht O. Eriksson S. Bergmark I. Incidence and clinical characterization of unprovoked
seizures in adults: a prospective population-based study. £/>;/e/»ia. 1996.37 224-9
10. Jallon P, Ooumaz M. Haenggeli C, Morabia A. Incidence of first epileptic seizure in the canton of
(iencva. Switzerland £/>f/<pj«j. 1997.38 547-52
11. Mauser WA. Kurland LT The epidemiology of epilepsy in Rochester, Minnesott, 1935 through 1967.
£/>//r/Mi<i 1975,16 1-66.
12. Joensen P Prevalence, incidence, and classification of epilepsy in the Faroes. /4c/c Afacro/Scam/.
1986.74 150-5
13. Olafsson fc. Hauser WA. Ludvigsson P, Gudmundsson G. Incidence of epilepsy in rural Iceland: a
population-based study £/»/«/MI<J 1996.37 951-5
14. Granieri E, Rosati G, Tola R, el al. A descriptive study of epilepsy in the district of Copparo, Italy,
1964-1978 £/></<r/M/<f 1983:24:502-14
15. Kertnen T. Riekkinen Pj. SillanpU M Incidence and prevalence of epilepsy in adults in Eastern
Finland. £pi/<yMia. 1989:30:413-21
16. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of
population-based studies from Rochester, Minnesota. A/oyo C/in /"roc. 1996;7l(6):576-86.
17. LUhdorf K. Jensen LK, Plesner AM. Epilepsy in the elderly: incidence, social function, and disability.
£/»/<yui<i. 1986:27:135-41.
18. Loiseau J. Loiseau P, Duche B. Guyot M. Danigues JF, Aublet B. A survey of epileptic disorders in
Southwest France: seizures in elderly patients. /4n/i AVuro/. 1990:27:232-7.
19. Tallis R, Hall G, Craig I, Dean A. How common are epileptic seizures in old age? /(ge am/ agemg.
1991:20:442-8.
20. Everitt AD, Sander JW. Incidence of epilepsy is now higher in elderly people than in children. BMV
1998:316:780
21. Sander JW, Hart YM. Johnson AL, Shorvon SD National General Practice Study of Epilepsy: newly
diagnosed epileptic seizures in a general population, /.ancff. 1990:336(8726):1267-71.
22. Forsgren L. Prospective incidence study and clinical characterization of seizures in newly referred
adults. £p(/e/Mia. 1990:31:292-301.
23. Jallon P, Loiseau P. Loiseau J. Newly diagnosed unprovoked epileptic seizures: presentation at
diagnosis in CAROLE study £/>//epjia. 2001:42.464-75.
24. Sander JW, Shorvon SD. Incidence and prevalence studies in epilepsy and their methodological
problems: a review. 7 AVuro/ \ewrajurx />jyc*ia«T 1987:50:829-39.
25. Berg AT. S.Shinnar, Levy SR, Testa FM, Smith-Rapaport S. Beckerman B. How well can epilepsy
syndromes be identified at diagnosis? A reassessment 2 years after initial diagnosis. £pi/e/u/a.
2000:41:1269-75.
26. Manford M, Hart YM. Sander JW. Shorvon SD The National General Practice Study of Epilepsy. The
syndromic classification of the International League Against Epilepsy applied to epilepsy in a general
population /<rc/i N*ur<>/. l992;49(8):801-8.
27. Zarelli MM. Beghi E. Rocca WA. Hauser WA Incidence of epileptic syndromes in Rochester.
Minnesota: 1980-1984. £ju/cp»a. 1999:40:1708-14.
28. Loiseau J. Loiseau P. Guyot M. Duche B. Dartigues JF. Aublet B. Survey of seizure disorders in French
southwest I Incidence of epileptic syndromes. E/»I7?/MI<J 1990:31:391-6.
29. Sundaram MB. Etiology and patterns of seizures in the elderly. A/furofp/</emio/c>gi-. !989;8(S):234-8.
Chapter 4 I 51
30 Stephen U . Brodie Ml Epilepsy in elderly people. LdficM. 2OOO;35S: 1441-6.
31 Hauser WA Incidence and prevalence. In: jr JE. Pedley TA. eds. £^>j/«pjy ^ conyyvAemh* fcr/fcoo*
Philadelphia Lippincon-Raven Publishers: 1997:47-57.
32. Annegers JF, Rocca WA, Hauser WA. Causes of epilepsy: contributions of the Rochester epidemiology
project Maryo C/m /Vor. l996;7l(6):57O-5.
33. Merode Tv, Krom MCTFMd. Knottnerus JA. Gender-related differences in non-epileptic attacks: a
study of patient's cases in the literature. Sriru/v I997;6:3II-315.
34 KCrumholz A. Nonepileptk seizures diagnosis and management. ,VVu/-o/ogv l999;53(Suppl. 2):S76-S83
32 I Incidence of epilepsy and US
CtM(*er$| 53
The diagnosis of epileptic and non-epileptic seizures
Authors: Kotsopoulos IAW, de Krom MCTFM, Kessels FGH, Loddcr J, Troost J, Twellaar
M, van Merode T, Knottnerus JA
54 I The diagnosis of epileptic and NES
Summary
/'wr/wse; To define systematically a cluster of diagnostic items which can assist in the early
identification of epileptic and non-epileptic seizures.
Mt'//)ot/v A cohort of patients aged > 14 years, suspected with a first seizure, were included in
this prospective population-based study. A team of neurologists evaluated and classified all
cases. Diagnostic items for epileptic and non-epileptic seizures were examined with a
multiple logistic regression analysis.
Ät-.vü/f.v In total 350 cases were entered in this study. Certain distinctive features were
identified for epileptic and non-epileptic seizures of organic origin (e.g. postictal confusion,
an cpilcptiform 1'lXi pattern, and abnormal neuroimaging findings vs. a history of
hypertension, and provoking factors such as exercise and warmth). Patients with seizures of
non-organic origin were characterized with items such as a history of febrile seizures,
treatment by a psychologist or psychiatrist, presentiment of the seizure (e.g. feeling of
choking, palpitations), a history of chronic obstructive pulmonary disease, gradual end of
seizure, and memory of seizure. A separate analysis for the patients who were systematically
investigated provided some additional diagnostic items for the different subgroups of patients.
For instance, back arching during the seizure for the patients with seizures of non-organic
origin and female sex for the patients with non-epileptic seizures of organic origin.
(V>m7u.v/on.v A number of diagnostic items differentiating patients with epileptic from
puticnts with non-epileptic seizures was identified. ITicsc items can improve the accuracy of
the diagnosis and classification of epileptic seizures at an early stage.
Chapter S| 55
INTRODUCTION
Despite several developments in the investigation of epilepsy, including functional magnetic
resonance imaging (fMRI). magnetoencephalography (MEG), and improvements in video-
EEG monitoring technology, there is still no test sufficiently sensitive or specific enough to
reliably diagnose epileptic seizures. As such, the diagnosis of epilepsy is mainly a clinical
one. A corollary is that a correct diagnosis and classification of epileptic seizures depends
highly on the extent and quality of evidence acquired at time of initial diagnosis and on
additional evidence accumulated over time. However, as yet, it is not clear which items of the
history and which findings of the physical examination and of diagnostic tests arc of
particular importance for the diagnosis of epilepsy and epileptic seizures.
Population-based studies conducted in a well-defined population have the advantage that they
can contribute to a comprehensive characterization of seizures and epilepsy. They provide a
representative sample to carry out unbiased evaluations of several variables of interest (1.2).
In this prospective population-based study, we attempted to define in a systematic way which
criteria can assist in the early identification of epileptic and non-epileptic seizures and can
improve the accuracy of their diagnosis and classification. Tor this purpose, we evaluated in a
standardized manner all patients with possible epileptic seizures recruited from a well-defined
population.
METHODS
Study population
The investigation was conducted as part of an ongoing prospective population-based study in
Maastricht and its surroundings, which is a well circumscribed area located at the southern
part of the Netherlands. This area, which lies within the zip-code area 6200 to 6299, includes
90 general practitioners and one hospital, the Maastricht University Hospital. The baseline
survey was conducted from October 1998 until October 2000 and included all patients aged ä
14 years of age suspected with a first epileptic seizure. These patients were identified through
different sources (general practices, nursing homes, emergency room, hospital departments
and outpatient department of neurology of the university hospital, survey of EEG and
neuroradiology reports, and survey of the medical files of patients who received the diagnoses
syncope, convulsion, epilepsy or attacks of unknown type during the inclusion period of the
study). All patients identified in this process were evaluated and , whenever possible, were
examined in a standardized manner by one of the authors (IK) (medical history, physical and
neurological examination). Blood screening tests and ECG were performed in all cases. EEG
(awake and/or sleep deprived), video-EEG, and neuroradiological examinations (CT or MR1)
were performed if indicated for a more precise diagnosis. Excluded from this study were all
patients who had an acute symptomatic seizure.
Definitions
The seizure that led the patient to seek for medical advice (general practitioner, emergency
room, or department of neurology) was defined as index seizure.
Epilepsy and epileptic seizures were defined and classified according to the Commission on
Classification and Terminology and the Commission on Epidemiology and Prognosis of the
International League Against Epilepsy (ILAE) (3-5).
Diagnosis and classification of seizures
Two authors (the neurologists MdK and JL) independently evaluated all cases and classified
the patient's index seizure as an epileptic seizure, a non-epileptic seizure of organic origin
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(e.g. syncope, benign drop attacks), or a non-epileptic seizure of non-organic origin (e.g.
panic attacks, hyperventilation attacks, non-epileptic psychogenic seizures). The classification
of cases was based on the clinical manifestations, EEG findings, neuroimaging findings,
laboratory and ECG data acquired within six months after the index seizure. As such, for all
cases there is a first diagnosis, obtained immediately after the index seizure, and a definite
diagnosis obtained six months after the index seizure. For statistical analysis, only the definite
diagnosis was taken into account. In cases of disagreement a consensus was reached with the
aid of a third neurologist (the author JT). The kappa value for the inter-observer consistency
of the two neurologists (MdK, JI.) was also determined.
Statistical analyai*
In order to determine which cluster of items is important to establish a correct diagnosis of
epileptic and non-epileptic seizures, we performed the statistical analysis in the following
steps:
(1) Two groups of patients were compared with respect to age, sex, ancillary tests (laboratory
tests, EEG, CT, and MRI), diagnosis and clinical characteristics of the index seizure (number
of seizures before the index seizure, onset of first seizure, duration of index seizure, and
seizure frequency): patients seen in a standardized manner (PS) by one of the authors (IK),
and patients not seen by this author (PNS). For categorical variables, comparisons of
percentages were made with the chi-square test, whereas for continuous variables, a
comparison of means was performed by using the T-test. For the variable seizure frequency,
which is a categorical variable with an intrinsic order (i.e. ordinal variable), also a comparison
was performed by using the Mann-Whitney rank sum test.
(2) Diagnostic items for epileptic and non-epileptic seizures were examined by means of a
multiple logistic regression analysis. The model contained three sets of variables (i.e. history,
hetero-anamnesis, findings from physical examination and diagnostic tests), as is shown on
Table 1 The variable age. which is the only continuous variable, was transformed into a
categorical variable according to the age limits defined by the Central Bureau of Statistics for
the general population (i.e. 14-24. 25-44, 45-64, and >65 years). A profile was obtained by
stepwise logistic regression retaining only the most strongly related variables. Ninety-five
percent confidence intervals (CI) for the statistically significant variables were calculated.
Two outcome contrasts were defined. First, the unprovoked seizures and non-epileptic
seizures of organic origin were compared to the non-epileptic seizures of non-organic origin.
Second, the unprovoked seizures were contrasted with the non-epileptic seizures of organic
origin seizures. As a form of sensitivity analysis and to ensure the entry of variables with
coefficients different from zero, we successively used as a criterion for the inclusion of a
variable the values 0.05,0.15, and 0.20, as recommended by Hosmer and Lemeshow (6).
(3) The multiple logistic regression analysis was repeated for two groups of patients
separately (i.e. the PS and PNS group). In this analysis, we did not vary the significance level
which was set on 0.05.
RESULTS
Study population
A total of 350 cases was entered in the study. This sample consisted of 163 (46.6%) men and
187 (53.4%) women aged between 14 and 92 years (mean. 49 years for men and 51 years for
women). In all. 71.1 % of the patients were examined in a standardized manner by one of the
authors (IK) whereas 28.9% of the patients were not seen by this author. Unprovoked seizures
were diagnosed in the majority of the cases (49.7%). followed by the non-epileptic seizures of
organic origin (22.3%). the non-epileptic seizures of non-organic origin (18%). and the acute
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symptomatic seizures (7.7%). In eight cases (2.3%) no definite diagnosis could he determined
due to lack of data. Ninety-four (54%) of the 174 cases with unprovoked seizures fulfilled the
diagnostic criteria for epilepsy as they appeared to have had two or more recurrent
unprovoked seizures. The kappa value for the inter-rater agreement was good (0.93.
pO.0001).
Table 2 shows the baseline characteristics of the patients with unprovoked seizures, with non-
epileptic seizures of organic origin, and with non-epileptic seizures of non-organic origin. In
contrast with the group of patients with unprovoked seizures, the two groups of patients with
non-epileptic seizures are characterized with a greater proportion of females than males.
TABLE 1. Car/aft/« urcJ in fAe mu/fi/j/e
Set
History
Hetero-anamnesis
Physical examination,
ancillary tests
Variables
age. sex. living situation (e.g. living alone or with others), occupation (e.g. full-
time, pan-time, unemployed), education level ( e g low or high), medication,
history of febrile seizures, epileptic seizures, head injury, and eating disorders,
complaints of headache or memory loss, concomitant diseases ( e g diabetes
mellitus, cardiovascular diseases, depression), treatment by a psychiatrist or
psychologist, family history of epilepsy, number of seizures before the index
seizure, onset of first seizure, frequency of seizures, duration of the index seizure,
the way the index seizure starts and ends (i.e. acute or gradually), provoking
factors ( e g alcohol abuse, sleep deprivation, stress) and presentiment ( e g
dizziness, rising epigastric sensation) of the index seizure, loss of consciousness.
tongue bite, incontinence for urine or feces. injury during the seizure, postictal
confusion and muscle pain, time and location ol the index seizure, witnessci,
emotions before the index seizure, memory of the index seizure, and epileptic
seizure ever witnessed
relation of witness with patient, falling on the ground during the index seizure,
jerks, movement of arms or legs, pelvic thrust, back arching, state of the body,
head and eyes during the index seizure, color of the skin, making sounds with the
lips, responsiveness and reaction on painful stimuli during the index seizure
findings from physical and neurological examination, laboratory tests, ECU,
EEG, CT, and MRI
TABLE 2. Oase/ine cAarac/er/s//cs o/zAe pa//en/s vW/A e/)//ep//c am/ n«n-tyj/7e/rf/c se/zwrev
Age groups (yr) 1
14-24
25-44
45-64
265
Total
Male
n (%)
18 (20.0)
13 (14.4)
26 (28.9)
33 (36.7)
90
US
Female
n (V.)
8 (9.6)
16 (19.0)
29 (34.5)
31 (36.9)
84
NES of organic origin
Male
n (•/.)
5 (16.1)
7 (22.6)
12 (38.7)
7 (22.6)
31
Female
7 (14.9)
10 (21.3)
16 (34.0)
14 (29.8)
47
NES of psychogenic origin
Male Female
n (%1 n (%)
7 (33.3) 15 (35.7)
7 (33.3) 10 (23.8)
6 (28.6) 13 (30.9)
1 (4.8) 4 (9.6)
21 42
US, unprovoked seizures: NES. non-epileptic seizures
Comparison of two groups of patients
The group of patients who were not investigated in a standardized manner appeared to be
significantly oldeT than the other group of patients. The mean age of the first group was 57.4
whilst the mean age of the latter group was 47. These groups of patients also differed
significantly with respect to the findings on CT and MRI. The PNS group had more
abnormalities on the CT-scan (40%) and the MRI (19%) than the PS group 18.6% and 15.9%,
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TABLE 3. /»reva/c/ice am/ ooik ra//oj tfM; wifA 95% Con/iaence /n/erva/s f95% C/>
</ia/f/ioj//c/ac/orjybr //» eyri/ep/i'c a/«/ no/i-epi/epfic seizures.
re£re\js/o/i arw/y.m
Diagnostic factors
Age group« (yr)
25-44
45-64
265
Febrile seizures
Treatment by psychologic*/
psychiatrist
()nsct of first seizure
more than 1 month ago
I'ottictal confusion
MRI
abnormal
Presentiment of index seizure*
Potticul muscle pain'
EEG'
epileptiform discharges
History of COPD*
End of Index seizure'
gradually
loss of consciousness'
Memory of index seizure'
Jerks'
Movement of arms/legs'
State of the body during index
seizure'
other than normal
Color of skin'
other than normal
OR (95% Cl)
Predicting for NES of
non-organic origin
0.27 (009-0.76)
0 23 (0.08-0.65)
0.66 (0 18-0 24)*
5.8 (1.19-28.04)
9.1 (3.41-24.26)
3.3 (1.49-7.45)
0 09 (0.03-0.27)
009 (002-0.38)
3.7 (1.38-10.09)
4.2 (1.002-17.52)
0.09 (001-0.53)
34.8(1 79-677.08)
22.1 (2.39-205.09)
1141.9 (40.64-32081.86)
279.8 (12.45-6287.98)
0.004 (0.001-0.12)
57.9 (2.15-1556.82)
0.03 (0.002-0.32)
0.02 (0.002-0.27)
US and NES of
organic origin
n-252
Prevalence
n
46
83
85
I I
14
113
120
54
99
35
47
10
6
205
39
131
105
59
67
18
32.9
33.7
4
7
45
55.8
21.9
39.3
14
19
4
2
82.3
15
54.1
51.9
23.4
27.9
NES of
non-organic on gin
n=63
Prevalence
n
17
19
5
7
24
46
8
-
45
I I
3
4
6
51
18
20
18
12
14
TO
27
30
8
I I
43
73
14
-
71
17
5
6
9
80.9
29
34
37
19
24
US, unprovoked seizures; NES, non-epileptic seizures; COPD, chronic obstructive pulmonary diseases
° p<0.00l
* added after changing the significance level into p~0 15
' added after changing the significance level into p-0.20
respectively. In the first group of patients, no vascular malformations or mesial temporal
sclerosis was identified. However, in this group of patients proportionally more brain
metastases and brain tumors were identified on the MRI than in the PS group. Concerning the
diagnosis of the index seizure, the PS group was significantly associated with non-epileptic
seizures of non-organic origin (22% versus 10% in the PNS group) whereas the PNS group
was significantly associated with acute symptomatic seizures (12% versus 6% in the PS
group). Other characteristics of the index seizure were also significantly different between
these two groups. As such, in the PNS group, more patients were seen immediately after one
seizure (52% versus 36% in the PS group) and more patients were seen in less than a month
after the first seizure (65% versus 49% in the PS group). Moreover, the PNS had more
patients with a seizure that lasted less than five minutes (87%) than the PS group (56%). As
well the chi-square test as the Mann-Whitney rank sum test were significant for the frequency
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of seizures. It appeared that the PS group included more patients with a variable frequency of
seizures (20% versus 14% in the PNS group) while the PNS group had more patients who had
experienced just one seizure (68% versus 44% in the PS group). Finally, both groups did not
differ significantly with respect to sex and findings from blood screening tests and HEG.
TABLE 4. /Veva/en« a/idodtfY ra/ioj (ÜÄJ HI/A 95% C
/ac/ors/br f>»e </>
mi///ip/< regression ana/v.m
/n/rnw/.v 7>
Diagnostic factors
Medication
History of hypertension
Provoking factors of index seizure
Postktal confusion
Location of index seizure
out of doors
Movement of arms/legs
EEG
epileptiform discharges
CT
abnormal
MRI
abnormal
OR(95HC! )
Predicting for NES of
organic origin
50 (1 51-16 5«)
7.5 (1.57-36 36)
13 4 (3.34-54.02)
0 09 (0.03-0.29)
11.4 (3.47-37.14)
0.07 (0.02-0.27)
0 02 (0 002-0 12)
0.04 (0.01-0.16)
0.07 (0.02-0 27)
US
n-174
Prevalence
n
89
1«
24
104
66
94
43
62
51
(* )
55.6
14
18
70.3
43.4
65.7
31
36
296
NES of organic
n-7X
Prevalence
n
47
I I
27
16
53
II
3
7
3
origin
< * )
66
33
42
24
72.6
19
5
9
4
US. unprovoked seizures; NES, non-epileptic seizures
Diagnostic items
Tables 3 and 4 show the diagnostic factors for epileptic and non-epileptic seizures that
appeared to be statistically significant from the logistic regression analysis. Several items
from the history, the hetero-anamnesis, and findings from diagnostic tests discriminated
significantly the one group of patients from the other. However, the findings from the
laboratory or ECG tests and from the physical and neurological examination did not prove to
discriminate significantly the different groups of patients.
For instance, older age, postictal confusion, a change of the state of the body (e.g. stiffness)
and of the skin (e.g. turning blue or red) during the index seizure, having jerks during the
index seizure, an abnormal MRI, and an epileptiform EEG pattern were more likely to appear
in patients with unprovoked seizures and non-epileptic seizures of organic origin than in the
group of patients with non-epileptic seizures of non-organic origin. Alternatively, the latter
group of patients was characterized with ten items from the history and hetero-anamnesis
(history of febrile seizures, treatment by a psychologist or psychiatrist, the first seizure
experienced at least more than a month ago, history of chronic obstructive pulmonary
diseases, presentiment of the index seizure, loss of consciousness, postictal muscle pain,
movement of arms or legs during the index seizure, gradual end of the index seizure, and
memory of the index seizure). The difference between movements of arms or legs and jerks
during a seizure is that the term movements of arms or legs is more general than the last one,
and that it can also include uncoordinated and asymmetric movements of the extremities. As
such, jerks seem to be more specific for seizures of somatic origin than for seizures of non-
organic origin. Concerning the presentiment of the index seizure, it appeared that the most
common forebodes for the group of patients with non-epileptic seizures of non-organic origin
were: difficulties with vision (33.9%), a feeling of choking (22.3%), tingling (20.3%), and
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TABLE 5. rreva/e«ce' a«a oocu ra//os fOÄ^ v
a7a#H0j/ /c / a c / w j / o r //»e 5i//>£rouj
Diagnostic factors
Febrile seizures
Treatment by
psychologist/ psychiatrist
Number of seizures before
index seizure
1 or mure
Presentiment of index
seizure
I'ostictal confusion
Hack arching
Diagnostic factors
Sm
Female
Loss of consciousness
Postictal confusion
Location of index seizure
out of doors
Movement of arms/legs
F.EG
cpilcpliform discharges
CT
abnormal
MRI
abnormal
y/tfi 95% Con/1ia^nci? /n/erva/5 /"95% C7; o/7/je-
p o/pa//en/j w/7/i e/Ji/ep/ic ana* non-ep/'/epf/c
/Aa/ /save Aeew inve5//'^a/ea' »w a J/amiar J/ret/ marjn^r
Äe5«//j o//Ae mi//n/>/e rfgre55i'o/t ana/yj«.
OR(95'/»CI) US and NES of organic origin NES of non-organic origin
Predicting for NES of
non-organic origin
116 (1.71-78.42)
26.4 (7.02-98.95)
8.2(1.94-34.92)
5.2 (1.72-15.52)
0 04 (0 01-0 IS)
102.2(2.42-4310.37)
OR(95SCI)
Predicting for NES of
organic origin
3.4 (1.16-10.23)
0.16 (0.04-0.70)
0.19 (0.06-0.57)
5.6 (1.77-17.69)
0.17 (0.04-0.64)
005 (0.01-0.36)
0.08 (0.02-0.28)
0.05 (0.01-0.22)
n= 177
Prevalence
n I
10
13
106
79
95
1
US
n-119
Prevalence
n
SS
110
81
49
60
32
35
34
[*)
6
7
60.2
44 9
54.6
0 6
(%)
46.2
92.4
69.2
41
63.8
33
30
29
n
7
24
4t
40
7
4
n=53
Prevalence
(%)
13
46
91
75
13
8
NES of organic origin
n-58
Prevalence
n
39
40
14
41
9
2
S
1
/•/ \
67
69
25
71
22
5
9
2
US, unprovoked seizures; NES, non-epileptic seizures
palpitations (15.2%). Only patients from the other group reported forebodes that are more
specific for seizures such as a rising epigastric sensation, and the feeling of a strange smell or
taste in the mouth. Conversely, this last group did not include any patient who reported
hyperventilation just before the index seizure started.
Furthermore, the items postictal confusion, movement of the arms or legs during the index
seizure (e.g. jerks), an epileptiform EEG pattern , and abnormal findings on CT or MRI
discriminated significantly the group of patients with unprovoked seizures whereas four items
from the history (medication, history of hypertension, provoking factors of the index seizure,
and location of the index seizure out of doors) characterized the group of patients with non-
epileptic seizures of organic origin. The most common provoking factors reported by this
group of patients were exercise and warmth (25%), followed by stress (10.9%), and tiredness
(6.2%). The sensitivity analysis showed that the analysis for these two groups of patients
provided a quite robust model since no other items were added after a change of the
significance level.
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Finally, the multiple regression analysis was repeated for two groups of patients separately
(i.e. the PS and PNS group) in order to evaluate the value of the standardized investigation of
patients with seizures (Table 5). This analysis showed that for the PS group, several items
from the history, the hetero-anamnesis and findings from diagnostic tests can discriminate
significantly the subgroups of patients with epileptic and non-epileptic seizures In particular,
postictal confusion was more likely to occur in the group of patients with epileptic sei/urcs
whilst the group of patients with non-epileptic seizures of non-organic origin was
characterized with five items from the history (history of febrile seizures, treatment by a
psychologist or psychiatrist, one or more seizures experienced before the index seizure,
presentiment of the index seizure, and back arching). Moreover, the items loss of
consciousness, postictal confusion, movement of arms or legs, an cpileptiform KFCi pattern,
and abnormal findings on CT or MRI discriminated significantly the group of patients with
unprovoked seizures. Conversely, two items from the history (female sex and location of the
index seizure out of doors) were more likely to appear in the group of patients with non-
epileptic seizures of organic origin. The majority of the women with non-epileptic seizures of
organic origin appeared to have had a vasovagal syncope. However, in the case of the PNS
group, no diagnostic item was found to discriminate significantly the subgroups of patients
with epileptic and non-epileptic seizures.
DISCUSSION
This study shows that certain items from history, hetero-anamnesis and findings from
ancillary tests can be helpful in differentiating epileptic seizures from non-epileptic seizures.
As expected, postictal confusion, movement of the arms or legs during the index seizure (e.g.
jerks), an epileptiform EEG pattern , and abnormal findings on CT or MRI were diagnostic
indicators for the group of patients with unprovoked seizures whereas medication, history of
hypertension, provoking factors of the index seizure, and location of the index seizure out of
doors proved to be diagnostic indicators for the group of patients with non-epileptic seizures
of organic origin. Exercise and warmth were the most common provoking factors reported by
this group of patients which may explain the high likelihood of this type of seizures in
occurring out of doors. With respect to patients with non-epileptic seizures of non-organic
origin, the diagnostic items that differentiated this group of patients from the group of patients
with seizures from somatic origin were a history of febrile seizures, treatment by a
psychologist or psychiatrist, the first seizure experienced at least more than a month ago,
history of chronic obstructive pulmonary diseases, presentiment of the index seizure (e.g. a
feeling of choking, tingling, and palpitations), loss of consciousness, postictal muscle pain,
movement of arms or legs during the index seizure (e.g. uncoordinated and asymmetric
movements of the extremities), gradual end of the index seizure, and memory of the index
seizure. The fact that patients with non-epileptic seizures of non-organic origin were more
likely to have a history of febrile seizures and of psychiatric disorders is in keeping with the
literature. Several authors indicate that patients with non-epileptic seizures of non-organic
origin have often a personal and family history of psychiatric disorders, a history of
neurological disease, including true seizure disorders, and a family history of epilepsy (7-10).
A history of chronic obstructive pulmonary disease also appeared to be a distinctive feature
for this group of patients. Apparently, because of this disease these patients have breathing
difficulties and in some cases they might hyperventilate, which can lead to a loss of the
consciousness. Another possible explanation is that pulmonary obstructive diseases give rise
to stress and anxiety, which under certain circumstances can cause hyperventilation or anxiety
attacks. Furthermore, the characteristic postictal muscle pain seems to be related to a
prolonged seizure with prominent movements of the extremities. In contrast, the
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characteristics loss of consciousness and memory of the seizure seem to be opposed to each
other. However, it is likely that these patients encounter a disturbance of consciousness rather
than a true loss of consciousness. This disturbance of consciousness explains the reverse of an
apparent amnesia in patients with seizures of non-organic origin by hypnosis, as has been
indicated by Kuyk ct al. (11)
In this study we attempted to investigate the patients with seizures in a standardized manner.
However, we were not able to systematically evaluate a subgroup of patients with seizures
(i.e. the PNS group). This group of patients was consisted mostly of patients who had a bad
clinical condition at the time of their admittance and were usually discharged to the nursing
homes directly. In a few cases, this group of patients included patients with a known
neurological disease such as brain tumor or cerebrovascular disease. These patients were often
referred to the neurologists who had seen them regularly at the outpatient department of
neurology.
To some extent, the PNS group differed from the group of patients who were seen by one of
the authors (i.e. the PS group). I "he PNS group consisted mainly of older patients, who had
proportionally more abnormalities on ncuroimaging studies, including brain metastases and
brain tumors, than the PS group. The PNS group had also experienced more acute
symptomatic seizures and, therefore, compared to the other group of patients, the patients
were more likely to be seen immediately after the index seizure which in most of the cases
was also the first seizure. Consequently, we separately analyzed these groups of patients. This
unalysis provided for the PS group some additional diagnostic items whereas for the PNS
group no diugnostic item could discriminate significantly the subgroups of patients with
epileptic and non-cpilcptic seizures. Among other diagnostic items, the items back arching
during the seizure and one or more seizures experienced before the index seizure
iliflcrcnliutcd the subgroup of patients with non-cpilcptic seizures of non-organic origin from
the patients with seizures of somatic origin. The item one or more seizures experienced before
the index seizure is related to the item onset of first seizure more than a month ago and may,
therefore, be interchangeable. Seizures of non-organic origin can manifest themselves with an
extreme variety of individual symptoms (11, 12). Thus, at an early stage these seizures may
not be recognized immediately as an entity by the patient as well as by the referring
physician. Unsurprisingly, the item loss of consciousness was added as a diagnostic indicator
for the subgroup of patients with unprovoked seizures, whereas for the subgroup of patients
with non-epileptic seizures of organic origin the characteristic female sex was added. There is
evidence that females consult more often their general practitioner for episodes of disturbed
consciousness than males (13) and in this study more than half of the patients with seizures
was female (53.4%). In particular, proportionally more women than men had non-epileptic
seizures whilst the population of patients with unprovoked seizures consisted of more men
than women.
It is obvious that the symptomatology of epileptic and non-epileptic seizures varies widely.
Hence, the differentiation between epileptic and non-epileptic seizures is complex. So et
al.(14) presented a comprehensive list of non-epileptic events that are often confused with
epilepsy. The potential of misdiagnosis is higher when clinicians have to deal with a single
event that may be imperfectly described to them. A structured investigation of patients with
seizures allows a better characterization of patients with epileptic and non-epileptic seizures
and a more precise diagnosis early in the course of the seizure disorder. This study found after
a standardized investigation of patients with seizures a number of certain diagnostic items that
can assist in distinguishing patients with epileptic from patients with non-epileptic seizures.
The diagnosis of the dilTerent types of seizures may be much more complicated when they co-
exist in the same individual. However, such cases were not included in this study. Moreover,
the studied number of patients did not allow the analysis of infrequent subgroup patterns.
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Therefore, the findings of this study need to be verified by other population-based studies
with larger samples of patients. Also, in such studies a further differentiation of subgroups
would be possible.
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Summary
e. To review systematically studies of the costs of epilepsy and to describe key
methodological issues of these studies.
A/t//ioc/.v A Mcdline literature search was conducted from 1966 to March 2000. Several
methodological aspects (perspective, study design, estimation basis, estimation procedure,
cost components, estimation of indirect costs, sensitivity analysis, costs associated with
comorbid conditions, and different prognostic groups) were examined to the extent to which
these aspects have been employed in the studies reviewed.
Jfr.fu//.v. Fifteen studies were identified and analyzed. 67% of the selected studies had a
retrospective study design and used data commonly derived from existing databases. Almost
all studies estimated the costs by using the bottom-up approach and prevalence based data but
did not use a sensitivity analysis to control for the assumptions made in the calculations. Only
three studies mentioned the method they used to estimate the indirect costs.
( Vmc/w.v/«n.v Studies of the costs of epilepsy care show a wide variation in the methods and
definitions used. Recommendations (e.g. a transplant methodology and analysis of data, a
clear description of the definitions used, and consideration of the temporal aspects of epilepsy
by stratifying the costs and by obtaining data prospectively) are given to increase the
comparability among studies and to make the information provided by these studies suitable
for economic evaluation studies.
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INTRODUCTION
As the costs of health care in general are rising, there is a growing interest in the economic
aspects of epilepsy. Epilepsy has a financial burden with regard to individual patients and
society. Persons with intractable epilepsy have greater demands on health and social services
than those of the general epilepsy population and they often have associated learning or other
mental and physical disabilities.
Furthermore, new antiepileptic drugs (AHD) are several times more expensive than the older,
existing AED. Similarly, epilepsy surgery, when considered in isolation, is a rather expensive
intervention based on high technological developments. Next to medical expenses, when
epilepsy is not well controlled, the patient has a reduced productivity and a reduced quality of
life (1,2). In these cases the introduction of a new AED or epilepsy surgery' may appear to be
the most cost effective among other therapeutic modalities.
Economic appraisal studies consider several aspects of care of people with epilepsy and assist
decisions on the allocation of health care services. In the last few years the costs of epilepsy
have been studied in various countries.
In this chapter, first, key methodological issues in Cost of illness studies (C'OI) arc described.
Second, epilepsy cost studies are systematically reviewed with the aim of describing several
methodological aspects of these studies. Moreover, methodological issues which have to be
considered in order to make COI studies more relevant for health policy decisions are
discussed.
METHODOLOGICAL ASPECTS OF COST OF ILLNESS STUDIES
Cost of illness studies (COI) estimate the burden of specific diseases for the community.
Some authors (3, 4) have disputed the value of COI studies while others, such as Luce and
Elixhauser (5), indicate that the information provided by this type of studies can be useful
because (1) it provides an estimate of the social impact of the disease which can help decision
maker in priority setting, and (2) it can be incorporated in other economic evaluation studies
like cost-effectiveness analysis by providing a baseline estimate against which new
interventions can be assessed
Before undertaking a COI study several methodological issues should be considered:
1. Perspective
The perspective of the study defines the viewpoint from which the cost analysis is conducted.
The choice of the study perspective determines which costs will be counted and how they will
be valued (6). The costs incurred by a disease can be considered from the viewpoint of the
affected individual, third party payer, health provider or society. The preferred approach is the
societal perspective, which is the broadest and is always relevant (6, 7).
2. Study design
Costs of illness can be assessed by using: (1) self reported data. (2) medical chart data, or (3)
a model which defines patterns of treatment.
The data may be primary (a primary or prospective research design), secondary (a secondary
or retrospective research design) or hypothetical (a modeling design). The validity of the
results of a secondary or modeling design depends primarily on the degree of error introduced
by using data derived from a variety of sources and on the accuracy of the estimations based
on expert opinions (6, 8).
3. Estimation basis
COI studies can estimate costs using prevalence or incidence based data. Prevalence based
data provide an estimate of the economic burden resulting from the prevalence of disease
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during a year. The incidence approach is a longitudinal analysis which takes into account the
temporal aspects of a disease and the impact of a particular treatment on the course of a
disease (9, 10). Costs estimated by the prevalence approach, which is a cross-sectional
analysis, generally have to be disaggregated into costs by disease stage or phase before they
can be incorporated in economic evaluation or disease models. For this reason, cost
estimations based on the incidence of a disease are preferred (9-11).
4. Estimation procedure
There are two methods of analyzing the costs of a disease: the bottom up (BU) and the top
down (ID) approach. According to the TD approach, CO1 is a percentage of the total health
expenditure. The BU approach uses the summation of cost data of individual patients or
specific patient groups to arrive at total disease costs (11 ).Thc first method is a service-based
analysis, whereas the latter one is an individual-based analysis.
5. Cost components
Because of time and resources detailed and actual data of all cost components associated with
a disease can not be obtained. Drummond (7) suggested that only the costs from the most
important settings should be used. There arc two main types of economic cost: direct and
indirect.
a. Direct costs. Direct costs are the costs of goods and services used to treat a disease. These
include medical costs such as drugs, investigations, hospital care and non-medical costs, such
as transportation to and from medical services (10, 12). The estimation of the direct costs can
be based on billing data, on nationally representative payment rates data or on existing data
from previous economic evaluation studies. There is no consensus as to which components of
the direct costs should be included in the cost analysis.
b. Indirect costs. Indirect costs arc the monetary value of lost output due to reduced
productivity of a patient us a result of morbidity or mortality. Included in this category are the
losses due to reduced puid and unpaid production of a patient and the indirect costs generated
by the family and/or friends for taking care of the patient (10, 12, 13).
Beside the direct and indirect costs the total burden of a disease for the patient consists also of
the intangible costs which reflect the patient's perspective of the disease and its
complications. Although the intangible costs arc a significant component of the total burden
of illness, they arc difficult to quantify in a standardized manner and it is difficult to integrate
their non-monetary information with the direct and indirect cost estimations (10).
6. Estimation of indirect costs
While there is much variation as to how direct costs are measured, there are standard
approaches for the estimation of indirect costs (14). Several approaches can be used to
calculate the indirect costs (13). The most common approach is the Human Capital method.
According to the Human Capital (HC)-cost approach indirect costs are estimated as foregone
earnings due to reduced mortality and morbidity (13). Psychosocial costs are not included in
this method as it is difficult to put a monetary value on them. Thus, the HC method is an
incomplete measure of the value of life (12). A method which attempts to estimate the
psychosocial costs is the willingness to pay method (WTP). The WTP method is a method of
valuing indirect costs based on the values people place on health and illness. These values can
be deduced from the amount people would be willing to pay in order to reduce the risk of
illness or death (5).
7. Sensitivity analysis
Luck of knowledge regarding mortality, morbidity, and medical care utilization associated
with disease leads to uncertainty regarding the study results. Under such circumstances a
sensitivity analysis can test the importance of particular assumptions. Sensitivity analysis can
demonstrate the dependence or, alternatively, the independence of the study s conclusion on a
particular assumption (5-7).
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8. Costs associated with comorbid conditions
Economic consequences associated with clinical conditions unrelated to the disease under
study should be identified when apportioning appropriate costs. It is difficult to separate the
costs of a disease from the costs of coexisting conditions. Johnson et al. (8) describe three
methods of analyzing group differences in costs, i.e. the control-experimental group method,
attribution of costs by procedure or diagnosis codes, and decomposition of cost differentials.
Begley et al. (15) also address the problem of cost attribution and suggest different
approaches for the direct and indirect costs. They note that the choice of a method for the
attribution of direct costs is associated with the type of data which are used to measure the
direct costs (survey data, chart or billing data).
9. Different prognostic groups
The costs of a disease may vary enormously with the nature, severity and complications of the
disease. Different prognostic groups will incur different costs. Thus, a stratification of costs is
desirable.
COST OF ILLNESS STUDIES IN EPILEPSY-A META-ANALYSIS
Approach
A Medline literature search from 1966 to October 1999 was conducted under the search term
"Costs of epil*" and thesaurus terms "Costs of illness" and "epilepsy". In addition, in order to
maximize the number of studies reviewed, the references cited in the selected studies were
screened for additional relevant publications. Only articles written in English were included
In the selected studies the methodological aspects mentioned earlier were examined to the
extent to which several issues regarding the techniques used and cost components included
have been employed.
Results of the meta-analysis
14 studies were identified and analyzed. Most of these studies have been performed in the US
and UK. The methodological aspects of these COI studies are summarized in table 1. Of the
14 COI studies one appears to be a "general" study, i.e. estimating the costs of a range of
diseases (16). The remainder is "specific" i.e. estimating the costs of 1 specific disease.
The majority of the COI studies have been performed from the broad societal perspective.
Griffiths et al. (17) estimated the annual medical costs of care for patients with epilepsy from
the perspective of a third-party payer. This perspective ignores costs paid by other payers (for
example patient, health provider) or incurred by the patient due to disability, such as lost
wages, and by other caregivers.
65% of the selected COI studies have a retrospective research design and use data commonly
derived from existing databases. Only few COI studies used a model to assess the costs of
care of people with epilepsy. Blom (18) developed a model which expresses the impact of a
disease on the Gross National Product (GNP) by comparing two samples of a population
equal in all aspects except the prevalence of the studied disease. This model provides no
accurate estimation of the costs, but expresses the costs of a disease in relation to the costs of
other diseases and the total GNP. Murray (19) estimated the annual costs of refractory
epilepsy in adults by using expert opinions and evidence from published studies. The study of
Begley et al. (20) describes the lifetime costs of a cohort of hypothetical patients with
epilepsy using expert opinions to define different patterns of health care utilization. Only one
study assessed the costs of care of people with epilepsy by obtaining prospective cost data
(21). In this study the cost analysis was based on a prevalent and an incident population of
patients with epilepsy. Longitudinal costs were calculated for each year after a patient with
newly diagnosed epilepsy entered the study up to 8 years of follow up.
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Almost all COI studies estimated the costs by using the BU approach and prevalence based
data. However, few studies define which costs are due to comorbid conditions. In their cost
analysis Blom (18) and Begley et al. (20) excluded from the estimates the indirect costs for
the patients who were institutionalized. They assumed that the productivity losses of this
group of patients are not attributed to epilepsy but to coexisting conditions. In addition,
Begley et al. (20) counted only the medical care costs of the institutionalized patients in the
direct cost estimates.
Some COI studies have considered the distribution of costs in different prognostic groups.
However, these studies stratified patients with epilepsy differently according to the
perspective and estimating methods of the study. For instance, the prevalence studies by Blom
(18)and Gessner et al. (22) assessed the costs of epilepsy by using the top down approach and
divided the population of subjects with epilepsy in 3 main categories: (a) outpatients, (b)
inpatients requiring temporary care, and (c) inpatients requiring chronic care. Griffiths et al.
(17) stratified patients with epilepsy according to the type of health services they received
during the observation period. The incidence study by Begley et al. (20) identified six
prognostic groups based on the clinical course or epilepsy. Furthermore, other studies (21, 23,
24) stratified patients with epilepsy by seizure frequency. Table 2 shows the cost components
of the COI studies. Although almost all studies calculated direct and indirect costs it is
difficult to compare them as in each study different components of the direct and indirect
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costs were investigated. The list of cost items included in the cost estimations can van from
lists limited to the medical direct cost items to comprehensive lists of direct and indirect costs
which include medical and non-medical direct costs as well as components of the indirect
costs such as productivity losses, household activity' losses and employment related items.
Only 2 studies mention the method they used to estimate the indirect costs. Both studies (20,
22) used the HC method to calculate the indirect costs.
Furthermore, only a minority of studies used sensitivity analysis to control for the
assumptions made for calculating the costs. Not mentioning the methods used to estimate and
analyze the indirect costs introduces potential uncertainties into the results, thereby, limiting
their value.
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DISCUSSION
Up till now a few studies of the costs of epilepsy have been performed. Only 2 studies
describe the impact of epilepsy on the Gross National Product (GNP) which is the total value
of goods and services produced in a nation over a certain period, normally a year. Gessner et
al. (22)estimated that the total direct costs of epilepsy equal approximately 0.08% of the GNP
while Polder et al. (16) estimated that these costs of epilepsy equal approximately 0.06% of
the GNP. The analysis of the impact of a disease on the GNP or on the total health
expenditures makes a comparison of different diseases with respect to their influence on a
nation's economy possible. However, the potential utility of this analysis for studies of the
costs of epilepsy has not been adequately explored. The failure to use this type of analysis can
be considered as an important shortcoming of the research to date.
The studies by Beran et al. (25), Gessner et al. (22), Cockerell et al. (21), Jacoby et al. (24),
Begley et al. (20)and van Hout et al. (23) provide the most comprehensive estimates of direct
and indirect costs and clearly describe their methods and the limitations of the results.
These studies differ in terms of selection of a sample of cases, the cost elements that are
included or the methods of estimation. Begley et al. (15) proposed which important items of
the direct costs (medical and non-medical) should be considered for the cost estimations.
With respect to the indirect costs, the HC method appears to be the most frequently used
method for estimating the indirect costs. In spite of its limitations the ILAE (26) recommends
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the Human Capital (HC) model because it has a more reliable access to valid statistics and
productivity.
There is no consensus regarding the various methodological issues of the COI studies. Thus,
until COI studies adopt more comparable methods, the true costs of epilepsy will remain
unknown. The value of the information provided by most of the COI studies is very limited
because prevalence based cost estimations are not directly suitable for economic appraisal
studies. These cost estimations provide information on current costs without links to expected
cost development. Moreover, the results of most of the COI studies are difficult to use in
economic evaluations since the methods used in estimating the costs are often not clear.
Furthermore, the results of COI studies differ due to the differences in health care provision
across the countries. Countries with approximately similar demographic and economic
features may differ in the balance between primary and secondary care, the provision of
inpatient and outpatient services, the availability of specialized investigations and epilepsy
surgery, the quality of training, audit and research, and the total expenditure on health. In
addition, countries may differ with regard to the intensity and type of treatment of patients
with epilepsy, modes of reimbursement and insurance.
An important item of the assessment of the costs of epilepsy care is also the type of the health
care setting. Different types of health care setting may have different standards of epilepsy
care. 'Ihcrcforc, the management of a certain prognostic epilepsy group may vary
significantly when university hospitals arc compared to general hospitals.
Optimal management of people with epilepsy meets medical, social and economic
considerations. A better knowledge of the economic factors will support the further
development of epilepsy services. A COI study can assist health policy decisions if the COI
information can be incorporated in economic evaluations. Therefore, a COI study needs to: a.
have a Irunspurunt methodology and analysis of the data. b. clearly describe the definitions
used, c. state the limitations of the data. d. mention which costs are associated with comorbid
conditions, and d. take into account the temporal aspects of epilepsy by stratifying the costs
and by obtaining prospectively data from an incident population of patients with epilepsy.
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Summary
/'wr/wre To systematically compare the national and per capita estimates of the cost of
epilepsy in different countries.
A/e/Aodfr Studies for this literature review were selected by conducting a Medline literature
search from January 1966 to March 2000. Key methodological, country-related and monetary
issues of the selected epilepsy cost studies were evaluated in order to compare their direct cost
estimates and explore their distribution. The results of the selected studies were made
comparable by converting them with different types of conversion factors and expressing
them as a proportion of the national expenditure on health care.
/?cvi///.v 10 epilepsy cost studies were reviewed. The proportion of national health care
expenditure on epilepsy shows a range of 0.12% to 1.12% or 0.12% to 1.05% depending on
the type of conversion factor. The list of cost components included in the estimation of the
direct costs of epilepsy differs from study to study. A comprehensive list is associated with a
decrease in the contribution of drug and hospital costs to the total direct costs of epilepsy.
Com./««/»«.« This study highlights the importance of studying the economic consequences of
epilepsy and of interpreting the results on the international level. The results of epilepsy cost
studies can provide insighl into the distribution of the costs of epilepsy and the impact of
epilepsy on the national expenditure on health care.
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INTRODUCTION
Epilepsy is a common chronic neurological disorder which affects about one of 200 people
(1). creating significant economic and social burdens. The economic consequences of
epilepsy are vast in terms of the use of health-care resources and loss of productivity. The
prevailing emphasis on cost containment and managed care has led to increased interest in the
economic evaluation of epilepsy. Economic appraisal studies consider several aspects of care
for people with epilepsy and assist in making decisions on the allocation of health care
services. Cost-of-illness (COD studies are widely used in epilepsy research. COI studies
estimate the burden of specific diseases for the community in a descriptive manner: they
quantify all costs related to a particular disease without comparing alternative uses or
resources. Some authors (2. 3) have disputed the value of COI studies while others, such as
Luce and Elixhauser (4). indicate that the information provided by this type of study can be
useful because (1) it provides an estimate of the socioeconomic impact of the disease, which
can help decision makers in setting priorities, and (2) it can be incorporated in other economic
evaluations by providing a baseline estimate against which new interventions can be assessed.
Over the last 5-year period there has been a marked increase in the number of publications on
the economic aspects of epilepsy (5). With the rapid international spread of new diagnostic
and treatment measures for epilepsy, there is a need to understand the economic implications
of these changes and interpret economic evaluations on the international level The ways in
which cross-national differences affect the costs of epilepsy or their evaluation have never
been studied systematically.
This article is the first to explore these issues by systematically reviewing epilepsy cost
studies and comparing their results. It presents an international comparison of health care
expenditure on epilepsy in order to assess if extra information can be gained from this cross-
national comparison. Therefore, key methodological, country-related and monetary issues in
epilepsy cost studies have been evaluated in order to compare the direct cost estimates of
studies which have a similar study design and methodology and to analyze the distribution of
the direct costs of epilepsy.
METHODS
Selection of studies
The studies for this literature review were selected by conducting a Medline literature search
from January 1966 to March 2000 with the search term "Costs of epil*"and thesaurus terms
"Costs of illness"and "Epilepsy". Additional relevant publications were found by tracking
references.
The selected studies had to meet the following criteria: (a) the study had to have been
published as an article, (b) costs were estimated by using prevalence-based data and (c) costs
were estimated from the societal perspective.
Most of the recently published prevalence studies of epilepsy define it and use measurement
indexes as recommended by the International League Against Epilepsy in 1993 (6).
However, incidence studies of epilepsy lack common definitions. The inclusion of single
seizures, febrile seizures and acute symptomatic seizures may vary from study to study, and
this may increase incidence rates several-fold (7). Thus, COI studies which assessed the costs
of epilepsy by obtaining incidence-based data were not included, as it is difficult to find
comparable incidence figures across countries.
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A cross-national comparison of COI studies
ßegley et al. (8), Johnson et al. (9) and Begley et aJ. (10) have critically evaluated the
methodologies of COI studies and pointed out the following methodological issues as being
relevant: (a) perspective of the study, (b) study design (model, prospective or retrospective
research design), (c) estimation basis (data sources, study population), (d) estimation
procedure (bottom up or top down approach), (e) types of economic costs and list of cost
components included in the study (direct and indirect costs), (g) costs associated with
comorbid conditions, and (h) stratification of costs in different prognostic groups.
A cross-national comparison of the results of COI studies must take into account not only the
differences in the studies' methodology, but also issues associated with the countries in which
the COI studies have been conducted, such as: (a) demographic factors (incidence, prevalence
of epilepsy), (b) stage of economic development, and (c) organization of the health care
sector.
Countries with approximately similar demographic and economic features may differ in the
balance between secondary and primary care, the provision of inpatient and outpatient
services, the availability of specialized investigations and epilepsy surgery, the quality of
training, audit and research, and the total expenditure on health. Moreover, countries may
differ with regard to the intensity and type of treatment of patients with epilepsy, cultural
attitudes about health and health care, modes of reimbursement and insurance, absolute and
relative price structures and administrative costs.
To enable a comparison among the COI studies we developed a checklist which took into
account the aforementioned issues (Appendix 1). The selected COI studies which met the
criteria of the checklist formed a subset of COI studies with a similar methodology and study
design. The results of these studies could then be compared and analyzed.
Conversion of the results of COI studies
In addition, in u cross-national comparison of COI studies several monetary issues have to be
considered, such as fluctuating exchange rates, different purchasing powers of currencies and
(he rate of inflation.
lor comparison, estimates from different countries were translated into US dollars using the
foreign exchange rate at the time of the study; this was obtained from the OECD
(Organization for Economic Cooperation and Development) health data published in 1998. In
addition, all the COI results were converted with GDP (Gross Domestic Product) PPPs
(Purchasing Power Parities), i.e. global PPP, and Health PPPs at the time of the study. All the
figures were updated to 1996 dollars according to the rate of inflation. Inflation was measured
by the Consumer Price Index, published by the U.S. Bureau of Labor Statistics. PPPs were
obtained from the OECD health data, published in 1998.
GDP PPPs and Health PPPs were defined as followed:
-GDP PPPs arc the rates of currency conversion that equalise the purchasing power of
different currencies. This means that a given sum of money, when converted into different
currencies at the PPPs rates, will buy the same basket of goods and services in all countries.
Thus PPPs are the rates of currency conversion which eliminate differences in price levels
between countries (11).
-Health PPPs arc the rates of currency conversion that equalise the purchasing power of
different currencies across the full range of goods and services contained in health care (11).
Comparison of the direct costs of epilepsy
The selected COI studies were compared with respect to the direct costs of epilepsy. Direct
costs are the costs of goods and services used to treat a disease. These include medical costs
such as drugs, investigations, hospital, and non-medical costs, like transportation to and from
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medical services (12. 13). Indirect costs are the monetary value of lost output due to a
patient's reduced productivity as a result of morbidity or mortality (12. 13).
In each CO1 study, the total direct costs of epilepsy have been estimated by using the
prevalence figures reported in the study. If the study did not provide any prevalence rates, the
rates reported in prevalence studies conducted in the same country and at approximately the
same period of time as the CO1 study were used. We excluded transfer costs from our
estimations since these are not real costs to society, but simply represent the redistribution of
money between individuals (4). The estimated total direct costs are expressed as a proportion
of the national expenditure on health. Figures for the national expenditure on health in
different countries and demographic figures at the time of the study were obtained from the
OECD health data, published in 1998.
Direct cost distribution
Although the list of cost items included in the direct cost estimations may vary from study to
study, almost all studies assessed the costs of hospital services (inpatient- and outpatient-care,
emergency) and the costs of drug(s) treatment. Thus, in order to explore the distribution of the
costs of epilepsy, direct costs were split into three items: hospital, drugs and others. The
results were aggregated by applying the same criteria to all studies: costs of hospital services
and drug costs were distinguished from other costs. The costs of general practice
consultations were excluded.
TABLE 1. CO/s/Mt//es on
Study
Silfvenius (33)
Blom(2l)
Banks et al (34)
Cockerell et al. (26)
Gessner et al. (29)
Swingleretal. (24)
Jacoby et al. (28)
Murray et al. (22)
Polder et al. (27)
Begley et al. (25)
Country
Sweden
Netherlands
Australia
UK
Switzerland
UK
UK
USA
Netherlands
USA
Study
Population
83,000
110.000
102.000
1,628
37,000
303
785
335,167
110,000
2,326,513
Year of
estimate
1975
1987
1990
1990
1990
1991
1993
1994
1994
1995
Study design
R
M
R
R
R
R
R
M
R
R
Estimation
procedure
TO
TO
TD
BU
TD
BU
BU
BU
TD
BU
Specific patient
group
N
N
N
N
N
Y
N
Y
N
N
M and R, model and retrospective; BU and TD, bottom up and top down; N and Y, no and yes
RESULTS
Selected studies
The literature search identified 17 studies of the costs of epilepsy care. A further evaluation of
the selected studies resulted in the inclusion of 10 COI studies and the exclusion of the
following studies: Begley et al. (14) (incidence-based COI study), Baker et al. (15) and Hout
et al. (16) (described the costs for three months of a small sample of patients with epilepsy
from different countries), Burke et al. (17) (estimated the costs attributable to epilepsy by
using two approaches), Beran et al. (18) (estimated only the indirect costs of epilepsy), Mak ct
al. (19) (no OECD health data are available for China) and Griffiths et al. (20) (estimated
costs from the perspective of a third-party payer).
Table 1 presents general information for the 10 COI studies reviewed. Eight of the selected
COI studies have a retrospective research design and used data commonly derived from
existing databases. Only two studies (21, 22) used a model to assess the costs of care of
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people with epilepsy. Blom (21) developed a model which expresses the impact of a disease
on the Gross National Product (GNP) by comparing two samples of a population equal in all
aspects except for the prevalence of the studied disease. This model provides no accurate
estimation of costs, but expresses the costs of a disease in relation to the costs of other
diseases and the total GNP. Murray et aJ. (22) estimated the annual costs of refractory
epilepsy in adults by using expert opinions and evidence from published studies. An equal
number of studies used the Top Down (TD) and the Bottom Up (BU) approach to estimate the
costs of epilepsy care. According to the TD approach, CO1 is a percentage of the total health
expenditure. I "he DU approach uses the summation of cost data of individual patients or
specific patient groups to arrive at tout disease costs (23). The first method is a service-based
analysis, whereas the latter one is an individual-based analysis. It appears that the studies of
Swingler et al. (24) and Murray et al. (22) have restricted their cost estimations to patients
attending a specialist epilepsy service and to adults with refractory epilepsy respectively.
Therefore, the results of these studies were analyzed separately from the other COI studies.
TABLE 2. £f//ma/fonf o/na/»'o«a/ faa/r/t care erpendVfure* OH «pi/e/uy/ier cown/ry"
design «nd estimation procedure: R and T P
Study
Direct cons NEH* % NEH on Rank % NEH on epilepsy Rank % NEH on epilepsy
Banks et i l (34)
Oessneretal (29)
Polder et al. (27)
SllrVmhu(33)
per person
2,167
5.278
1,601
6M
33.984
29.790
34.067
21,696
epilepsy
0.82
076
0.55
0.28
1
2
3
4
(GDP PPPs)'
0.75
0.41
0.47
0.18
1
2
3
4
(Health PPPs)
0.12
0.50
Study design and estimation procedure:
Cockerell et al (26) 2.179 79.833
Jacoby et al (28) 2.546 79,833
Beiley el al. (25) 750 1,035,080
Study desltn and estimation procedure:
Btem(21) 1.532 34,067
1.12
0.99
0.12
0.52
R
1
2
3
M
and
and
BU
1.05
1.04
0.12
TD
0.45
1
2
3
1.50
2.02
Abbreviations as in Table I.
° in 1996 US $
* NEH: National expenditure on health (in thousand US $)
' GDP PPPs: Gross Domestic Product Purchasing Power Parities
T A B L E 3. £.vf/ma//om o / H O / W H O / nea/f/j core «pem/j /wre OH
/ienf grow/»
coMH/ry"
Study design and estimation procedure: R and BU
Study
Swingler et al. (24)
Direct costs per
person
1,060
NEH*
79,833
%NEH on
epilepsy
0.41
> NEH on epilepsy
(GDP PPPs)'
0.37
Study design and estimation procedure: M and BU
Murray et al. (22) 2,885 1,035,080 0.44 O44
Abbreviations as in Table 1.
" in 1996 US $
* NKH: National expenditure on health (in thousand US S)
' GDP PPPs: Gross Domestic Product Purchasing Power Parities
Estimates of the cost of epilepsy
Tables 2 and 3 show the results of all the papers reviewed, in US dollars at the exchange rate
in 19%, the year on which the costs estimations of the most recently published studies (19.
20) have been based. The estimated proportions of national health care expenditure on
epilepsy, estimated with a different study design and a different estimation procedure, overlap
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each other and range from 0.12% (25) to 1.12% (26) and 0.12% (25) to 1.05% (27) depending
on the type of conversion factor.
However, the per capita estimates of the costs of epilepsy vary greatly from country to
country. For instance, in studies with a retrospective study design and a TD estimation
procedure the direct costs per patient with epilepsy range from $680 (33) to $5,278 (29).
These different estimates reflect partly differences in the list of cost components included in
the direct cost estimations. Silfvenius (33) assessed the direct costs of epilepsy in Sweden by
calculating the health care costs, whereas Gessner et al. (29) included in their estimations also
costs outside the health care sector such as the costs of special education and vocational
training of patients with epilepsy.
The three COI studies which were performed in the UK at approximately similar periods of
time and with a similar study design and estimation procedure, show great differences with
regard to the size of the estimated expenditure on epilepsy care. These differences may be
attributed to the type of study population. The study of Swinglcr et al. (24) is restricted to a
specific patient group, whereas the studies of Cockcrell ct al. (26) and Jacoby et al. (28) are
both community-based studies.
For many of the countries studied, a conversion of the expenditures on epilepsy with Health
PPPs was not possible because of lack of data. In addition, no Health PPPs earlier than the
year 1980 could be obtained from the OECD health data.
In general, the size of the national health care expenditure on epilepsy depends on the type of
conversion factor. It appears that all studies with a retrospective design, which have not
restricted their cost estimates to a specific patient group, show the same rank with exchange
rates and GDP PPPs conversion.
TABLE 4. D«fr/*M/
Study
Polder et al. (27)
Swingler et al. (24)
Murray et al. (22)
Begley et al. (25)
Silfvenius (33)
Banks et al. (34)
Jacoby et al. (28)
Cockerell et al. (26)
ion o/ a/recf co5fj
% Hospital
costs
82.19
29.73
55,44
39.07
19.51
33.59
31.99
29.80
%Drug
costs
11.55
48.48
17.21
30.98
36.59
10.83
10.26
8.30
Others
6.25
21.79
27.35
29.94
43.90
55.58
57.76
61.90
Distribution of direct costs
The majority of the COI studies assessed the costs of hospital services (inpatient- and
outpatient-care, emergency) and the costs of drug(s) treatment. The distribution of these
components of direct costs shows great variability (Table 4). Two COI studies did not allow
this analysis because data were not provided (21,29). The list of cost components included in
the estimation of the direct costs of epilepsy differs from study to study. A comprehensive list
of cost components is associated with a decrease in the contribution of drug and hospital costs
to the total direct costs of epilepsy.
DISCUSSION
Studies of the costs of epilepsy have been conducted in a few industrialized countries. The
existing COI studies provide a range of estimates of the total cost of epilepsy, the average cost
per person and the distribution between direct and indirect costs.
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In the present analysis, we evaluated different studies of the costs of epilepsy by means of a
checklist in which several methodological, country-related and monetary issues were taken
into consideration. However, many of these COI studies do not fully explain their methods,
introducing potential uncertainties into the results and consequently limiting their value. This
might be due to the researchers' lack of economic awareness, as the majority of the studies
were performed by medical specialists.
Inevitably, there are some limitations related to several methodological issues of the epilepsy
cost studies, and these limitations should be considered in interpreting the results. These
limitations, which have also been indicated by Begley et al. (8), are the lack of consideration
of non-medical and family-related costs, and the problem of attribution and variation of costs
by severity.
Economic consequences associated with clinical conditions unrelated to the disease under
study should be identified when apportioning appropiate costs. It is difficult to separate the
costs of a disease from the costs of coexisting conditions. In their cost analysis Begley et al.
(25) counted only the epilepsy-related medical costs in the direct cost estimates.
Few studies explored the variation in costs by severity. The costs of a disease may vary
enormously with the nature, severity and complications of the disease. Different prognostic
groups will incur different costs. Ihus, a stratification of costs is desirable. Although some
COI studies have considered the distribution of costs in different prognostic groups, these
studies stratified patients with epilepsy differently according to the estimating methods of the
study. For instance. Blom (21) and Gcssner et al. (29) divided the population of subjects with
epilepsy into three main categories: (a) outpatients, (b) inpatients requiring temporary care,
and (c) patients requiring chronic care. Begley et al. (25) divided cases into three broad
prognostic groups based on the clinical course of epilepsy. Furthermore, other studies (26,28)
stratified patients with epilepsy by seizure frequency.
Although the selected COI studies used different methodologies, databases and study periods,
the size of the estimated expenditure on epilepsy care is roughly similar. The proportion of
national health care expenditure on epilepsy, estimated from studies performed from the
societal perspective, shows a range of 0.12% to 1.12% or 0.12% to 1.05% depending on the
type of conversion factor.
Gerdtham et al. (30) indicate that the results of COI studies are preferably made comparable
with purchasing power parities rather than with exchange rates. They (30) argue that
exchange rates conversion tends to overstate the spread of health care expenditure as the
production of non-tradables (such as health care) differs from the production of tradables, and
exchange rates reflect only the equalization of prices of internationally traded goods. Thus
costs converted with purchasing power parities reflect differences in the size of medical
consumption or of health care quantity but do not reflect price differences. However, there is
great uncertainty regarding the calculation of PPPs, in particular of Health PPPs. The
measurement of Health PPPs is a recent development, and for this reason the OECD cannot
provide Health PPPs before 1980.
If we convert the results of the Griffiths'study (20) and express them as a proportion of the
national expenditure on health, then the estimated proportion of national health care
expenditure on epilepsy will be 0.00016%. In comparison with other COI studies, the
Griffiths'study (20) estimated the costs of epilepsy from the narrow perspective of a third-
party payer, ignoring costs paid by other payers (for example patients, health provider) or
costs incurred by the patient due to disability, such as lost wages, as well as costs incurred by
other caregivers. As a consequence of this narrow perspective, there is an underestimation of
the total direct costs of epilepsy which is reflected in a low estimate of the health care
expenditure on epilepsy.
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Therefore, when interpreting the results of a CO1 study, one has to consider factors such as
the perspective of the study and the type of the study population. The studies of Griffiths et al.
(20) and Swingler et al. (24) indicate that a narrow perspective and a specific patient group
can affect the cost estimations.
The total indirect costs of epilepsy were not calculated, as in the majority of the studies the
method used to estimate these type of costs is not clear. Not mentioning the methods used to
estimate and analyse the indirect costs introduces potential uncertainties into the results,
thereby prohibiting further analysis. Nevertheless, these studies show that the indirect costs
are several times higher than the direct costs of epilepsy (31). In addition, no epilepsy cost
study has estimated the intangible costs of epilepsy which are difficult to quantify (32) and
which, combined with the other costs of epilepsy, contribute to the burden for the patient with
epilepsy. This means that the direct costs of epilepsy arc only a small proportion of the total
costs of epilepsy for society.
Therefore, the results of this study have to be treated with great caution, as neither the indirect
costs nor the intangible costs were included in the calculations. However, the results of the
study do provide insight into the distribution of the direct costs of epilepsy and the impact of
epilepsy on the national expenditure on health care.
Analysis of the impact of a disease on the national health care expenditure makes it possible
to compare different diseases with respect to their influence on a nation's economy as well as
making it possible to assess the impact of a specific disease on the national health care
expenditure across countries. Based on this analysis, decisions on budgets and the allocution
of health care services can be tailored much more specifically to the needs of patients with
different diseases.
In conclusion, this study highlights the importance of studying the economic consequences of
epilepsy and of interpreting the results on the international level. As Pachlatko (5) noted, a
better understanding of the economic aspects of epilepsy leads to the further development of
epilepsy care. COI studies can assist the improvement of care for people with epilepsy if they
can be incorparated in economic evaluations. Therefore, COI studies should have a clear
methodology and analysis of the data. In this way, COI studies could provide more
comprehensive results and would facilitate the extrapolation of results from country to
country.
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APPENDIX 1. Checklist of epilepsy cost studies
A. Methodological issues
1. Perspective
-societal
-individual
-third party payer
-health provider
2. Study design
-a model
-a prospective research design
-a retrospective research design
3. Estimation basis
-type of study population: community based or specific patient groups
4. Estimation procedure
-bottom up approach
-top down approach
5. Types of costs
-direct costs
-indirect costs
•intangible costs
6. Costs associated with comorbid conditions
7. Stratification of costs in different prognostic groups
8. Cost components of direct costs
-medical costs: drug, hospital and other costs
-non-medical costs
K. ('ounlr) -related issues
1. Stage of economic development
-developed country
-developing country
2. Demographic factors
-incidence of epilepsy
-prevalence of epilepsy
('. Monetary issues
-exchange rate
-different purchasing powers of currencies
-rate of inflation
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The costs of epilepsy in three different populations of patients
with epilepsy
Authors: Kotsopoulos IAW, Evers SMAA, Ament AJHA, Kessels FGH, de Krom MCTFM,
Twellaar M, Metsemakers JFM, Knottnerus JA
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Summary
To estimate the costs of care in three different populations of patients with epilepsy
(general practices, university hospital, and epilepsy center), and to evaluate for each group of
patients the association of the costs of epilepsy with the quality of life and seizure seventy.
A/e//wifr A cost diary was developed to obtain prospective information on epilepsy-
attributable service use over a period of three months. Similar information over the previous
three months was obtained from a cost questionnaire. In addition, a quality of life inventory
(QOLIE-31) was used. Standard cost lists were applied for the valuation of the direct cost
items. A sensitivity analysis was performed for certain cost items for which no reliable data
were available.
/fe.vu/M 116 patients with established epilepsy were included and the mean costs per patient
per month (in Euros €) ranged from 52.08 to 357.63. Patients from general practices appeared
to have lower direct costs, spent less time in seeking or undergoing a treatment, and reported
lower seizure frequencies and less severe seizure types than the patients from the other patient
groups. Patients from the epilepsy center reported the highest productivity changes and
unemployment rates and also had the lowest scores on the QOLIE-31. The cost items
unticpilcptic drugs, hospital services, unpaid care, and transportation accounted for the
majority of the total direct costs.
Cum-/w.<riVm.v The costs arc influenced by the prognosis of epilepsy and patients groups from
different health care settings arc characterized by different patterns of medical consumption.
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INTRODUCTION
There has been an exponential growth in the treatment and diagnosis of epilepsy during the
last decade. New antiepileptic drugs (AEDs) and other therapies, such as vagal nerve
stimulation, have recently been introduced alongside several developments in the
investigation of epilepsy including functional magnetic resonance imaging (fMRI),
magnetoencephalography (MEG), and improvements in video-EEG monitoring technology.
These innovations in epilepsy care have a significant impact on health care expenditures.
Along with these medical costs epilepsy has. as a chronic health condition, a wide range of
added health care costs such as the costs of unemployment, and the costs of caregivcrs.
Estimates of the costs of epilepsy are often based on retrospective data or models of epilepsy
management because of the time and resources involved in obtaining direct actual data (I).
There are various sources to obtain direct data such as patient records, data bases from
insurance companies, interviews with patients or providers, questionnaires and diaries. Cost
diaries can provide detailed resource use information prospectively. Thus, they generally
provide detailed and reliable data reporting over a period of time. Although cost diaries have
been used for the estimation of the direct and indirect costs of chronic diseases such as
fibromyalgia and chronic back pain (2), so far, no cost diary has been developed to estimate
total resource use for patients with epilepsy. Therefore, we developed a cost-diary to estimate
the costs of care for three different populations of patients with epilepsy prospectively und we
also estimated the costs of epilepsy retrospectively with cost questionnaires, which have been
applied earlier as a method to measure the direct and indirect costs of epilepsy retrospectively
(3).
A number of epilepsy cost studies have investigated the relationship between the costs of
epilepsy, seizure frequency, and the quality of life (4, 5). According to these studies higher
seizure frequencies are associated with poorer outcomes with respect to the costs of epilepsy
and the quality of life. Other studies have stratified the costs of epilepsy by prognosis and
found that the costs of epilepsy vary significantly depending on the severity of the disease (3,
6-8). Moreover, previous studies have identified that particular aspects of care contribute the
most to the overall cost of epilepsy (1,3,7,9-11). These aspects were antiepileptic drug
treatment and medical services. Concerning the aspect of employment in patients with
epilepsy, the studies by Begley et al. (7) and Jacoby et al. (3) reported high rates of
unemployment and large productivity changes among patients with epilepsy. Similarly,
underemployment seems to occur often in patients with epilepsy (12). However, so far, only
one study has compared the costs of epilepsy from three different health care settings (6).
Based on these considerations, we conducted a study of the costs of epilepsy care in three
different populations of patients with epilepsy in the Netherlands. The objectives of this study
were: (a) to gain insight into the direct and indirect costs of epilepsy care, (b) to compare the
costs estimated prospectively with a cost diary and retrospectively with a cost questionnaire,
and (c) to investigate for each group of patients the association of the costs of epilepsy with
the patients' perception of their quality of life, and with their seizure severity.
METHODS
Selection of patients
Patients with established epilepsy were recruited from three different patient populations. The
first subgroup of patients was selected from 14 general practices throughout the province of
Limburg, which is located in the south of the Netherlands. These patients were expected to
have a good prognosis of epilepsy with seizures that were easily controlled with antiepileptic
drugs (AEDs). They were included in the study if (a) only general practitioners were
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responsible for their actual care and if (b) at least three months before their enrolment in the
study they had been discharged from further follow-up visits at the outpatient department of
neurology. The patients of the second and third subgroup were treated by specialists from the
outpatient department of neurology of the university hospital in Maastricht and from the
outpatient department of the epilepsy center in Hecze respectively. The university hospital is
the only hospital in the area of Maastricht to which patients with epilepsy can be referred to.
Consequently, selection bias for patients with severe epilepsy is unlikely.
We hypothesized that patients from the outpatient department of neurology of the university
hospital would have a good or uncertain prognosis of epilepsy (13), whereas patients from the
outpatient department of the epilepsy center would have an uncertain or bad prognosis of
epilepsy. Thus, we assumed that the different subgroups of patients with epilepsy would, as a
result of their different prognosis of epilepsy, have different patterns of medical consumption
and would therefore incur different costs. Accordingly, patients with frequent seizures would
be more likely to incur significant direct costs and be unemployed than patients with well
controlled epilepsy.
Data collection
We developed a cost questionnaire and a cost diary to obtain detailed information on several
elements of epilepsy care responsible for the direct (medical, non-medical) and indirect costs
of epilepsy care. In order to obtain as complete information as possible, the layout of the
questionnaire and the cost diary was designed to be suitable for self-completion by the patient
or his carcgiver. The cost diaries collected information about service use and the state of
employment prospectivcly over a period of three months, each diary covering a period of four
weeks. l"hc cost questionnaire obtained similar information over the last three months. The
cost questionnaire as well as the cost diaries were accompanied by instructions and an
example of a completed questionnaire or diary. In addition, we used the quality of life in
epilepsy inventory (QOL1K-3I)(14), which provides insight into the burden imposed on the
patients as a consequence of their epilepsy.
Patients who could not reasonably complete the questionnaire satisfactorily (young children,
patients with severe developmental disabilities), were considered ineligible for this quality of
life questionnaire. We were able, though, to elicit information about these patients' resource
use from their caregivers who were asked to complete the cost questionnaire and cost diaries.
Patients and caregivers were instructed to record only epilepsy-related issues.
To encourage a high response, prepaid envelopes were provided to return the questionnaires
and diaries. Each patient was asked to return a cost diary after one month and received two
diaries thereafter to complete for the subsequent two months. If the diaries or the
questionnaire were incomplete or not returned, the patients were called and received a
reminder letter with the kind request to complete and return them.
With respect to the patients from the outpatient department of neurology and the epilepsy
center, the cost questionnaire was completed through an interview of the patient by one of the
investigators (IK). For practical reasons, for patients from general practices we had to adopt
the postal method for data collection.
Cost estimation
For the estimation of the direct costs of epilepsy we used the following steps:
First, we used as much as possible standard cost lists for the valuation of the direct cost items.
However, for several cost items no standard cost list was available. For these items we had to
use other sources to obtain nationally representative unit costs. The cost measures and sources
used to estimate the cost items captured in the study are shown in Table 1.
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Second, a number of assumptions was taken in order to estimate the direct costs of epilepsy.
Patients with epilepsy were treated with specified (e.g. physiotherapy, speech therapy) and
unspecified forms of therapy. In the case of the unspecified forms of therapy, we assumed that
the most common form would be Cesar/Mensendieck therapy and used its unit cost unless it
was otherwise reported by the patient. After physiotherapy, Cesar/Mensendieck therapy is the
most common paramedical treatment of Dutch patients (15, 16). The drug costs were
calculated from the Drug Formulary by multiplying the price of a certain drug at its defined
daily dosis (DDD) by the duration of its prescription (17). For topiramate we had to use its
unit price for the year 2000 since it was not reimbursed earlier by the public and/or private
insurance companies. Based on the standard distances from a patient's house to the general
practice or hospital (18), we could calculate the transportation costs by taxi for the groups of
patients from the general practices and university hospital. However, for the patients from the
epilepsy center no such information existed. Hence, the transportation costs by taxi were
calculated on the basis of the mean of distances from the patients" private addresses to the
epilepsy center. For the cost items child minder and unpaid care no market prices were
available and we used the "shadow price" suggested by Oostcnbrink et al. (18) to value them.
"Shadow pricing" is a method to impute values on cost items for which no market prices are
available. In this case, for the estimation of the cost of care provided by relatives or friends of
a patient with epilepsy the relevant wage of professional caregivers was used, lor each cost
item, the overall mean costs per patient per month were derived by dividing the sum of costs
across services by the number of study observations. All figures were updated to 1999 Dutch
guilders according to the rate of inflation and then the costs were converted into Hums (1
/=0.45 €). Inflation was measured by the Consumer Price Index published by the Dutch
Central Bureau of Statistics (internet: www.cbs.nl).
Third, as a form of sensitivity analysis, we used the mean of the reported patient's out-of-
pocket expenses for a child minder to calculate this cost item. We also performed a sensitivity
analysis for other cost items (unspecified forms of therapy, transportation costs by taxi).
Therefore, a range of 5 % was chosen to test the likelihood of the assumptions made when
measuring these costs. This range has also been applied in other cost studies (19).
We reported time costs as the mean number of hours per month spent by the patient in
seeking a treatment or undergoing an intervention, and we reported lost or reduced
productivity as the mean number of days per month or hours per month of work lost
respectively. Furthermore, we reported the current employment status of the enrolled patients
(e.g. employment full- or part-time, unemployed, retired, registered permanently sick).
In order to determine the frequency of several types of seizures, we assumed that a patient
would have had at least ten seizures per day if he reported that he had had a countless number
of seizures per day over a certain period of time. In this study, only three patients reported
that they had experienced a countless number of absences per day.
Statistical analysis
Since cost variables and seizure frequencies are not normally distributed, we used non-
parametric tests such as the Kruskall-Wallis test for global cost differences across the three
patient groups and, in case of significance, we used Mann-Whitney tests for group-by-group
comparisons.
The Wilcoxon Signed Ranks test was used to evaluate for each patient group the significance
of differences between the estimated retrospective data (reflect mean data in the last three
months) and mean prospective data.
To compare the results of our study with those of other Dutch cost studies, we had to
extrapolate our findings. Therefore, we estimated for each patient group the total number of
patients with established epilepsy living in the circumscribed area of Maastricht, which has
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194,540 inhabitants: 467 from the general practices, 266 from the outpatient department of
neurology of the university hospital, and 74 from the outpatient department of the epilepsy
center. We then multiplied the number of patients from each patient group with the cost
estimates for each patient group. Next, we summed up these products and divided this sum by
the total number of patients with epilepsy to arrive at the total direct costs of epilepsy per
patient per month.
We also calculated the Spearman's rank correlation coefficients to test in each patient group
the level of association between the direct costs of epilepsy and each seizure type and the total
score on the QOUIi-31. I ricrefore, based on the Chalfont Seizure Seventy Scale (20) we
rated the severity of seizures as follows: 0.5 for seizures of unknown type, 1 for simple partial
seizures, 2 for absences, 18 for mild complex partial seizures or 86 for severe complex partial
seizures, and 104 for generalized seizures. Subsequently, we multiplied the frequency of each
seizure type with its rate of severity and estimated the level of association of this product with
the direct costs of epilepsy. We performed this twice and each time we used a different score
for the complex partial seizures. All statistical tests were two sided, with a P-value <0.0l
considered statistically significant.
TABLE I.UKmea.'
Cost tan
UP services
Phone calls
Visits
Visit« at home
Physician services
Hotpilal services
Diagnostic procedures
Laboratory tests
EEG
CT
MRI
Physiotherapist
Speech therapist
Occupational therapist
Social worker
Psychologist
Other therapy
Transportation
Taxi
Ambulance
Paid care
Home care
Family care
ADL help
Child minder
Unpaid care
rure.t ana 501/rcM i«ea /o erf/ma/e* / « * COJ/J 0/e,
Cost measures
Cost per call
Cost per visit
Cost per visit
Cost per visit
Cost per admission day
Cost per procedure
Cost per procedure
Cost per procedure
Cost per procedure
Cost per visit
Cost per visit
Cost per visit
Cost per visit
Cost per visit
Cost per visit
Cost per km
Cost per trip
Cost per hour
Cost per hour
Cost per hour
Cost per hour
Cost per hour
Unit costs (in Euros €)
1.71
16 59
26 14
72.60 UH
54 45 EC
331.71 UH
291.33 EC
9.46
77.43
186.01
411.21
18.15
19.06
9.98
34.29
56.72
17.69
1.35
334.89
22.82
25.09
32.67
7.94
7.94
p/7e/7xv
Sources of costs
C T G '
d«
CTG
CTG, (18)
CTG, ( U )
(18)
(27)
(27)
(27)
(18)
(18)
CTG
CTG
CTG
(18)
(18)
(18)
(18)
(18)
(18)
(18)
(18)
UH; university hospital. EC; epilepsy center
" National Institute for tariffs in health care: www.ctgzorg.nl
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RESULTS
Study population
In total 116 patients with established epilepsy [24 patients from general practices (GP). 49
from the outpatient department of neurology of the university hospital (UH). and 43 patients
from the outpatient department of the epilepsy center (EC)] returned at least one cost diary or
cost questionnaire. In total 67% of the returned diaries and cost questionnaires were
completed for all variables whereas the rest was partly completed for some of the variables. In
particular, 71 % of the patients from the GP, 81 % of the patients from the I'll, and 51 % of
the patients from the EC returned the cost diaries and questionnaires. Furthermore, 43 % of
the patients completed the diaries and cost questionnaire for the entire study period (i.e. 38 %
of the patients from the GP, 59 % of the patients from the UH, and 27.9 % of the patients
from the EC). The patient characteristics are shown in Table 2.
TABLE 2. /*a//en/ cAaroc/era/ics
Sex
N (mean age)
Male
Female
Total
Mean score on QOLIE-31
GP"
10(52.4)
14(49.1)
24 (50.5)
70.98
UH*
25 (47.8)
24 (44.0)
49 (45.9)
64.31
EC
24 (42.0)
19(33.0)
43 (38.2)
62.87
Total
59(46.3)
57(41.4)
116(44 0)
6560
°GP: patients from general practices
* UH: patients from the university hospital
' EC: patients from the epilepsy center
TABLE 3. /I verage cos/s per par/en/ per wonfA/br eacA paf/en/ group am/ fype
Cost items
GP services
Physician services
Hospital services
Diagnostic procedures
Paramedical therapy
Drugs
Total
Transportation
Paid care
Unpaid care
Total
Total direct costs
Total patient's out-of-
pocket expenses
GP
3.97
10.08
0
7.32
6.92
23.31
51.60
0
0
0.48
0.48
52.08
7.03
UH
2.70
28.95
49.76
27.59
15.83
53.31
178.14
16.97
3.18
84.43
104.58
282.72
147.25
EC
5.91
17.33
137.57
13.49
15.90
84.33
274.53
28.48
3.48
51.14
83.10
357.63
97.00
Abbreviations as in Table 2
Direct costs
The average costs per patient with epilepsy per month for each patient group and type of cost
are presented in Table 2. Overall, patients from general practices appeared to incur the least
direct costs (52.08 € vs. 282.72 € of the patients from the UH, and 357.63 € of the patients
from the EC). Patients from the EC produced the most direct medical costs (274.53 €)
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whereas patients from the UH produced the most direct non-medical costs (104.58 €). In
particular, the items hospital services and drugs contributed the most to the medical costs, and
these were the highest in the group of patients from the EC. Concerning the non-medical
costs, the cost items transportation and unpaid care contributed the most to these costs. The
costs for the unpaid care were the highest in the group of patients from the UH.
Table 2 also displays the mean patient's out-of-pocket expenses per month for each patient
group. It appeared that patients from the UH had the highest patient's out-of-pocket expenses
(147.25 €).
Distribution of the costs of epilepsy across the patient groups
In general, the direct costs differed significantly across the three patient groups (PO.01), but
only for the patients from the UH were these costs significantly higher compared with the
patients from the general practices. Figure I shows the distribution of the several cost items in
each patient group. For the patients from the GP as well as for the patients from the EC. the
drug costs obtained the largest proportion of the total direct costs of care (57.7% and 45.3%
respectively). In contrast, for the patients from the UH. the costs of unpaid care constituted
the largest proportion of the total direct costs (41.6%). For this group of patients the drug
costs formed the second largest proportion of the total direct costs (16.9%).
Comparison of prospective with retrospective cost data
Compared to the estimated retrospective direct cost data, the prospective data differed
significantly only in the patients from the UH for the cost items physician services, diagnostic
procedures, and unpaid care In particular, the prospective cost data of the first two cost items
appeared to be significantly smaller than the retrospective data, while the prospective data of
the latter cost item (unpaid care) were significantly larger than the data collected
retrospectively.
Time costs and the indirect costs of epilepsy
In comparison with the other patient groups, patients from the GP had the least time costs (i.e.
the costs of the time a patient spends per month in seeking or undergoing a treatment). The
mean number of hours per month that this patient group spent in seeking or undergoing a
treatment was 0.13, while patients from the UH and EC spent 0.93 and 0.73 hours per month
respectively.
During the inclusion period of the study one patient with epilepsy, a patient from the epilepsy
center, 55 years of age, died. The productivity changes varied with each patient group, and the
highest changes were found in patients from the EC. For this patient group the mean reduced
productivity was 0.92 hours per month, and the mean lost productivity was 0.26 days per
month. In comparison, the mean reduced productivity for the patients from the UH was 0.30
hours per month. Moreover, it was found that the mean lost productivity for this patient group
and the mean lost and reduced productivity for the patients from the GP obtained such small
values that they could be considered as negligible.
Among the patients who agreed to participate, 34.5% supplied information regarding their
employment state. The mean age of these patients was 60 whereas the mean age of the
patients who did not provide any information about their employment state was 37. As
expected, the highest unemployment rates were reported from the patients from the epilepsy
center. Of the 14 patients from the EC who provided information about their employment
state, four were registered as temporarily sick, three were registered as permanently sick, two
worked on therapeutic base, two were unemployed, two patients were retired and one patient
got an early retirement. The majority of the patients from the UH were retired. In particular,
11 of the 21 patients who provided information on this subject were retired, while seven were
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registered as temporarily sick, two patients were early retired, and one patient had a part-time
job. Similarly, most of the patients from the GP were retired. More specifically, three of the
five patients who reported on this subject were retired, whereas one patient was registered as
temporarily sick, and one patient was employed part-time.
Patients from GP
Unpaid care
41,6%
Paid care
1,7%
Transportation
3,6%
Patients from UH
_ _ / J^
OP services
.7%
Physician services
8.3%
Hospital services
15.8%
1 Diagnostic tests
f 7 ,3%
f
Paramedical therapy
4,2%
AFID therapy
16.9%
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UapMdcoc
.9%
PMdcvc
4 J *
Tramporuiun
5.2%
AEl) therapy
45JS
Patients from EC
A»f1
GP lernen
2.9H
Pfcyucun KXYICCS
7J%
V Hop«! Mrvtca
V "•**
^ 1 DufTCAK ICO1
^ ^ 6.7%
J r Paramedical therapy
7.9S
FIG. 1. Distribution of the direct costs items of epilepsy in each patient group
(OP; general practice, UH; university hospital, EC; epilepsy center)-
Comparison with other cost studies
Two prevalence-based studies in the Netherlands have reported earlier the costs of epilepsy
(21, 22). Although these studies are difficult to compare with this present study due to
differences in study design, in the valuation of the cost items, in the types of costs and the list
of cost components included in the study, we attempted to compare their cost estimations with
our estimates of the costs of epilepsy by extrapolating our results. Thus, we estimated that the
total direct cost of epilepsy per patient per month (in Euros €) are 156.12 compared to 115.83
(22) and 112.08(21).
The costs of epilepsy in relation to the quality of life and the seizure severity
As it is shown in table 2, patients from the EC had the lowest mean total scores (62.87) on the
QOLIE-31, indicating that these patients, compared with the patients from the other patients
groups, experienced a diminished quality of life. However, the total score on the QOLIE-31
was not significantly associated with the total direct costs across the different patient groups.
Only for the patients from the general practices there was a moderate, but non significant,
association between the total score on the quality of life inventory and the total direct costs
(P-0.056). In contrast, the total score on the QOLIE-31 was significantly associated with the
total sum of direct costs from all patient groups (Spearman's rho=-0.263, P=0.017).
The distribution of seizure frequencies across the three patient groups according to seizure
type is shown in figure 2. It appeared that patients from GP reported lower seizure frequencies
than patients from the UH or EC. Moreover, these patients recorded less severe seizure types
(e.g. absences and seizures of unknown type) than the patients from the other two groups. In
accordance with these findings, the seizure severity appeared to be significantly associated
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with the total direct costs of epilepsy in the patient groups from the UH and the EC. This
result also confirms that the three different patient groups were well defined with respect to
the prognosis of the epilepsy.
unknown type
GP Patients from general practices
UH Patients from the university hospital
EC Patients from the epilepsy center
GP UH
Patient group
Fig. 2. Mean seizure frequency according to patient group and seizure type
Sensitivity analysis
For the estimation of the costs of a child minder we used the "shadow price" 7.94 €, which
resulted in 0.76 € per month for the group of patients from the UH. However, if we use the
mean of the reported patient's out-of-pocket expenses for a child minder to calculate this cost
item (9.80 €), then the mean costs for the group of patients from the UH would be 16.13 € per
month. For the other two patient groups the mean costs per month would remain negligibly
small.
Moreover, based on the 5 % range to test the likelihood of the assumptions, the mean costs of
the unspecified forms of therapy would vary from 2.19 € to 2.42 € per month.
The estimation of the transportation costs by taxi for the patients from the EC were based on
the mean of distances from the patients' private addresses to the epilepsy center (43 km). If
this distance would range from 40.85 km to 45.15 km, the corresponding costs would vary
between 4.90 € and 5.42 € per month.
The cumulative effect of these changes on the total mean direct costs, using the minimal and
maximal plausible values, would result in a 1.9 to 2.2 % change.
DISCUSSION
In this study, we estimated the costs of care in three different populations of patients with
epilepsy by obtaining direct actual data on epilepsy-attributable services from cost diaries and
questionnaires. The mean direct costs per month varied between 52.08 € and 357.63 €.
In total, two thirds of the returned cost diaries and questionnaires were completed, which
corresponds with the response rate reported by Goossens et al. (2). For the direct cost
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estimations we attempted to be complete by including as many epilepsy-related cost items as
possible. However, these cost estimates are conservative since we did not put a monetary
value on the time costs. We also did not assess the monetary value of the indirect and
intangible costs of epilepsy. Nevertheless, the results of these difficult to quantify items
indicate that epilepsy has significant implications for the costs of health care and emphasize
the importance of good seizure control.
The methods used to collect information about medical consumption and service use of the
patients with epilepsy had some limitations. First, we based our cost estimations on the data
reported by the patients, which we assumed that they have been correctly recorded. Goossens
et al. (2) examined in their study the validity of their cost diary by comparing the self-reported
information with data obtained from insurance companies. They (2) noted that precautions
should be taken when relying on patients to record cost data. However, many of the epilepsy-
related items cannot be easily identified (23). These items are often indirect effects of epilepsy
or its treatment but are not registered as such (e.g. admission to the hospital due to a seizure
related accident, or due to serious side effects of the AEDs). Moreover, the cost diary and cost
questionnaire enabled us to obtain actual data on direct non-medical costs such as
transportation costs and the costs of unpaid care which cannot be easily captured through
other sources such as hospital databases and patient records.
Patients from the general practices are probably a selection of the more severe cases, since
these patients may be more inclined to participate at this study. Consequently, the cost
estimates from this patient group show less contrast with the cost estimates from the other
patient groups. Nevertheless, the findings from this patient group corroborate with our
assumption, namely that patients with a good prognosis of epilepsy will require less service
use and will incur less costs.
A further limitation of our study is that we did not enroll patients admitted at the epilepsy
center, which means that our cost calculations are likely to underestimate the true costs of
epilepsy care.
The relatively short time perspective of the study (three months retrospectively and three
months prospectivcly) may have also affected our cost estimations. In general, the time
perspective of a study should be long enough to include all the major consequences of
epilepsy (24). It is likely that the information obtained during six months through the cost
diaries and cost questionnaire is representative for the information drawn from prevalent cases
of epilepsy during a longer period of observation (e.g. one year). However, this issue needs to
be verified by further research. Goossens et al. (2) examined in their study whether keeping a
cost diary for a part of a year would be representative compared to keeping a diary for the
whole year. They (2) concluded that collecting data for an abbreviated period can be a good
alternative but they also noted that, in general, in this way the variance of the estimates will
increase. Thus, requiring less effort per patient must be weighted against including more
patients.
A number of important findings were observed in this study. We found that the patient
groups, reflecting patients with a different prognosis of epilepsy, were significantly associated
with the total direct cost estimates and that patients with a good prognosis of epilepsy are
likely to incur less costs than patients from other prognostic groups. Similar results have been
reported in other studies (3, 5, 7, 25). Antiepileptic drugs and hospitalization were responsible
for the majority of the direct medical costs, which corresponds with the findings in other
studies (3, 7, 9-11). Moreover, it appeared that transportation and unpaid care accounted for
the majority of the non-medical direct costs, and that a great proportion of patients with
severe epilepsy (i.e. patients from the epilepsy center) is unemployed and reports large
productivity losses. These findings are reflected by the low score of these patients on the
quality of life inventory, which provides insight into the social consequences of epilepsy.
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Similar patterns of unemployment and productivity changes have been reported by Begley et
al. (7) and Jacoby et al.(3). Elwes et al. (26) indicated that high unemployment rates among
patients with epilepsy consist only one aspect of a wider spectrum of social and economic
disadvantages. In addition, patients from the epilepsy center and university hospital spent
more time in seeking or undergoing a treatment than patients from the general practices.
With respect to the distribution of the total direct costs, the direct costs differed significantly
across the three patient groups, but only for the patients from the university hospital were
these costs significantly higher compared with the patients from the general practices.
Furthermore, in contrast with the other patient groups in which drug costs obtained the largest
proportion of the total direct costs, in the group of patients from the university hospital the
costs of unpaid care contributed the most to the total direct costs. It was also found that only
in this patient group the prospective data differed significantly from the retrospective data for
the cost items physician services, diagnostic procedures, and unpaid care. These findings may
indicate that these patients may have a totally different pattern of health care resource use
across time than the patients from the other two patient groups.
In this study, no reliable data were available for certain cost items. To investigate the extent to
which the assumptions we made for the estimation of these cost items may have induced
some bias, we performed a sensitivity analysis. The cumulative effect of the modifications in
the total mean direct costs gives rise to a 1.9 to 2.2 % change. Consequently, we may
conclude that our findings regarding the total direct costs of epilepsy are quite robust.
Despite the fact that we did not include in our calculations the costs of patients admitted at the
epilepsy center as the studies by Polder et al. (22) and Blom (21) had done, we estimated
higher total direct costs than these studies. This might indicate that cost diaries can provide
more meticulous information on service use of the patients with epilepsy than retrospective
databases or models.
In summary, this study demonstrates that cost estimations can be influenced by the prognosis
of epilepsy and that certain cost items (drugs, hospitalization, transportation, and unpaid care)
account for the majority of the total direct costs. Moreover, it can be deduced from the
comparison of the retrospective with the prospective cost data that different patient groups
may be characterized by a certain pattern of health care resource use across time. However,
more studies with a larger number of patients from each health care setting are needed to
investigate the pattern of health care resource use across the different patient groups.
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General discussion
102 I General discussion
Epilepsy is a common chronic neurological disorder that affects people worldwide
irrespective of age, sex or race, creating significant economic and social burdens. In this
thesis the epidemiologica) as well as the economic aspects of epilepsy have been studied.
Thus, this thesis consists of two sections, a section about the incidence and diagnostic aspects
of epileptic seizures and a section about the costs of epilepsy. In this chapter, the main
findings and conclusions of both sections will be discussed followed by some
recommendations for future research.
Incidence of epilepsy and diagnostic aspects of epileptic and non-epileptic seizures
During the last three decades several studies of the incidence of epilepsy and unprovoked
seizures (i.e. seizures that are not resulting from an acute disturbance of brain structure or
metabolism or an acute systemic metabolic disturbance) have been performed in
industrialized and in developing countries. In a systematic review of the methodology of
incidence studies of epilepsy and unprovoked seizures and a meta-analysis of their results, we
showed that the age-specific incidence of epilepsy had a bimodal distribution with the highest
peak in childhood. Possible causes of epilepsy in childhood are congenital, developmental,
and genetic conditions (1.2). The most common cause of epilepsy in the elderly population is
ccrcbrovascular disease (1-3). However, our findings regarding the incidence of unprovoked
seizures and other specific incidence rates of epilepsy (i.e. sex-specific incidence and
incidence by seizure type) did not reach significance due to the low power of the studies. For
the same reason, no definite conclusions could be reached for the trends of both the incidence
of epilepsy and unprovoked seizures over time and the pattem of the age-specific incidence of
epilepsy in developing countries. In addition, these studies appeared to have a considerable
heterogeneity in study design and definitions. Therefore, a sensitivity analysis was carried out
by removing successively incidence studies with a low methodological quality score. This
resulted in lower median incidence rates of epilepsy and unprovoked seizures, which may
reflect a better case ascertainment method, classification, and definition of epileptic seizures.
Our evaluation of the methodology of the incidence studies was based on a checklist which
we developed according to proposals for reporting meta-analyses of observational studies (4).
So far, though, no standardized checklist for the methodological assessment of observational
studies has been developed yet.
Similarly, our conclusions from the systematic review of the recent literature on the etiology
of the non-epileptic seizures (NES) are not based on a earlier available standardized checklist.
We developed a checklist in order to evaluate the methodological quality of the studies
reviewed and assess the information provided by these studies regarding the etiology of NES.
Concerning the methodological quality of the reviewed studies, this systematic review
showed that the studies of NES are characterized by a wide methodological heterogeneity and
generally have a low methodological quality. Thus, the quality of evidence regarding the
possible risk factors is low. Several psychological factors may underlie the development and
maintenance of NES. but a number of issues, such as unclear definition and selection criteria,
lack of standardized methods to assess and describe patients with NES. small sample size,
short follow up and lack of control groups, inhibit definite conclusions.
Based on the findings of both systematic reviews we concluded that for unbiased evaluations
of several variables of interest population-based studies with a prospective design are needed.
Therefore, we conducted such a study from October 1. 1998 to September 30. 2000 in
Maastricht and its surroundings, which is a well circumscribed area located at the southern
part of the Netherlands. In this study a strong effort was made to identify all possible cases
with epileptic seizures and to avoid selection bias. For this purpose, the surveillance
procedure used several sources to identify cases and all cases were discussed collectively and
decisions were consensus-based. A total of 350 cases was entered in this study. Unprovoked
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seizures were diagnosed in the majority of the cases (49.7%), followed by the non-epileptic
seizures of organic origin (22.3%). the non-epileptic seizure of non-organic origin (18%). and
the acute symptomatic seizures (7.7%). Ninety-four (54%) of the 174 cases with unprovoked
seizures fulfilled the diagnostic criteria for epilepsy as they appeared to have had two or more
recurrent unprovoked seizures. The comprehensiveness of our case-ascertainment could be
confirmed by the fact that for more than half of the patients (62.4%) the first seizure had
appeared in a period of less than a month. In addition, we also attempted to examine as much
as possible cases in a standardized manner. Thus, the information collected would be more
likely to provide the clinical details necessary for a reliable diagnosis of the seizures and for
an accurate classification of the epileptic seizures according to the ILAE criteria. In all. 71.1%
of the patients were examined in a standardized manner by one of the authors (IK) whereas
28.9% of the patients were not seen by this author. This last group of patients was consisted
mostly of patients who had a bad clinical condition at the time of their admittance and were
usually discharged to the nursing homes directly. In a few cases, this last group of patients
included patients with a known neurological disease such as brain tumor or ccrebrovascular
disease. These patients were often referred to the neurologists who had seen them regularly at
the outpatient department of neurology. The overall incidence of epilepsy and unprovoked
seizures found in this study was similar to results from other population-based studies in
industrialized countries. Moreover, the age-specific incidence increased with age in
concordance with other studies in developed countries. Similarly, the incidence and
distribution of certain seizure types and epilepsy syndromes was in accordance with other
studies. However, in this study a relatively high proportion of cases remained unclassified, as
compared to other studies (5-7), partly due to differences in the interpretation of the ILAE
classification. These difficulties in interpretation of the ILAE classification have also been
highlighted by other authors (8, 9) and recently, a proposal for a new classification of the
epilep§ie§ and epilepiy §yndrome§ ha§ been published (10).
Furthermore, in this study we also focused on the characteristics of the cohort with epileptic
and non-epileptic seizures in order to identify predictive factors with which patients with
epileptic seizures can be distinguished from patients with non-epileptic seizures. As expected,
the strongest predictor for patients with unprovoked seizures was an epileptiform EEG pattern
whereas for the patients with non-epileptic seizures of organic origin there was a high
probability of a history of hypertension or cardiovascular disease. The predictive model of
patients with non-epileptic seizures of non-organic origin included female sex and, quite
unexpectedly, a history of head injury. However, there is evidence that a history of trauma
and physical abuse may be common in patients with this type of seizures (11). In addition,
head injury as an event can give rise to stress in susceptible individuals. However, as this
study included no cases who had both epileptic and non-epileptic seizures, these conclusions
probably can not be applied to these patients.
Since two thirds of the cases included in this study were evaluated in a standardized manner,
we investigated whether there is a cluster of diagnostic items which can assist in the early
identification of patients with epileptic seizures. It appeared that certain items from the
history, hetero-anamnesis and findings from ancillary tests can be helpful in differentiating
epileptic from non-epileptic seizures. In particular, the logistic regression analysis for the
group of patients who were evaluated in a systematic way showed that for the subgroup of
patients with unprovoked seizures the items loss of consciousness, postictal confusion,
epileptiform EEG pattern and abnormal finding on the CT and MRI were a distinctive feature.
Similarly, the items female sex and location of the seizure out of doors were diagnostic
indicators for the subgroup of patients with non-epileptic seizures of organic origin. The fact
that females more often than males consult their physician for episodes of disturbed
consciousness (12) and that exercise and warmth were the most common provoking factors
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reported by this group of patients, may explain these items as a distinctive feature for the
group of patients with non-epileptic seizures of organic origin. The group of patients with
non-epileptic seizures of non-organic origin was characterized with the items a history of
febrile seizures, treatment by a psychiatrist or psychologist, more than one seizure
experienced, presentiment of the seizure (e.g. a feeling of choking, tingling, palpitations) and
back arching during the seizure. These findings are in agreement with other studies which
report probable characteristics of this group of patients (11, 13-16).
In sum, this study showed that certain ancillary tests (EEG, CT, and MRI) are in particular a
diagnostic indicator for the group of patients with unprovoked seizures whereas for the two
subgroups of patients with non-epileptic seizures (seizures of organic and non-organic origin)
certain items from the history and hetero-anamnesis rather than from ancillary tests seem to
be an important distinctive feature. Thus, by obtaining information on certain items from the
history and hetero-anamnesis a physician would be able to reach a reliable diagnosis of the
non-cpileplic seizures at an early stage. In contrast, for the diagnosis of epileptic seizures a
physician would first need to apply some ancillary tests in order to obtain more certainty
about the diagnosis of these seizures. However, the conclusions of this study are to some
extent limited because they are based on a relatively small sample of patients. Only 63 (18%)
of the 350 cases included in this study were diagnosed with non-epileptic non-organic
seizures. In addition, these findings probably can not be applied to patients in whom both
epileptic and non-epileptic seizures co-exist. Therefore, the findings of this study need to be
verified by other population-based studies with larger samples of patients. Also, in such
studies a further differentiation of subgroups would be possible.
Coiti of epilcpty
Cost of illness (C'OI) studies estimate the burden of specific diseases in the community.
1 pilcpsy has a financial burden with regard to individual patients and society and in the last
few years the costs of epilepsy have been studied in various countries. In a systematic review
we first assessed several methodological aspects of these studies and second we compared
systematically their results. We found that epilepsy cost studies are not directly comparable
due to differences in the methods and definitions used and due to the differences in the health
care provision and economic conditions between different countries. We concluded that COI
studies can provide comprehensive estimates of the cost of epilepsy and can assist health
policy decisions if they have a transparent methodology and analysis of the data, clearly
describe the definitions used, state the limitations of the data, mention which costs are
associated with comorbid conditions, and take into account the temporal aspects of epilepsy
by stratifying the costs and by obtaining data from a population of patients with epilepsy
prospectively.
Furthermore, based on key methodological, country-related, and monetary issues in epilepsy
cost studies, we compared the direct cost estimates of studies that have a similar study design
and method, and we analyzed the distribution of the direct costs of epilepsy. Thus, we
estimated that the proportion of the national health care expenditure on epilepsy varies
between 0.12 and 1.12% or between 0.12 and 1.05% depending on the type of the conversion
factor (i.e. exchange rate, purchasing powers of currencies). In addition, the majority of the
epilepsy cost studies assessed the costs of hospital services and the costs of drug treatment.
However, the contribution of these costs components to the total direct costs of epilepsy
decreases in more comprehensive lists of cost components. In our estimations of the direct
costs of epilepsy we encountered a number of limitations related to several methodological
issues of the epilepsy cost studies. These limitations are the lack of consideration of the non-
medical and family-related costs, the problem of comorbid conditions, which can lead to an
overestimation of the costs of epilepsy, and the variation of the costs by severity of epilepsy.
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Moreover, we did not calculate the indirect and intangible costs of epilepsy. Consequently,
our estimations of the costs of epilepsy are conservative. Nevertheless, we concluded that an
analysis of the impact of a disease on the national health care expenditure provides the
possibility to make comparison across different countries and across different diseases.
Since prospective studies can provide reliable data over the costs of epilepsy over time, we
prospectively calculated the direct and indirect costs of epilepsy in three different populations
of patients with epilepsy: general practices (GP), university hospital (UH). and epilepsy center
(EC). These groups of patients reflected patients with a different prognosis of epilepsy. We
also used a quality of life inventory to obtain information on the intangible costs of epilepsy
(i.e. the economic cost of the burden imposed on the patients as a consequence of their
epilepsy). This study showed that the mean costs per patient per month ranged from 52.1 to
357.6 (in Euros €). Unsurprisingly, patients from the GP, who were assumed to have a good
prognosis of epilepsy, generated the lowest direct costs and reported lower seizure
frequencies and less severe seizure types than the other groups of patients. In contrast,
patients from the EC, who were assumed to have an uncertain or bad prognosis of epilepsy,
incurred the highest direct costs and had the lowest scores on the quality of life inventory.
Although we attempted to be comprehensive by including as many epilepsy-related cost items
as possible, our cost estimations are conservative since we did not put a monetary value on
the time costs (i.e. the time a patient spends in seeking or undergoing a treatment) and on the
indirect and intangible costs of epilepsy. Our cost estimations encountered also some other
limitations. First, the estimations are based on a cost diary which was developed according to
cost diaries of other chronic diseases. Second, we assumed that the data have been correctly
reported by the patients, since it was difficult to evaluate the value of this information by
using other data sources. Third, no patients admitted at the epilepsy center were included in
this study. This exclusion means that the true costs of epilepsy care in the epilepsy center are
likely to be underestimated. Fourth, the short time perspective of the study (i.e. three months
prospectively) may have also afflicted the cost estimations. Despite these limitations, our cost
estimations are more comprehensive compared to those of other studies in the Netherlands
(17,18), which did not have a prospective design. Our cost estimations proved also to be
higher than those estimated in the other Dutch studies (17,18).
Future perspectives
The prospective population-based study described in this thesis resulted in a cohort of patients
with newly diagnosed epilepsy and a cohort of patients with non-epileptic non-organic
seizures (NES). Since population-based studies provide the opportunity to make unbiased
observations resulting in an elucidation of risk factor-outcome associations, it would be very
interesting to enlarge this cohort of patients and study their long-term outcome.
A long-term follow up of patients with newly diagnosed epilepsy can provide more insight
into the prognosis of epilepsy, the risk factors for medical resistance, and the associated
morbidity and mortality of these patients. Most patients with newly diagnosed epilepsy
become seizure free, and the majority of them can also discontinue the antiepileptic drugs
without experiencing further seizures. The challenge is to clarify factors associated with a
good or bad prognosis. Kwan et al.(19) found in their prospective study of 525 patients with
epilepsy that the subgroup of patients who had many seizures before therapy or who had an
inadequate response to initial treatment with antiepileptic drugs were more likely to have
refractory epilepsy. In addition, there is evidence that patients with epilepsy, particularly
patients with epilepsy of unknown cause, are at increased risk for death (20). The reasons for
this are unclear. Similar epidemiological projects are now being conducted in other European
countries (e.g. Germany, Sweden) and in the future it is likely that through scientific
cooperation the long-term outcome of patients with epilepsy will be much more clarified.
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Much less is known about the long-term outcome of patients with NES. Patients with NES are
a heterogeneous group and it is important to identify them early in the course of the seizure
disorder in order to offer them appropriate treatments. It is still unclear which risk factors
contribute to the development and maintenance of these seizures. An enlargement of the
cohort of these patients would shed more light on these factors and would help in determining
the baseline characteristics of this group of patients. In this way, a cluster of diagnostic and
prognostic items with which these patients can be distinguished from patients with epileptic
seizures could be defined, and the long-term prognosis could be predicted.
Concerning the costs of epilepsy, in this thesis a new instrument for estimating the costs of
epilepsy care prospectively has been investigated. Cost diaries have already been used in cost
studies of other chronic diseases and proved to provide detailed and reliable information
prospectively (21). In this thesis, the cost diary has been studied in a relatively small sample
of patients with epilepsy. Its utility needs to be confirmed in a larger sample of patients with
epilepsy. Thereafter, the cost diary can be implemented in other economic evaluations studies
(e.g. cost-effectiveness, cost-utility studies), which estimate the value of several interventions
for patients with epilepsy.
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Summary
Epilepsy is a complex symptom caused by a variety of pathological processes in the brain. It
is characterized by recurrent (two or more) epileptic seizures, unprovoked by any immediate
cause. An epileptic seizure has been defined as a clinical manifestation resulting from an
abnormal and excessive discharge of a set of neurons in the brain.
After headache, epilepsy is the second most common chronic neurological condition.
Epilepsy affects about one of 200 people in the developed countries, creating significant
economic and social burdens. The social and personal costs of epilepsy are significant, as
evidenced by the high rate of unemployment and underemployment among epileptic patients.
The first part of this thesis (chapters 2 to 5) focuses on the incidence (annual rate of
appearance of new cases) and diagnosis of epileptic seizures whereas the second part
(chapters 6 to 8) focuses on the economic aspects of epilepsy.
In chapter 2, a systematic review of incidence studies of epilepsy and unprovoked seizures is
described with the aim to evaluate the methodology of these studies and assess the value of
their findings by synthesizing their results. The literature for the period January 1966 to
December 1999 was searched and independently evaluated by two authors who used a newly
developed checklist. In total, 40 studies met the inclusion criteria. There was a considerable
heterogeneity in study methodology and the methodological quality was generally low. The
median incidence rate of epilepsy and unprovoked seizures was 47.4 and 56/100,000
respectively. The age-specific incidence was high in those aged 60 years or older but the
highest in childhood. However, no definite conclusions could be reached for the incidence of
unprovoked seizures and other specific incidence rates of epilepsy (sex- and seizure-specific
incidence) due to the small number of the incidence studies.
The recent literature (from January 1995 to December 1999) is systematically reviewed in
chapter 3 in order to provide more insight into the recent evidence on the risk factors and
mechanisms that are associated with the non-epileptic seizures (NES). NES are defined as a
sudden change in a person's behavior, which is usually time limited, and is often mistaken for
epilepsy, but is unaccompanied with the characteristic changes on the EEG which indicate
true epilepsy, and is not caused by an organic disease. The methodological quality was
independently evaluated by two authors who used a newly developed checklist. In addition,
several items which can provide evidence about the possible risk factors for NES were
assessed. Overall, 33 studies met the inclusion criteria. There was a wide heterogeneity in
study methodology which was associated with a low methodological quality. While several
psychological factors may underlie the development and maintenance of NES, no definite
conclusion could be reached regarding their etiology.
Chapter 4 describes a prospective population-based study in the area of Maastricht with the
aim to estimate the incidence of unprovoked seizures and epilepsy in this area in relation to
age, sex, etiology and seizure type and to identify predictive factors of the epileptic and non-
epileptic seizures. All patients aged > 14 years who have experienced their first seizure or
who had undiagnosed seizures before the study period (October 1998 to September 2000)
were included in this study. These patients were identified through different sources and were
independently evaluated and classified by a team of three neurologists. Moreover, predictive
factors for the diagnosis of epileptic and non-epileptic seizures were examined.
The total incidence was 55/100,000 and 30/100,000 for the unprovoked seizures and epilepsy
respectively. The age-specific incidence increased with age and was highest for the patients
aged > 65 years. In males the incidence of epilepsy and unprovoked seizures was higher than
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in females and partial seizures prevailed over the generalized seizures. In about 35% of the
patients with epilepsy and epileptic seizures an underlying cause could be identified. The
most common causes were cerebrovascular disease and brain tumors. The results of this study
are similar to those reported by other developed countries. Furthermore, certain predictive
factors were identified for patients with epileptic and non-epileptic seizures of organic origin.
These were an epileptiform EEG pattern for the first group and a history of hypertension or
cardiovascular disease for the second group of patients. Strong predictors for the patients with
non-epileptic seizures of non-organic origin were female sex a history of head injury.
A prospective-population based study of a cohort of patients aged £ 14 years, suspected with
a first seizure, is reported in chapter 5. The aim of this study was to define systematically a
cluster of diagnostic items which can assist in the early identification of epileptic and non-
epileptic seizures. Two thirds of the patients included in this study were examined in a
standardized manner. In these patients, several diagnostic items (history', hetero-anamnesis.
and findings from the physical examination and diagnostic tests) for epileptic and non-
epileptic seizures were investigated. In total 350 cases were entered in this study. Certain
distinctive features for patients with epileptic and non-epileptic seizures of organic origin
were identified. For instance, patients with epileptic seizures were characterized with items
such as postictal confusion, an epileptiform EKG pattern, and abnormal neuroimaging
findings. Similarly, patients with non-epileptic seizures of organic origin were characterized
with items such as a history of hypertension, and provoking factors (e.g. exercise and
warmth). Distinctive features for the patients with non-epileptic seizures of non-organic origin
were items such as a history of febrile seizures, treatment by a psychologist or psychiatrist,
presentiment of the seizure (e.g. feeling of choking, palpitations), a history of chronic
obstructive pulmonary disease, gradual end of the seizure, and a memory of the seizure. A
separate analysis for the patients who were investigated systematically provided some
additional diagnostic items for the subgroups of patients with epileptic and non-epileptic
seizures. For example, back arching during the seizure for the patients with seizures of non-
organic origin, and female sex for the patients with non-epileptic seizures of organic origin.
Concerning the patients who were not examined in a systematic way, no diagnostic item was
found that could discriminate significantly the different subgroups of patients.
In chapters 6 and 7 a systematic review of epilepsy cost studies is provided. The purpose of
this review is twofold. First, to review systematically key methodological issues of these
studies and second, compare in a systematic way the national and per capita estimates of the
costs of epilepsy in different countries. The literature was searched from 1966 to March 2000.
Several methodological aspects, concerning the study design and estimation procedure used
for the calculation of the costs of epilepsy, were examined to the extend to which these
aspects have been employed in the studies reviewed. In total. 15 studies were identified and
analyzed. 67% of the selected studies had a retrospective design and used data commonly
derived from existing databases. Only a minority of studies used a sensitivity analysis to
control for the assumptions made in the calculations. In general, studies of the costs of
epilepsy show a wide variation in the methods and definitions used. Therefore, several
recommendations were proposed. In particular, a transparant methodology and analysis of the
data, a clear description of the definitions used, and consideration of the natural course of
epilepsy by analyzing the costs for each prognostic group separately and by obtaining data
prospectivcly. was suggested.
Furthermore, in this review key melhodologic. country-related, and monetary issues of the
selected epilepsy costs studies were evaluated to compare their direct cost estimates (costs of
goods and services used to treat a disease) and to explore their distribution. Ten epilepsy cost
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studies were reviewed. The proportion of national health care expenditure on epilepsy showed
a range of 0.12-1.12% or 0.12-1.05% depending on the type of the conversion factor. The
conversion factors were exchange rate and purchasing power of currencies. Purchasing power
parities (PPPs) mean that a given sum of money, when converted into different currencies at
the PPPs rates, will buy the same amount of goods and services in all countries. Moreover, it
was found that the list of cost components included in the estimation of the direct costs of
epilepsy (e.g. drug costs, hospital costs, transportation costs from and to the hospital) differed
from study to study. A comprehensive list was associated with a decrease in the contribution
of the drug and hospital costs to the total direct costs of epilepsy.
Chapter 8 describes a study of the costs of epilepsy care in three different populations of
patients with epilepsy (general practices, university hospital, and epilepsy center). The costs
were calculated for three months prospectively by means of a cost diary and for three months
retrospectively with a cost questionnaire. In addition, a quality of life inventory was used to
obtain insight into the burden imposed on the patients as a consequence of their epilepsy. 116
patients with established epilepsy participated in this study and the mean costs per month
ranged from 52.1 to 357.6 (in Euros €). Patients from the general practices, who were
assumed to have a good prognosis of epilepsy, appeared to have lower direct costs, spent less
time in seeking or undergoing a treatment, and reported lower seizure frequencies and less
sever seizure types than the patients from the other patient groups. In contrast, patients from
the epilepsy center, who were assumed to have an uncertain or bad prognosis of epilepsy,
reported the highest productivity changes and unemployment rates and also had the lowest
scores on the quality of life inventory. Furthermore, higher cost estimations were found in this
study compared to other studies in the Netherlands which had a retrospective study design.
In chapter 9 the results of the studies are discussed and some future perspectives arc given.
The prospective population-based study described in this thesis resulted in a cohort of patients
with newly diagnosed seizures and a cohort of patients with non-epileptic non-organic
seizures (NES). A long-term follow up and an enlargement of both cohorts has been
suggested in order to obtain more insight into the prognosis of epilepsy, the associated
mortality and morbidity of patients with epilepsy, and the long-term outcome of patients with
NES. In addition, an enlargement of the cohort of patients with NES would help in clarifying
which risk factors contribute to the development and maintenance of these seizures, and
would help in determining the baseline characteristics of this group of patients. Thus, a cluster
of diagnostic items with which these patients can be distinguished from patients with epileptic
seizures could be defined. Concerning the study of the costs of epilepsy, the estimation of the
costs prospectively were based on a cost diary. More research is warranted to evaluate the
utility of this cost diary, which can be also implemented in other economic evaluation studies
(e.g. cost-effectiveness, cost-utility studies). Economic evaluation studies could then estimate
the value of several interventions for patients with epilepsy.
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Samenvatting
Epilepsie is een chronische ziekte die kan ontstaan door een groot aantal aandocningen van de
hersenen, zoals een hersentumor. een herseninfarct. een erfelijke aanleg of zo maar. zonder
dat een oorzaak kan worden vastgesteld. Wordt de diagnose epilepsie gesteld. dan is er sprake
(geweest) van twee of meer epileptische aanvallen die niet werden opgewekt door een dirccte
oorzaak. Deze aanvallen heten dan ook ongeprovoceerde aanvallen. Als onmiddellijk wel een
dirccte oorzaak kan worden aangewezen zoals een klap op hct hoofd. een koortsendc ziekte.
nekkramp met een bijkomende ontsteking van de hersenen. ernstig slaapgehrck of
alcoholmisbruik dan spreekt men van acuut symptomatische epileptische aanvallen maar niet
van epilepsie.
Een epileptische aanval bestaat uit uiteenlopende klinische verschijnselen die opgewekt
worden door spontane, plotselinge en kortdurende ontladingen van een groep herscncellcn.
Na hoofdpijn is epilepsie de meest voorkomende chronische neurologische anndoening.
Ongeveer een op de 200 mensen in ontwikkelde landen hceft epilepsie. hctgeen betekent dat
epilepsie belangrijke economische en maatschappelijke gevolgen heeft. De maatschappelijkc
en individuele kosten die gepaard gaan met epilepsie zijn niet onaanzienlijk aangc/icn vele
patienten met epilepsie werkloos zijn of beduidend onder hun opleidingsnivcau werken.
In Nederland is geen recent epidemiologisch onderzoek gedaan naar het aantal nieuwe
gevallen van epilepsie per 100,000 inwoncrs. naar risicofactorcn voor hct ontstaan van
epileptische en niet epileptische aanvallen en naar de manier waarop je de diagnose epilepsie
stelt. Ook de economische aspecten van epilepsie verdienden een nieuw onderzoek in
Nederland.
De hoofdstukken twee tot en met vijf van dit proefschrift richten zieh op de ineidentie (aantal
nieuwe gevallen per 100,000 inwoners per jaar) en de diagnose van epileptische aanvallen.
terwijl in de hoofdstukken 6 tot en met 8 de economische aspeclen van epilepsie worden
besproken.
Hoofdstuk 2 biedt een systematisch overzicht van de literatuur betreffende de ineidentie van
epilepsie en van ongeprovoceerde aanvallen. Van de geselecteerde onderzoeken werd de
methodologie beoordeeld en de resultaten samengevat. Hiervoor werd een nieuwe checklist
ontwikkeld waarmee twee onderzoekers onafhankelijk van elkaar de literatuur uit de periode
januari 1966 tot december 1999 hebben beoordeeld. In totaal voldeden 40 onderzoeken aan de
inclusie criteria. Deze onderzoeken verschilden aanzienlijk met betrekking tot de
methodologie die veelal ondermaats was. De mediane ineidentie ratio van epilepsie en van
ongeprovoceerde aanvallen was respectievelijk 47.4 en 56/100,000. De leeftijdspecifieke
ineidentie van epilepsie was hoog onder mensen van 60 jaar en ouder maar was het hoogst op
kinderleeftijd. Desondanks konden met betrekking tot de ineidentie van ongeprovoceerde
aanvallen en van andere specifieke ineidentie ratio's van epilepsie (aanvalstype- en
geslachtspecifieke ineidentie) geen duidelijke conclusies getrokken worden vanwege het
kleine aantal onderzoeken.
In hoofdstuk 3 wordt een systematische samenvatting gegeven van de literatuur van januari
1995 tot december 1999 inzake niet epileptische aanvallen. Er is gekozen voor de periode
vanaf januari 1995 omdat in 1994 een nieuwe editie van de DSM criteria gepubliceerd werd
(DSM IV) waarmee in de samen te vatten literatuur rekening zou zijn gehouden. Bij het
bewerken van de recente literatuur hebben we sterk rekening gehouden met recente inzichten
inzake de risieofactoren en de mechanismen die geassocieerd zijn met het ontstaan van niet
epileptische aanvallen (NEA). NEA worden gedefinieerd als aanvallen met een plotselinge
gedragsverandering, die meestal kortdurend is en vaak lijkt op een epileptische aanval, maar
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die niet gepaard gaat met de voor epilepsie kenmerkende Veränderungen op het EEG en
waarvoor geen organische oorzaak gevonden kan worden.
Onafhankclijk van elkaar hebben twee onderzoekers de geselecteerde onderzoeken
beoordecld op de methodologische kwaliteit. Hiervoor werd een nieuwe checklist ontwikkeld.
33 onderzoeken voldeden aan de inclusie criteria. Bij deze onderzoeken werden ook de
rcsultatcn beoordecld die inzicht leverden in de mogelijke risico factoren voor het krijgen van
NEA. De diverse onderzoeken waren methodologisch vaak verschillend en op zijn best matig
van kwaliteit. Hoe we I er aanwijzingen zijn dat verschillende psychologische factoren een rol
kunnen spelen bij het onlslaan en in stand houden van NEA, was het niet mogelijk om op
basis van de rcccnte litcratuur duidelijkc conclusies te trekken ten aanzien van de etiologie
van NEA.
I loofdstuk 4 bcschrijft ccn prospecticf onderzoek onder de algemene bevolking in de regio
Maastricht, een aancengcsloten gebied met ongeveer 150.000 inwoners. Doel van dit
onderzoek was cncr/.ijds het berekenen van de ineidentie van ongeprovocccrde aanvallen en
cpilcpsic in dczc rcgio en andcrzijds het bestuderen van deze ineidentie in relatie met leeftijd,
gcslacht, ctiologic en aanvalstypc teneinde factoren te identificeren die epileptische dan wel
niet epileptische aanvallen voorspellen (de voorspcllende factoren). Geincludeerd werden alle
patifnicn vanaf 14 jaar die gedurende de onderzoeksperiode (1 oktober 1998 tot en met 30
September 2000) ccn ccrstc aanval hebben gchad dan wcl vöör die onderzoeksperiode
aanvallen hebben gchad waarvan dc diagnose nog niet bekend was. Deze patie'nten werden
gctdcntificeerd via verschillende bronnen (huisarts, poll neurologic EHBO en andere
afdelingcn in het academisch ziekenhuis Maastricht, het enige ziekenhuis in die regio) en
werden bcoordccld en gcclassificcerd door twee ncurologen, die onafhankelijk van elkaar tot
een gclijkluidcnde diagnose probecrden te komen en die bij verschil van mening met de hulp
van ccn dcrdc neuroloog tot een bcsluit kwarnen. Daamaast werden voorspellende factoren
voor de diagnose van epileptische en niet epileptische aanvallen onderzocht.
De totale ineidentie was 55/100,000 en 30/100,000 respectievelijk voor de ongeprovoeeerde
aanvallen en voor epilepsie. De leeftijdspecifieke ineidentie nam toe met de leeftijd en was
het hoogst bij de patie'nten van 65 jaar en ouder. Bij mannen was de ineidentie van epilepsie
en ongeprovoeeerde aanvallen hoger dan bij vrouwen. Daamaast kwamen de partiele
aanvallen vakcr voor dan de gegeneraliseerde aanvallen. Bij ongeveer 35% van de patie'nten
met epilepsie en epileptische aanvallen kon een onderliggende oorzaak vastgesteld worden.
De meest voorkomende oorzaken waren cerebrovasculaire aandoeningen en hersentumoren.
De resultaten van dit onderzoek zijn vergelijkbaar met de bevindingen van onderzoeken in
andere ontwikkelde landen.
In dit onderzoek werden ook specifieke voorspellende factoren voor epileptische en niet
epileptische aanvallen gevonden. Epilcptiforme afwijkingen op het EEG bleken voorspellend
te zijn voor de groep patie'nten met epileptische aanvallen, terwijl hart- en vaatziekten of
hypertensic in de voorgeschiedenis voorspellend waren voor de groep patie'nten met niet
epileptische aanvallen van organische origine. Voor de groep patienten met niet epileptische
aanvallen van niet organische origine bleken het vrouwelijk geslacht en een hersenletsel in de
voorgeschiedenis een hoge voorspellende waarde te hebben.
In hoofdstuk 5 wordt een prospectief onderzoek onder de algemene bevolking besproken van
een cohort patienten van 14 jaar of ouder die een eerste aanval hebben gehad. Dit onderzoek
had als doel de systematische identificatie van een cluster van factoren waarmee epileptische
en niet epileptische aanvallen vroegtijdig gediagnostiseerd kunnen worden. In totaal zijn 350
patienten gcVncludeerd in dit onderzoek. Twee derde van de patienten zijn op een
gestandaardiseerdc wijzc onderzocht. Bij deze patienten zijn verschillende diagnostische
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factoren (voorgeschiedenis. hctero-anamnese. en bevindingen van het lichamelijk en
aanvullend onderzoek) voor de epileptische en niet epileptische aanvallen bestudeerd. Via
logistische regressie analyse werden de volgende spccifieke diagnostische factoren voor
epileptische en niet epileptische aanvallen gevonden:
1. patienten met epileptische aanvallen werden gckcnmerkt door factoren als postictale
verwardheid. epileptiforme afwijkingen op het EEG en afwijkende bevindingen bij het
radiodiagnostisch onderzoek (CT scan. MRI scan);
2. patienten met niet epileptische aanvallen van organische origine werden gekuraktcriseerd
door factoren als hypertensie in de voorgeschiedenis en uitlokkende factoren
(bijvoorbeeld wärmte en inspanning);
3. patienten met niet epileptische aanvallen van niet organische origine werden gekenmerkt
door koortsstuipen of een chronische obstmctieve longziekte in de voorgeschiedenis.
behandeling door een psycholoog of psychiater, het voelen aankomen van dc aanval
(bijvoorbeeld een gevoel van benauwdheid of hartkloppingen). het gclcidelijk stoppen van
de aanval. en het zieh herinneren (althans van een gedeelte) van de uanval
Een analyse van de groep patienten die op een gestandaardiseerde wijze werden onderzocht
leverde enkele aanvullende diagnostische factoren op voor de subgrocpen van patienten met
epileptische en niet epileptische aanvallen:
1. het achterwaarts krommen van de rug tijdens de aanval (waardoor de patient als het ware
op hielen en achterhoofd Staat, de zogenaamde arc de cercle) bleek gcassociecrd te zijn
met niet-epileptische aanvallen van niet organische origine;
2. het vrouwelijk geslacht bleek gcassocieerd te zijn met niet-epileptische aanvallen van
organische origine.
Bij de groep patienten die niet op een gestandaardiseerde wijze onderzocht zijn daarcntcgen,
is geen diagnostische factor gevonden die de verschillcnde subgroepen van putiönlcn statisch
significant van elkaar kon onderscheiden.
De hoofdstukken 6 en 7 bieden een systematisch overzicht van de onderzoeken naar de kosten
van epilepsie. Literatuur uit de periode 1966 tot maart 2000 werd gelezen. Hierbij werd
gestreefd enerzijds naar een systematische beoordeling van de methodologie van deze
onderzoeken en anderzijds naar een systematische vergelijking van de resultaten van deze
onderzoeken in de vorm van de nationale en per individu geschatte kosten van epilepsie in
verschallende landen. Verschillende aspecten van de methodologie, zoals de opzet van het
onderzoek en de procedure waarmee de kosten van epilepsie geschat zijn, zijn onderzocht
naar de mate waarmee deze aspecten zijn toegepast in de geselecteerde onderzoeken. In totaai
werden 15 onderzoeken geselecteerd en geanalyseerd. Van de geselecteerde onderzoeken had
67% een retrospectieve opzet en gebruikte gegevens van bestaande databestanden. Opvallend
was dat slechts een klein percentage van de onderzoeken een gevoeligheidsanalyse heeft
gebruikt als controle voor de veronderstellingen die gemaakt zijn tijdens de berekeningen.
Over het algemeen vertoonden de onderzoeken naar de kosten van epilepsie een grote variatie
in de toegepaste methoden en defmities. Naar aanleiding hiervan zijn verschillende
aanbevelingen geformuleerd zoals:
(a) het gebruik van een transparente methodologie en analyse van de data;
(b) een duidelijke beschrijving van de toegepaste defmities;
(c) een kostenanalyse naar prognose zodat rekening wordt gehouden met het natuurlijke
beloop van epilepsie;
(d) het verzamelen van prospectieve data.
In het literatuur overzicht werden ook methodologische, land gerelateerde, en monetaire
aspecten van de geselecteerde onderzoeken beoordeeld om de directe kosten van epilepsie
(kosten die gemaakt worden om een ziekte te behandelen) en hun verdelingspatroon te
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kunnen verge I ij ken. Tien onderzoeken naar de kosten van epilepsie werden hiervoor
geselecteerd. Het percentage van de nationale uitgaven in de gezondheidszorg op het gebied
van epilepsie varicerde tusscn 0.12-1.12% of 0.12-1.05%, afhankelijk van het soort conversie
factor. De conversie factoren waren de wissclkoers en de kooppariteiten. Een kooppariteit is
gclijk aan het bedrag dat nodig is om een identieke set goederen en voorzieningen in
verschillendc landen te kunnen kopen. Daarnaast bleek dat in deze onderzoeken de schart ing
van de dircetc kosten van epilepsie gebasecrd was op een verschillend aantal kostenposten
(bijvoorbeeld kosten van medicamenten, ziekenhuiskosten, transportkosten van en naar het
ziekenhuis). Hoe groter het aantal kostenposten hoe kleiner het aandeel van de
ziekenhuiskosten en van de kosten van medicamenten was aan de totale kosten van epilepsie.
In hoofdstuk 8 wordt een onderzoek naar de kosten van epilepsie in drie verschillende
populates van patiCntcn met epilepsie beschreven (huisartspraktijken. academisch ziekenhuis,
en cpilcpsicccntrum). I.)e kosten werden berckend enerzijds prospectief voor drie maanden
door middel van een kostendagbock en ander/ijds retrospectief voor eveneens drie maanden
met een vragcnlijst. Ilicrbij wcrd ook ccn vragenlijst over de kwaliteit van het leven gebruikt
om meer inzicht te verkrijgen in dc ziektelasi ten gevolge van epilepsie. 116 patienten met
epilepsie numen deel aan dit ondcrzoek en er werd geconstateerd dat de gcmiddelde kosten
per maand variecrden van 52.1 tot 357.61. Patienten uit de huisartspraktijken, voor wie een
rclaticf gunstig beloop van hun epilepsie verondersteld kon worden, hadden lagere directe
kosten, bestcedden minder tijd aan het zocken of ondergaan van een bepaalde behandeling. en
rapportccrden lagere aanvalsfrequentics en minder crnstigc typen aanvallcn dan de patiönten
afkomstig uit dc twee andere patidntengrocpen. Patienten uit het epilepsiecentrum
durentegen, die doorgaans een onzekere of een siechte prognose van epilepsie hebben,
rapporteerden de grootste vcrandcringen in productiviteit en in werkloosheid cijfcrs, en
KOordcn ook het laagst op dc vragenlijsten over de kwaliteit van het leven. In dit onderzoek
waren de schattingen van de directe kosten van epilepsie hoger dan in andere onderzoeken in
Nederland die uitsluitend een retrospectieve opzet hadden.
In hoofdstuk 9 worden de resultatcn van de onderzoeken besproken en enkele toekomst
pcrspccticven wecrgegeven. Het prospectief onderzoek onder de algemene bevolking uit dit
proefschrift rcsulteerde in een cohort van patienten met epileptische en niet epileptische niet
organische aanvallcn (NEA). Bij dit onderzoek werden ook een aantal diagnostische factoren
gevonden waarmee patienten met NEA sneller door de behandelend arts herkend kunnen
worden.
Ken langdurige follow-up en een vergroting van beide cohorten kan meer inzicht leveren in de
prognose van epilepsie, de hiermee samenhangende mortaliteit en morbiditeit, en de lange
termijn prognose voor de patienten met NEA. Een vergroting van het cohort patienten met
NEA kan ook bijdragen aan het vaststellen van de risico factoren die een rol spelen in het
ontstaan en pcrsisteren van dit type aanvallcn en in het herkennen van verschillende basale
kenmerken van deze groep patienten. Hierdoor is het mogelijk om een aantal diagnostische
factoren te definieren waarmee patienten met NEA kunnen worden onderscheiden van
patienten met epileptische aanvallcn.
Met betrekking tot het onderzoek van de kosten van epilepsie, is de schatting van de directe
prospectieve kosten gebaseerd op een kostendagboek. Geconcludeerd werd dat meer
onderzoek nodig is om de waarde van dit kostendagboek te kunnen evalueren. Dit
kostendagboek kan ook toegepast worden in andere economische evaluatie onderzoeken
(bijvoorbeeld kosten-eflectiviteit. kosten-utiliteit) zodat de kosten van verschillende
interventies op het gebied van epilepsie berekend kunnen worden. Middels kostendagboeken
kunnen ook de kosten van andere aandoeningen berekend worden, waardoor economische
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vcTgelijkingen tussen de verschillende zickten mogelijk worden. Dit laatste zou dan
uiteindelijk de weg openen om op een verantwoorde wijze de voor dc gezondheidszorg
beschikbare gelden op een effectieve en eerlijkc wijze te vcrdelen.
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